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Transmissible spongiform encephalopathies (TSEs) or prion diseases are 
defined by infectivity and by the pathological damage they produce in the central 
nervous system (CNS), typically involving spongiform degeneration or vacuolation, 
deposition of abnormal PrP (PrPSc), glial activation and neuronal loss. Much of our 
understanding of the TSEs has derived from the study of murine scrapie models. The 
molecular basis of pathological changes is not clear, in particular the relationship 
between the deposition of PrPSc and neuronal dysfunction. A typical feature of TSE 
disease is neuronal loss, although the mechanisms leading to this loss are poorly 
understood. Apoptosis has been proposed as an important mechanism of TSE 
associated cell death, but which pathways are involved are still to be determined. The 
main aims of this thesis are to investigate the progression of the characteristic 
neuropathological changes observed in the TSE infected brain and to analyse the 
mechanisms involved in neuronal loss. In this study two contrasting scrapie mouse 
models were used : the ME7/CV model , and the 87V/VM model in which neuronal 
loss is targeted to different areas of the hippocampus, the CA1, and CA2 respectively. 
The role of the caspase-dependent pathway of apoptosis in the neuronal loss was 
investigated. The results of analysis of pro-apoptotic markers of disease in the two 
scrapie mouse models differed. The results observed in the ME7/CV scrapie mouse 
model suggest that apoptosis may not be the main mechanism of neuronal loss, 
whereas the 87V/VM model showed some indication that apoptosis may be involved. 
Detailed studies in the progression of neurodegenerative changes in the 
ME7/CV scrapie mouse model revealed that the initial pathological change observed 
in the hippocampus was the deposition of PrPSc followed by a glial response, 
spongiform change and subsequent neuronal degeneration.   
 xi
 xii
The role of the cytoskeleton and synaptic dysfunction in the neuronal damage 
observed in the CA1 of the ME7 infected hippocampus was analysed. Cytoskeletal 
disruption was observed in the post-synaptic dendritic spine, and the apical dendrites 
of CA1 neurons at 160days, a time point at which neurons are known to be lost.  
Changes in the expression of the pre-synaptic protein, synaptophysin and the post-
synaptic protein PSD-95 were not observed until the terminal stage of disease when 
the neuronal loss is profound.  
In conclusion, this research suggests that the mechanisms of neuronal loss may 
follow different biochemical pathways, which might not necessarily involve an 
apoptotic mechanism. Cytoskeletal disruption in the post-synaptic dendritic spine 
plays a major role in the neuronal dysfunction observed in ME7 infected CA1 
neurons, although the post synaptic density does not seem to be involved .Pre-
synaptic changes and disruption to the innervation of CA1 neurons is not apparent 
until the end stages of disease. The trigger for this cytoskeletal disruption and the 
subsequent neuronal loss may be the early deposition of PrPSc in the extracellular 
space but the precise mechanisms involved are still to be elucidated. The 
identification of the key events involved in the mechanisms of neruodegeneration in 
TSE diseases may lead to the development of therapeutic strategies to inhibit the 
neurodegenerative process.     




 Chapter 1 :  Introduction and background 
 
1.1. Transmissible spongiform encephalopathies 
 
 
The transmissible spongiform encephalopathies (TSEs), or prion diseases, are fatal 
infectious, non-inflammatory neurodegenerative diseases of the central nervous 
system (CNS). They are characterised by the pathological changes observed in the 
CNS, which include vacuolation (Fraser, 1976; Fraser & Dickinson, 1967) gliosis and 
the accumulation of an abnormal form of the host sialoglycoprotein, prion protein 
(PrP) (Bolton et al, 1982; Bruce et al, 1989; McBride et al, 1992). 
Scrapie, which naturally affects sheep and goats, is the most extensively 
studied member of the group of TSE diseases that affect a range of animal species and 
man (Table 1). These include Creutzfeldt-Jakob disease (CJD), Gerstmann-Straussler-
Scheinker disease (GSS), fatal familial insomnia (FFI) and kuru in humans, bovine 
spongiform encephalopathy (BSE) in cattle, chronic wasting disease (CWD) in 
captive or free-ranging deer, feline spongiform encephalopathy in cats (FSE) and 
transmissible mink encephalopathy (TME) in captively-reared mink.  
 Over the years these diseases have been widely studied and much debate on 
their origins and aetiology has ensued. They share many characteristic features that 
can be problematic when studying the disease. They have extremely long incubation 
periods (up to several decades in humans), although the time from onset of the clinical 
illness to death of a human or animal host can be short (several weeks); they are 
resistant to standard decontamination methods (Taylor, 2000; Taylor, 2004); the 
nature of the infective agent is still uncertain (Chesebro, 1998) and the absence of a 
pre-mortem diagnostic test. 
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 One of the features of these diseases is transmissibility, both within a host 
species, such as scrapie from sheep to sheep (Cosseddu et al, 2007) and Kuru from 
man to man (Gajdusek & Zigas, 1957), and across species, such as cattle BSE to 
humans, emerging as variant CJD (vCJD) (Hill et al, 1997). Several factors control 
the transmissibility of these diseases including the route of infection, (Eklund et al, 
1967; Kimberlin & Walker, 1979) the infectious dose, age of host (Ierna et al, 2006; 
Outram et al, 1973)  and the infecting strain.    
 
Table 1. TSE diseases in humans and animals 
Disease Species Cause 
Scrapie Sheep and goats Transmission of infection either horizontal or 
maternal 
BSE Cattle Ingestion of infected MBM in animal feed 
CWD Mule deer and elk Unknown, appears to be spread by horizontal 
transmission 
TME Mink Unknown, possible infection from animal 
feed containing material from infected 
sheep/cattle 
FSE Cats Ingestion of infected MBM in animal feed 
TSE not specifically 
named 
Zoo animals (includes 
ungulates and wild 
cats) 
Ingestion of infected MBM in animal feed 
sCJD Human Unknown 
fCJD Human PrP gene mutation 
iCJD Human Surgical/medical contamination 
vCJD Human Accidental transmission possibly from oral 
ingestion of BSE contaminated tissues 
Kuru Human Ritual cannibalism  
GSS Human PrP gene mutation 
FFI Human PrP gene mutation 
Atypical  scrapie Sheep Not known, but observed in genotypes 
associated with resistance to classical scrapie 
BASE Cattle Possibly sporadic, distinguished from 
classical BSE by deposition in the brain of 
Kuru-like plaques 
Abbreviations: BSE; Bovine Spongiform Encephalopathy, CWD; Chronic Wasting 
Disease, TME; Transmissible Mink Encephalopathy, FSE; Feline Spongiform 
Encephalopathy, GSS; Gerstmann-Strausler Syndrome, FFI; Fatal Familial Insomnia 
BASE; bovine amyloidotic spongiform encephalopathy 
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1.2 The history of TSEs 
 
1.2.1. TSEs in animals 
 
Scrapie has been recognised for hundreds of years as a disease of sheep and goats, 
with the first record in the UK reported in 1732 (McGowan., 1922). Scrapie is 
discussed in greater detail below. Other TSEs of animals have not been documented 
for as long as scrapie; TME has been recognised for more than 50 years, CWD for 
more than 30 years and BSE for over 20 years.  
TME 
Transmissible mink encephalopathy (TME) is a rare disease only occurring in farmed 
mink, which are an end host. This disorder was first reported in 1965 by Hartsough 
and Burger (Hartsough & Burger, 1965) , although  the disease had been recognised 
on mink ranches since 1947. There have been outbreaks recorded in Idaho; 
Wisconsin; Ontario, Canada; Finland; Germany and Russia, but it has never been 
recorded in the UK. The simultaneous occurrence of TME on several farms sharing 
the same feed firmly established it as a source of the infectious agent. The occurrence 
of the disease in Russia is said to have been traced to feeding carcasses of sheep 
affected with scrapie (Gorham J., 1991). TME has been experimentally transmitted to 
many other species including racoons (Eckroade et al, 1973), ferret, Syrian and 
Chinese hamster, rhesus monkey, sheep, goat and cattle  (Barlow, 1972; Marsh & 
Hadlow, 1992). Attempts to transmit TME to mice usually fail (Taylor et al, 1986) 
although Barlow and Rennie claim success (Barlow & Rennie, 1970).  
CWD 
Chronic wasting disease (CWD) is a naturally occurring TSE disease of mule deer, 
white-tailed deer, and Rocky mountain elk. The disease is found in both captive and 
free ranging deer and elk populations, the latter being under much less human control 
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and therefore difficult to manage. CWD was first identified as a fatal wasting 
syndrome of captive mule deer in the late 1960s in research facilities in Colorado and 
was recognised as a TSE in 1978 (Williams & Young, 1980; Williams & Young, 
1992). The disease was first recognised in the wild in 1981, when it was diagnosed in 
a free-ranging elk in Colorado (Williams & Miller, 2002). By the mid-1990s 
surveillance studies had confirmed that CWD was endemic in North America and 
apparently spreading through both wild and captive cervid populations. The exact 
mechanism of natural transmission of CWD in the wild is not known. Nonetheless, 
some form of direct or indirect horizontal transmission apparently sustains epidemics 
(Miller & Williams, 2003). Concentrating deer in captivity or by feeding them 
artificially may facilitate transmission. Maternal transmission made little, if any, 
contribution to the occurrence of CWD. Environmental contamination may be a 
possible source of transmission, excreta or decomposed carcass remains may harbour 
some infectivity for years (Miller et al, 2004).    
Although CWD does not appear to occur naturally outside the cervid family, it 
has been transmitted experimentally by intracerebral injection to a number of animals, 
including mice, ferrets, mink, squirrel monkeys and goats (Bartz et al, 1998). More 
recently transgenic mice expressing PrP from mule deer, referred to as tg (Cer PrP) 
have been used successfully as a model for experimental transmission of CWD 
(Angers et al, 2006; Browning et al, 2004). Whether CWD is transmissible to humans, 
as has been shown for BSE, is unknown. Intracerebral infection with CWD of two 
lines of “humanized” transgenic mice that are susceptible to human TSE, failed to 
develop disease (Kong et al, 2005), suggesting there is a species barrier between 




In the late 1980s a new TSE emerged in cattle, bovine spongiform encephalopathy 
(BSE),(Wells GAH, 1987) which has accounted for the majority of TSE cases in the 
UK. The BSE epidemic has had devastating and far-reaching consequences for 
agriculture and man. It seems likely that BSE was transmitted to cattle by ingestion of 
TSE-contaminated protein supplements derived from rendered carcasses of sheep and 
cows (meat and bone meal). The exact source of this TSE and the conditions under 
which it emerged are unclear, although the evidence points towards the rendering 
processes involved in the production of meat and bone meal fed to cattle during the 
1970s and 80s, playing a major role (Wilesmith et al, 1991; Wilesmith et al, 1992). 
The BSE agent was also subsequently found to have been transmitted to other species 
including domestic cats, wild felines, ungulates such as kudu and oryx (Kirkwood et 
al, 1990) and American bison (Kirkwood and Cunningham 1999).  Surprisingly, dogs 
that where fed a similar commercially available diet to cats, and would have been 
exposed to contaminated meat and bonemeal (MBM) feed, did not seem to be 
naturally susceptible to the BSE agent (Bradley, 1996; Wells et al, 2003).  
Transmission studies of BSE to mice consistently produced a characteristic 
pattern of incubation periods and neuropathology that served as a ‘signature’ for the 
BSE strain (Bruce, 2003). This same signature was observed in primary transmissions 
of TSE from domestic cats (Doherr, 2003) and exotic ungulate species (Cunningham 
et al, 2004), confirming the suspected link with BSE and providing evidence for the 






Natural and experimental scrapie    
 
Scrapie is the most studied of the group of TSE diseases. The name ‘scrapie’ is an old 
Scottish word that describes the infected animal’s tendency to scrape or scratch itself 
against fence posts and similar objects, resulting in the loss of fleece. Scrapie has been 
studied in depth for more than 50 years and for many years the aetiology of the 
disease was far from obvious.  
 The first report of intra-species transmissibility was in 1939 by two French 
workers, Cuille and Chelle, who inoculated healthy sheep with spinal cord from 
infected sheep. (Cuille' J & Chelle PL, 1936). The success rate for transmission to 
sheep was only 25%; further studies in goats which gave 100% transmission rate 
(Cuille' J & Chelle PL, 1939) convinced the research community that this was an 
infectious, transmissible disease.  
In the natural disease, death occurs most frequently in sheep between 2 and 5 
years old.  Scrapie has a long incubation period, ranging from several months to 
years, the onset is slow and there are no visible indicators of early infection. The 
clinical phase of the disease is short in comparison to the protracted asymptomatic 
period, the symptoms of which are ataxia (abnormal gait), puritis (itching) and 
recumbency (inability to stand). Natural scrapie is transmissible both horizontally 
among the flock and vertically from ewe to lamb (Andreoletti et al, 2002). To date 
there is no cure and no therapeutic intervention that affects the lethal outcome.  
Genetic influence on scrapie pathogenesis 
Although there is no evidence for a genetically inherited TSE in animals, 
studies with natural and experimental scrapie of sheep have shown that the prion 
protein gene (prnp) is an important factor in disease susceptibility (Hunter et al, 
1997b; Hunter et al, 1997c) . In sheep and goats polymorphisms of the PrP gene have 
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been strongly associated with the incidence of natural and experimental scrapie. 
Studies of natural scrapie have confirmed the importance of three codons ( 136, 154 
and 171) that can encode one of two alternative amino acids , giving a range of 
possible variants or alleles (Hunter, 1997). Based on the variation found in the UK 
sheep population originally 15 three-codon genotypes were defined (Dawson et al, 
1998). In this standard model, codon 136 has two possible amino acids, A and V, 
codon 154 has also two, R and H and codon 171 has three possible amino acids, Q, R 
and H (table 2). These polymorphisms are combined to form five alleles (ARQ,VRQ, 
AHQ,ARR,ARH), ARR and AHQ are associated with resistance; ARQ, ARH and 
VRQ are associated with susceptibility. These alleles can be arranged into 15 
genotypes e.g. ARR/ARR, VRQ/ARQ, or ARH/AHQ (Goldmann, 2008). A five 
group risk classification system has been developed based on these fifteen genotypes 
which was modified to be applied in breeding and eradication programmes like the 
National Scrapie Plan of Great Britain and equivalent plans in other member states of 
the European Union (Dawson et al, 1998; Detwiler & Baylis, 2003). 
The 15 genotypes differ widely in their susceptibility to scrapie, ranging from 
complete resistance for the ARR/ARR genotype to extreme susceptibility for the 
VRQ/VRQ genotype. There are subtle effects of specific allele pairings, generally 
more susceptible genotypes have younger ages at death from scrapie, different strains 
of scrapie occur which may attack genotypes differently. Different sheep breeds vary 
in the assortment of the five alleles that they predominantly encode. Furthermore, 
certain genotypes may be susceptible to scrapie in some breeds and resistant in others. 
The explanation for this is not known, but may relate to different scrapie strains 
circulating in different breeds, or there may be effects of other genes which modulate 
the effect of PrP (Baylis et al, 2004; Baylis & Goldmann, 2004)  
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It is still a matter of some debate whether natural scrapie is a genetic disease 
arising from the PrP alleles , or whether PrP controls susceptibility to an infecting 
agent. There is strong evidence to support the fact that scrapie is not solely a genetic 
disease, as not only are VRQ/VRQ sheep found in countries such as Australia and 
New Zealand, which do not have endemic natural scrapie (Bossers et al, 1999; Hunter 
et al, 1997a), it has also been shown that VRQ/VRQ sheep from the NPU Cheviot 
flock can survive into old age when their environment is free of scrapie infection 
(Foster et al, 2006; Hunter et al, 1997a). 
 
Table 2. Sheep PrP gene – the three most important 
                          disease-related polymorphisms
   
Codon  Amino Acid alternatives  Single-letter code 
 
136  Valine     V136
  Alanine    A136 
 
154  Arginine    R154
  Histidine    H154 
 
171  Arginine    R171 
  Glutamine    Q171
  Histidine               H171
 
 
Atypical TSEs in ruminants: Atypical scrapie, Nor98 and BASE 
In 1998, an unusual type of scrapie was diagnosed in Norwegian sheep and was 
subsequently designated Nor98 scrapie. Active surveillance of small ruminants 
throughout the European Union (EU) to detect these “atypical” cases of scrapie has 
identified the presence of atypical forms of scrapie in a number of countries including 
Germany, Belgium and France (Baron et al, 2007; Buschmann et al, 2004). The 
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neuropathological, molecular and biochemical characteristics of Nor98 differ from 
those of classical scrapie. The primary structure affected in the brains of sheep 
infected with classical scrapie, the dorsal motor nucleus of the vagus (DMNV), is not 
a target in Nor98 scrapie. In western blotting analysis of protease-resistant PrP, an 
unusual band of low molecular weight (10-12KDa) is observed, in contrast to that of 
“classical” scrapie where the protease-resistant form of PrP is detected as three bands 
between 18 and 29 kDa corresponding to the un-, mono- and di-glycosylated forms of 
PrP (Baron et al, 2007). Evidence so far indicates that atypical scrapie affects animals 
with different PrP genotypes to those associated with classical scrapie, such as those 
with the A136H154Q171 or A136R154R171 genotypes (Benestad et al, 2008; Buschmann et 
al, 2004). 
Experimental transmission studies of atypical scrapie material into inbred mice were 
unsuccessful (Benestad et al, 2008). Later the development of lines of transgenic mice 
expressing ovine VRQ PrP were used successfully to transmit the disease, proving 
that atypical/Nor98 was an infectious TSE agent (Arsac et al, 2007). 
 An increase in the active surveillance for detection of TSEs in ruminants 
identified a number of atypical TSE cases in cattle. These included the identification 
of a novel TSE in cattle from Italy with unusual pathology in the form of amyloid 
plaques in the CNS (Casalone et al, 2004). Classical cattle BSE is not associated with 
PrP plaque deposition in the brain. Therefore this new form of BSE was termed 
bovine amyloidotic spongiform encephalopathy (BASE). Further surveillance 
identified other apparently novel BSE phenotypes, cases were reported in Japan 
(Nakamitsu et al, 2006; Yamakawa et al, 2003) and other European countries 
(Buschmann et al, 2006); (Biacabe et al, 2004). Transmission of BASE isolates to 
wild-type mice produced a neuropathological and molecular disease phenotype 
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indistinguishable from that of BSE-infected mice, whereas the characteristics of the 
BASE strain were preserved in transmissions to transgenic mice expressing bovine 
PrP (Capobianco et al, 2007). Strikingly, the glycoform patterns of  PrPSc BASE 
isolates and the PrPSc deposition observed in the CNS closely resembled those found 
in some cases of sCJD (Casalone et al, 2004)  
1.2.2 Human TSEs 
Kuru 
During the 1950s, when research into scrapie was growing, there was an increased 
interest in kuru, an epidemic disease amongst the Fore-speaking people of Papua New 
Guinea (Zigas & Gajdusek, 1957). The clinical signs and neuropathology of the 
disease was strikingly similar to scrapie; this was particularly noted by Hadlow 
(1959), who suggested that kuru may be a transmissible disease just like scrapie 
(Hadlow WJ, 1959). It was discovered that the Fore tribe of Papua New Guinea 
participated in endocannibalism; a ritualistic form of cannibalism involving the 
consumption of deceased relatives (Alpers, 1965; Gajdusek, 1963).  This cannibalistic 
ritual was shown to be responsible for the transmission of kuru (Collinge et al, 2006; 
Mathews et al, 1968). It was noted that a higher percentage of females than males 
contacted the disease, due to the predominant consumption of brain material, 
containing high levels of infectivity, by women and infants (Gajdusek, 1966). In 
comparison, the male members of the tribe mainly consumed muscle from the 
deceased (Hornabrook & Moir, 1970).  
The initial transmission studies of kuru to wild-type mice were unsuccessful 
(Gajdusek & Gibbs, 1964), this may have been due to the fact that the studies were 
terminated as early as 3 months, which would not have been long enough to produce 
disease in rodent models. Experimental inoculation of kuru infected brain into 
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chimpanzees resulted in a spongiform encephalopathy remarkably similar to kuru in 
humans (Gajdusek et al, 1966); (Beck et al, 1966). Studies by Klatzo et.al. also 
revealed neuropathological similarities between kuru and CJD (Klatzo et al, 1959). 
These studies in the 1960s were the first to demonstrate the infectious nature of kuru 
and its transmissibility.   
Creutzfeldt-Jakob disease (CJD) 
A peculiar progressive neurological disease termed spastic pseudosclerosis and its 
neuropathology were first described by Hans Gerhard Creutzfeld (Creutzfeldt, 1920) 
and Alfons Maria Jakob (Jakob, 1921). This disease was later named Creutzfeldt-
Jakob disease after its first two observers, Creutzfeldt and Jakob and is recognised to 
occur in several different aetiological forms: Sporadic CJD (sCJD), familial CJD 
(fCJD), iatrogenic CJD (iCJD) and variant CJD (vCJD) 
Sporadic CJD 
The sporadic form of CJD is the most common subtype of CJD, corresponding to 
about 80% of cases. The disease most commonly occurs in the seventh decade of life, 
with an average duration of illness of approximately 4-5 months. sCJD is thought to 
originate de novo and in terms of the prion hypothesis may be a spontaneous disease. 
The naturally occurring polymorphism at position 129 of the human prion protein 
gene (PRNP), which can encode either a methionine (M) or valine (V) allele, clearly 
influences susceptibility to sporadic CJD; there is also evidence of a strong influence 
of codon 129 genotype on the clinicopathological phenotype in sCJD. 
Genetic or familial CJD 
Familial CJD occurs as an autosomal dominant inherited disorder, associated with 
point mutations, deletions, or insertions in the coding sequence of the PRNP gene 
(Kovacs et al, 2002). Other familial forms of human TSE are Gerstmann-Straussler-
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Scheinker disease (GSS) and fatal familial insomnia (FFI). These familial diseases are 
also associated with mutations in the PRNP gene; the most common mutation 
observed in GSS is the P102L mutation (Kretzschmar et al, 1991). GSS is 
characterised by prominent ataxia, dementia in late stages of disease, and numerous 
kuru and multicentric PrP amyloid plaques in the brain (Hainfellner et al, 1995; 
Kretzschmar, 1993).  
 FFI is associated with a D178N mutation of the PRNP gene in association 
with methionine at codon 129. Clinically, FFI frequently begins with disturbances of 
vigilance and sleep that are often neglected. The patients go on to develop 
hallucinatory states, autonomic disturbances such as high blood pressure and 
hyperthermia, disturbances of gait, disequilibrium and myoclonus. The onset of 
disease is between 36 and 62 years and the disease duration varies from 8 to 72 
months (Krasnianski et al, 2008; Provini et al, 2008). Pathologically, FFI is 
characterised by severe Thalamic gliosis and neuronal loss, with little spongiform 
change and very scantly deposited PrP in the brain.  
iCJD 
This infectious form of CJD comprises cases transmitted following a range of medical 
and surgical procedures. The over-whelming majority of iCJD cases have been caused 
either by the parenteral administration of contaminated growth hormone preparations 
from the pituitary gland of the deceased (Caboclo et al, 2002; Cordery et al, 2003), or 
by contaminated grafts of dura mater (Croes et al, 2001). A few cases occurred after 
neurosurgery including insertion of deep brain electrodes, and corneal transplantations 





This new form of human TSE was discovered in 1996 and occurred in younger 
individuals than those with sCJD, with distinctive clinical features and 
neuropathology characterised by the presence of ‘florid’ PrP amyloid plaques in the 
brain. Unlike sCJD, in vCJD the peripheral lymphoid system becomes infected early 
in the disease (Hill et al, 1999b; Hill et al, 1997).  Transmission of brain material from 
vCJD affected individuals into mice produced a “signature” undistinguishable from 
that of BSE (Bruce et al, 1997). Incubation periods observed in specific mouse strains 
(Figure 1), lesion profiles in the brain and PrPSc glycoform profiles were identical to 
that of BSE. The most likely cause of transmission was suspected to be through 
dietary exposure (Bruce et al, 1997; Collinge et al, 1996; Hill et al, 1997). To date 
approximately 300 cases of vCJD have been identified worldwide, the majority of 
which have occurred in the UK (http://www.cjd.ed.ac.uk/). All cases tested were of 
the same PRNP genotype i.e. homozygous for methionine (M) at codon 129 (Colm H 
& knight R, 2002). Three cases of vCJD have occurred in recipients of packed red 
blood cells from donors who subsequently developed and died from vCJD (Llewelyn 
et al, 2004 ;Wroe et al, 2006). All three recipients were methionine homozygotes at 
codon 129 in the PRNP gene. A case of asymptomatic vCJD infection was detected 
following autopsy in a fourth recipient of packed red blood cells from a vCJD infected 
donor. However, this recipient was a heterozygote (methionine/valine) at codon 129 
in the PRNP (Peden et al, 2004). This raised fears of the possibility of a second 





Figure 1.  Incubation periods in mice injected with TSEs from naturally infected 
hosts. Results are shown for transmissions from six individual scrapie sheep. Pooled 
data from several transmissions are shown for cattle, feline spongiform 
encephalopathy (FSE) and human vCJD. Transmission of BSE, FSE and vCJD to 
inbred mice with different prnp genotypes show identical incubation periods, 
indicating that they are all from the same TSE strain. In comparison the six sheep 
scrapie transmissions all differ in the incubation period observed on transmission to 








1.3 The nature of the infectious agent 
1.3.1 Viruses, viroids, virinos and SAF 
 
The nature of the infectious agent is perhaps one of the most extensively studied 
aspect of TSE research and to this day remains a matter of passionate controversy.  
During the 20th century, different theories on the nature of the causative agent were 
put forward. Ranging from a sarcosporidia (1914) (M'Gowan J, 1914), a DNA-
polysaccharide complex (1968) (Adams D, 1968) and a holoprion, consisting of PrPSc 
and a nucleic acid (Weissmann, 1991). 
The properties of the scrapie agent did not fit with established criteria for how 
infectious diseases were known to behave i.e. the TSE pathogen is transmissible, 
replicates and exists as many strains with genetically stable phenotypes (Dickinson & 
Outram, 1979). These properties are consistent with the activity of viruses and 
initially the agent was thought to be a “slow virus” because of the unusually long 
incubation periods between time of exposure to the pathogen and the onset of 
symptoms (Cho, 1976). However in 1966, Alper and colleagues reported that the 
minimum molecular weight of the scrapie agent that still maintained infectivity was 
too small (≈2x105) to possibly be a virus (Alper et al, 1966). Later the same group 
demonstrated that the infectious agent was extremely resistant to treatments that 
normally destroy nucleic acids, such as ultraviolet and ionization radiation (Alper et 
al, 1967). Over the past 30 years despite extensive biochemical and electron 
microscopy analysis, no convincing evidence of an associated viral agent has 
emerged. Over the years several theories were proposed for the agent. One theory was 
that the infectious agent could be encoded by a viroid and, as in plants, could be a 
simple nucleic acid of very small size (Diener, 1973). One of the hypothese that 
gained some scientific support was the virino hypothesis, which was a modification of 
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the viral theory, in which a virino was defined as a small informational molecule, 
possibly a nucleic acid, that was associated with a host protein that serves as a coat 
(Carp et al, 1994; Kimberlin, 1982). 
Any hypothesis about the nature of the agent would have to take into account a 
number of diverse observations, including the infectious, familial and sporadic forms 
of the disease and the physiochemical properties of the agent. It would also have to 
explain the occurrence of multiple strains or isolates of infectious agent. It has been 
proposed that the only way that strain differences can be accounted for is to assume 
that there is nucleic acid associated with the agent (Dickinson & Outram, 1988). The 
virino hypothesis proposes that the infectious particle is comprised of a nucleic acid 
that is bound to and protected by PrP host protein. The presence of a nucleic acid is 
key to the virino hypothesis as this is the only molecule known to biology that is 
capable of replication and transfer of genetic information. To explain the lack of 
detection, the nucleic acid must be small and around 100-1000 base pairs in size, or 
infact does not exist. 
Scrapie associated fibrils (SAF) 
Electron microscopy techniques had been used successfully to detect viruses 
and viroid structures, therefore this technique was used to try and identify the scrapie 
agent. Amyloid-like fibrillar structures termed scrapie associated fibrils (SAF) were 
observed in membrane fractions from infected brain after treatment with mild 
detergents. These SAFs were observed in brains from animals affected with the 
disease (Merz et al, 1981) and from CJD in humans (Merz et al, 1983) and never 
observed in unaffected tissue. These fibrils were identified as paired or quadruple 
fibrillar structures 4-6 nm in size, resembling amyloid observed in some TSE strains 
(Isomura et al, 1991).  Prusiner identified similar structures and named them ‘prion 
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rods’ (Prusiner et al, 1983). It is now accepted that SAF and ‘prion rods’ are the same 
structural entity, varying only in their length. Co-isolation of SAF and infectivity from 
spleens and brain of scrapie infected mice suggested a close association with 
infectivity (Rubenstein et al, 1991).  The relationship between SAF and infectivity is 
hard to determine. Difficulties in isolating the infective agent restrict studies to crude 
preparations, and it is not known if the treatments used actually destroy any nucleic 
acid or protein components of the infectious agent. In order to properly identify the 
infectious agent further techniques need to be developed to isolate the agent to a high 
degree of purity.   
1.3.2 Prions 
 
The suggestion that the unconventional properties of the infectious TSE agent might 
be accounted for in a protein-only model was first proposed in 1967 by JS Griffith 
(Griffith, 1967), who believed that the agent was a self-replicating protein derived 
from a normal cellular protein. It was not until the early 1980s that progress was made 
furthering this hypothesis.  During purification for the scrapie agent it was found that 
infectivity was associated with a protein that was partially resistant to proteolytic 
degradation and had a molecular mass of around 27-30 kDa on SDS polyacrylamide 
gels (Prusiner, 1982; Prusiner et al, 1982). This protein was associated with infectivity 
from all scrapie fractions, but not from control samples. As this was the only molecule 
that could be linked with infectivity, Prusiner proposed the term ‘prion’ to describe 
the scrapie agent implying that it was a proteinaceous infectious agent. The prion 
protein that had been isolated was found to be the product of a cellular gene on the 
short arm of chromosome 20 in humans and in mice located on chromosome 2 (Liao 
et al, 1986; Sparkes et al, 1986). 
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1.3.3 The prion hypothesis 
 
The prion hypothesis suggested by Stanley Prusiner in the early 1980s claims that 
scrapie and related diseases were caused by prions, novel proteinaceous infectious 
particles that lacked a nucleic acid (Prusiner, 1982). These prion  proteins (PrP) were 
the sole component of the infectious agent (McKinley et al, 1983). It was suggested 
that some insult triggers host neuronal PrP (PrPc) to refold from the normal largely α-
helical form to the predominantly β-pleated sheet disease-causing form (PrPSc). 
Progressively more of the cellular PrPc being sequestered into the abnormal, protease 
resistant isoform which accumulates and may form amyloid. 
A number of studies have produced evidence which favour the prion 
hypothesis. These include the generation of infectivity in neuroblastoma cells (Race et 
al, 1987) and the cell free conversion of PrPc into PrPSc by Caughey and colleagues 
(Caughey et al, 1995). One of the most controversial studies in this field was the study 
by Legname. They demonstrated that a recombinant truncated fragment of mouse 
PrPc can misfold in vitro into β sheet rich fibrils and cause a prion disease after 
intracerebral (ic) inoculation (Legname et al, 2004). However, a major flaw in this 
work is that they only produced disease in transgenic mice overexpressing PrP, but 
not in wild type mice, although subsequent passage of brain material from the 
transgenic mice produced disease in wild-type mice.  
Protein misfolding cyclical amplification (PMCA) 
Another approach used in an attempt to prove the prion hypothesis was the use of 
PMCA (protein misfolding cyclical amplification). This technique was designed to 
mimic PrPSc autocatalytic replication. In a cyclic manner, similar to PCR cycling, a 
tissue homogenate “seed” containing PrPSc is incubated with excess PrPc, which is 
converted to PrPSc. The new PrPSc aggregates are then sonicated to generate multiple 
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smaller units for the continued formation of new PrPSc (Saa et al, 2006; Saborio et al, 
2001). This technology has been used successfully to replicate the misfolded protein 
from diverse species (Soto et al, 2005), and to prove that the newly generated protein 
exhibits the same biochemical, biological and structural properties as brain derived 
PrPSc and is infectious to wild-type animals, producing a disease with similar 
characteristics as the illness produced by brain-isolated prions (Castilla et al, 2005). In 
the studies by Castilla et al only the one strain of hamster PrPSc was used, and also the 
in vitro-generated infectious agent produced disease with a delay in the incubation 
period. This may be associated with a loss of infectivity in the de novo produced 
hamster PrPSc. Further work analysing the apparent discrepancy between the amount 
of PrPSc produced and infectivity related these changes to the differences in the size 
distribution of PrP aggregates that changed their clearance rate (Weber et al, 2007).   
 One of the main difficulties of the prion hypothesis has been to provide a 
molecular explanation for the TSE strain phenomenon. The prion hypothesis suggests 
that different strains of TSE agent could be attributed to different conformations of 
PrPSc, and that each conformation would interact differently with PrPc to determine 
strain characteristics (Bessen et al, 1995). Recent work has shown that PrPSc 
generated in vitro by PMCA from five different mouse TSE strains, maintains the 
strain-specific properties. Wild type mice inoculated with the in vitro generated PrPSc 
showed disease characteristics indistinguishable from those of the parental strains 
(Castilla et al, 2008).  Biochemical features were also maintained upon replication of 
four human TSE strains. Similar studies with CWD combining the use of PMCA with 
transgenic mouse models demonstrated the amplification of CWD prions with 
unaltered strain properties (Green et al, 2008). Also revealed in this study was the 
ability of the PMCA technique to abrogate the inter species barrier, although the 
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adaptation of mouse prions to form novel cervid prions required several hundred days 
and subsequent stabilisation in transgenic mice (Agrimi et al, 2008).  These studies 
provide additional support for the prion hypothesis and also that strain variation may 
be dependent on PrPSc properties.  
 However, all these studies rely on the conversion of PrPc into the abnormal 
protease resistant form, PrPSc and that PrPSc is the infectious agent. In other 
conversion studies proteinase K resistant PrP was generated but this did not result in 
infectivity (Hill et al, 1999a). It has been suggested that the PMCA technique may be 
useful as a diagnostic tool to identify pre clinical cases of TSE disease. However, 
some studies have shown that transmission of infectivity can occur in the absence of 
detectable PrPSc (Barron et al, 2007; Lasmezas et al, 1997). Moreover, the detection of 
PrPSc in the absence of clinical symptoms of disease or infectivity has been 
demonstrated in transgenic mice inoculated with brain material from a case of GSS 
(Piccardo et al, 2007).  
 Although it is widely accepted that both the normal and abnormal forms of 
PrP are intrinsic to the disease process, the precise mechanisms by which PrPc is 
converted into PrPSc is still not fully understood. While major improvements in the 
PMCA technology have provided further evidence to support the protein only 
hypothesis, it still remains a controversial subject within the field of TSE research. 
1.4 The prion protein (PrP) 
1.4.1 PrPc and the PrP gene 
 
 PrPc plays a key role in the pathogenesis of TSEs. PrPc is a 33-35KDa 
sialoglycoprotein and is the product of a single host gene, PRNP in humans and prnp 
in mice. The gene is found on chromosome 20 in humans and chromosome 2 of mice  
(Liao et al, 1986; Sparkes et al, 1986) and consists of 2 or 3 exons, a single open 
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reading frame and a cytidine/guanidine rich promoter. The structure of the gene and 
the sequence of the protein are highly conserved in various mammals. Primarily, 
transcription of the PrP gene is found in neurons of the central and peripheral nervous 
system (Bendheim et al, 1992; Kretzschmar et al, 1986; Manson et al, 1992). PrPc is 
also found in lower levels in heart, lung, kidney, spleen, liver, and lymphocytes 
(Caughey et al, 1988;Cashman et al, 1990;Mabbott et al, 1997).  
 Human and mouse genetics have made major contributions to TSE disease 
research, one of these being the discovery of mutations in the PRNP gene in families 
with fCJD, GSS and FFI. All familial forms of TSE disease are associated with  
mutations, deletions or insertions in the PRNP gene. Over 30 different mutations have 
been described (Figure 2), not all of which appear to be pathogenic (Gambetti et al, 
2003; Goldfarb et al, 1991). However, it is not known whether the presence of the 











Figure 2. Mutations observed in the human, mouse and sheep PRNP gene 
 
1.4.2 Structural features of the cellular (PrPc) and scrapie form of PrP (PrPSc) 
 
PrPc is the product of a single gene, called Prnp, that directs synthesis of a 254-
residue protein, which contains a signal peptide for secretion, five octapeptide repeats 
near the amino-terminus, two glycosylation sites, and one disulphide bridge (Cohen, 
1999) (Figure 3) A glycosylphosphatidylinositol (GPI) anchor attaches the protein to 
the outer surface of the cell membrane. PrPc is constitutively expressed in the brain 
and other tissues of healthy individuals as three glycoforms, mono-,di- and 
unglycosylated, the proportions of which differ in different species (Ermonval et al, 
2003). PrPc has a molecular weight of 33-35 kDa and is sensitive to digestion with 
proteinase K. The abnormal form of the protein, PrPSc is synthesised from the normal 
cellular isoform PrPc by a post translational process that probably occurs in 
endosomes (Griffiths et al, 2007; Porto-Carreiro et al, 2005). PrPSc has many 
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properties that differ from those of PrPc ; PrPSc is insoluble in detergents, while PrPc is 
readily solubilised under non denaturing conditions (Meyer et al, 1986). PrPSc is 
partially hydrolysed by proteases to form a fragment designated PrP 27-30, while PrPc 
is completely degraded under the same conditions (Oesch et al, 1985), and PrPSc 
accumulates within and around cells, whereas PrPc has a short half life and turns over 
rapidly in cells (Borchelt et al, 1990).  
Differences between the normal and abnormal isoforms of the protein occur in 
the secondary and tertiary structures that determine conformation. Fourier 
transformation infrared and circular dichroism experiments have shown that the 
structure of PrPc  comprises around 43% α-helix and only 3% β-sheet, while PrPSc has 
34% α-helix but incorporates a greatly increased, 43% β-sheet (Pan et al, 1993). 
The protease-resistant core of PrPSc designated PrP 27-30 was originally identified as 
being the major component of fibrillar structures, initially termed scrapie-associated 
fibrils (SAF) (Merz et al, 1981) that were isolated from detergent-treated tissue 
extracts of scrapie infected brains.  
In the brains of some animals and humans that have died of TSE diseases, 
amyloid plaques are found, which contain PrPSc. Amyloid is known to have a β-
pleated sheet structure (Glenner et al, 1974). The secondary structure of PrP 27-30 is 







Figure 3. Structure of PrP. An outline of the primary structure of cellular 
PrP(PrPc).A secretory signal peptide resides at the extreme N terminus. The numbers 
describe the position of the respective amino acids. CC defines the charged cluster, 
HC the ‘hydrophobic’ core. S-S indicates the single disulphide bridge. The proteinase 
K (PK) resistant core of PrPSc is depicted in gold and the approximate cutting site of 
PK within PrPSc is indicated by the lightning symbol. Figure adapted from Aguzzi 
et.al. 2008)Molecular mechanisms of prion pathogenesis. Annu.Rev.Pathol.Mech.Dis. 
3: 11-40 
 
1.4.3 The function of PrPc 
 
Investigating the biological activity of PrPc is likely to be crucial for understanding 
the pathogenesis of TSE diseases, since alteration of its function may play a role in 
the disease process. PrPc is expressed early in embryogenesis, and in the adult it is 
present at highest levels in neurons of the brain and spinal cord (Harris et al, 1993; 
Manson et al, 1992). PrPc is also found at lower levels in glial cells of the CNS as 
well as in a number of peripheral cell types (Ford et al, 2002b; Moser et al, 1995). 
Although the function of PrPc is not yet known, there is an abundant amount of 
literature describing the properties of the protein. The location of PrPc in lipid rafts, a 
membrane fraction specialised in signalling, pointed towards a potential role for PrPc 
in signal transduction (Taylor & Hooper, 2006). Yeast two hybrid screens have 
identified several signalling molecules that bind to PrP, including a neuronal 
phosphoprotein synapsin Ib, the adapter protein Grb2, and the still uncharacterised 
PrPc interactor protein Pint1 (Spielhaupter & Schatzl, 2001), although there is no 
evidence for the physiological relevance of these interactions. Most of these 
interactors are primarily cytoplasmic proteins and are therefore unlikely to associate 
directly with PrPc, which is localised to the outer surface of the plasma membrane. A 
 24
more likely candidate for interaction with PrP, would be a cell surface receptor.  Both 
the laminin receptor (LRP/LR) (Martins, 1999) and heparin sulphate have been 
identified as possible cell surface receptors of PrPc. Different isoforms corresponding 
to different maturation states of the laminin receptor have been identified, the main 
67KDa LR being the major receptor form expressed in the brain, found within the 
cytoplasm and plasma membrane in most neurons and a subset of glia cells (Baloui et 
al, 2004). Heparin sulphate proteoglycan functions as a co-factor/co-receptor, 
mediating the binding of PrPc to the laminin receptor (Caughey et al, 1994; Hundt et 
al, 2001) and may also act as a receptor for PrPSc (Horonchik et al, 2005). 
There are a number of studies suggesting that PrPc can activate transmembrane 
signalling pathways involved in several different phenomena, including neuronal 
survival, neurite outgrowth (Taylor & Hooper, 2006), and neurotoxicity. Recent 
studies have suggested a potential role for the P13 Kinase/AKt signalling pathway in 
the neuroprotective effects of PrPC (Satoh et al, 2009; Schmalzbauer et al, 2008). In 
one of these studies AKt activity was found to be diminished in neurons and brain 
tissue from PrP deficient mice (PrP-/-) in comparison to wild type mice. Moreover, 
pharmacological inhibition of AKt reduced the ability of PrPc to protect cells against 
oxidative damage (Vassallo et al, 2005).     
A major role for PrPc may be in promoting neuronal survival by suppressing 
programmed cell death. Support for this comes from in vitro experiments showing 
that PrPc can protect human neurons from Bax-induced apoptosis (Bounhar et al, 
2001).Furthermore, the C-terminal end of Bcl-2 protein interacts with PrPc in a yeast 
two-hybrid system (Kurschner & Morgan, 1995; Kurschner & Morgan, 1996). 
Therefore it is possible that PrPc actually acts as a member of the Bcl-2 family. The 
anti-apoptotic activity of PrPc was demonstrated in a human breast carcinoma cell line 
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(Diarra-Mehrpour et al, 2004).PrPc plays a role in neuronal survival by protecting 
neurons in culture against oxidative stress, and brain tissue against ischemia, hypoxia, 
or trauma (Lo et al, 2007; McLennan et al, 2004; Weise et al, 2004) 
PrPc  has been shown to be involved in the binding and metabolism of copper 
(Brown, 2001) (Viles et al, 1999). The octapeptide repeat region of PrPc is able to 
bind copper within the physiological concentration range (Todorova-Balvay et al, 
2005) , suggesting that PrPc may have a role in normal brain metabolism of copper 
(Brown et al, 1997; Kramer et al, 2001). Copper interaction with PrP may also 
modulate the conversion of the normal protein into the pathological isoform; it has 
been shown that binding of copper causes a change in both the secondary and tertiary 
structure of PrPc, leading to the formation of a protease resistant form (Qin et al, 
2000). 
Several strains of PrP-null mice have been generated to aid the search for 
possible biological functions of PrPc.  However, differences in the way gene 
disruption was achieved led to conflicting conclusions. A consistent finding in all 
mice devoid of PrPc is their resistance to scrapie, and their inability to propagate 
infectivity. Two lines generated, referred to as Prnp0/0 Zurich I and Prnp-/- Edinburgh, 
were viable and had no obvious neurological abnormalities (Bueler et al, 1992; 
Manson et al, 1994), although some minor electrophysiological and circadian rhythm 
defects were observed (Tobler et al, 1996). In another 2 lines, ICM Prnp-/- (Moore et 
al, 1995) and Japan Prnp-/- (Sakaguchi et al, 1996) the mice developed cerebellar 
Purkinje cell degeneration and demylination of peripheral nerves, causing late-onset 
ataxia. This phenotype was later discovered to be due to overexpression of a gene 
located downstream of PrP, termed Prnd whose product is a protein called doppel 
(Moore et al, 1999). These findings led to the suggestion that some of the TSE 
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clinical symptoms such as ataxia might be due to increased expression of doppel in 
the brain during disease. This was subsequently found not to be the case; TSE 
infection does not alter the levels of Prnd in the CNS and doppel expression in the 
brain had no influence on the incubation period, spongiform degeneration, or PrPSc 
deposition in TSE-infected mice (Tuzi et al, 2002). 
1.4.4 A role for PrPc at the synapse 
Several experimental observations suggest that PrPc may play a role in synaptic 
structure, function or maintenance. This hypothesis is consistent with the fact that 
synaptic pathology is often a prominent feature of TSE diseases (Jeffrey et al, 2000). 
Light and electron microscopic immunohistochemical studies, as well as localisation 
of PrP-EGFP fusion protein, indicate that PrPc is preferentially concentrated along 
axons and in presynaptic terminals (Barmada et al, 2004; Ford et al, 2002a; Ford et al, 
2002b; Laine et al, 2001; Mironov et al, 2003; Moya et al, 2000; Sales et al, 2002). 
Incubation of cultured hippocampal neurons with recombinant PrP induces rapid 
elaboration of axons and dendrites, and increases the number of synaptic contacts 
(Kanaani et al, 2005). This suggests that PrPc may play a regulatory role in synapse  
formation. PrPc expression has also been observed in peripheral synapses, and is  
concentrated at the neuromuscular junction where it is localised in the sub-synaptic 
sarcoplasm (Gohel et al, 1999).  
 Electrophysiological recordings from brain slices of  Prnp0/0 mice also support 
a functional role for PrP in synaptic transmission. Initially, it was reported that LTP 
was impaired and receptor mediated fast inhibition involving GABA-A receptors was 
decreased (Collinge et al, 1994; Manson, 1995), however this result has been disputed 
(Lledo et al, 1996). Other studies have demonstrated a positive correlation between 
the expression level of PrPc and the overall strength of glutamatergic transmission in 
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the hippocampus, the range of synaptic responses increasing with the level of PrP 
expression (Carleton et al, 2001). Prnp0/0 mice have also been shown to display 
several other neurobiological abnormalities that may also relate to the participation of 
PrPc in synapse formation and function. These include alterations in nerve fibre 
organisation (Colling et al, 1997), circadian rhythm (Tobler et al, 1996), and spatial 
learning (Criado et al, 2005). 
1.5 Experimental TSE strains 
1.5.1 Identification of strains 
 
Strain variation in scrapie was first recognised over 40 years ago, when experimental 
sheep scrapie, designated SSBP/1, was transmitted to and serially passaged in goats. 
Two separate passage lines were maintained which produced strikingly different 
clinical signs in unselected goats from the same herd, either a “drowsy” or a 
“scratching” syndrome (Pattison & Millson, 1961). This difference between the two 
isolates remained constant on repeated goat-to-goat passage which suggested that two 
different scrapie strains had been isolated from the original study (Chandler R L, 
1961; Pattison & Millson, 1961; Pattison & Smith, 1963).  The SSBP/1 inoculum 
was originally produced from a brain pool of 3 cheviot sheep with symptoms of 
natural scrapie. Serial passage of this brain material was continued in cheviot sheep 
with very little deviation from the original disease characteristics, incubation periods  
and clinical features of disease remained stable. The inoculum used in the goat 
transmission studies was acquired from the 18th  passage of this brain pool (Pattison & 
Millson, 1961; Pattison & Smith, 1963).   
Further studies in mice discovered that the two strains isolated from the goat 
studies actually contained a mixture of strains. The “drowsy” or “Chandler” isolate 
(Chandler R L, 1961) contained the 139A, 79A and 79V scrapie agent strains, 
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and the “scratching” isolate contained the  22C and 22H strains (Dickinson et al, 
1986). Further passage of the Chandler isolate at the Rocky Mountain Laboratory in 
Montana USA, led to what is now know as the RML isolate, which may be a mixture 
of 139A and 79A strains. Most of the studies described in this thesis were performed 
using the ME7 strain of scrapie. This strain was originally isolated from experiments 
of  intragastric transmission, to mice, of pooled spleen material from cases of natural  
scrapie (Zlotnik & Rennie, 1965). These transmission studies resulted in TSE disease  
initially in a group of mice termed mouse experiment 7 (ME7), subsequent passage of  
brain material from these mice led to the isolation of the strain that is now called  
ME7. In contrast, the 87V strain of scrapie has been isolated from many different  
breeds of sheep infected with natural scrapie following passage in VM mice (Bruce, 
1985; Bruce et al, 1987) 
   Most studies into strain variation in TSEs have been carried out in mouse 
models of disease. Long-term studies in mice started by Alan Dickinson in the 1960s, 
analysing different isolates of scrapie, revealed that there were numerous strains of 
the scrapie agent that produce distinct patterns of disease in the infected host (Bruce 
& Fraser, 1991; Bruce et al, 1991). There are many strains of scrapie, each with its 
own distinct, reproducible disease characteristics which are stable on repeated 
experimental passage. Murine scrapie strains are identified on the basis of these 
disease characteristics, in particular the incubation periods produced in mice of 
defined genotypes (Figure 4) and the severity and distribution of vacuolar pathology  
in the brains of these mice.  Additional useful indicators of disease are the particular 
clinical signs displayed at the end stage of the disease, changes in locomotor activity 
and posture and the physico chemical properties of the agent e.g. susceptibility to 
thermal inactivation (Dickinson & Taylor, 1978). 
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Figure 4. Incubation period data from the different strains of scrapie in 
the three PrP genotypes of mice.  Incubation periods between intracerebral 
injection and the development of clinical disease for eight TSE strains in mice 
showing different incubation periods. All of these TSE strains had been 
propagated in mice of the PrPa genotype. Diagram from Bruce et.al 2003 
British Medical Bulletin. 
 
1.5.2 Incubation periods of disease 
 
The incubation period of TSEs is defined by the interval between initial infection of 
the host and the development of clinical signs of disease. Each murine scrapie strain, 
under standard conditions of dose, route of infection and mouse genotype, has a 
characteristic, highly reproducible pattern of incubation period (Figure 4). The major 
influence on the length of the incubation period is exerted by the sinc (scrapie 
incubation) gene. The action of the sinc gene was first described over 20 years ago 
(Dickinson et al, 1968), due to the fact that in any experimental rodent model, the 
period of time from infection to death was extremely predictable. The action of the 
sinc gene was first recognised in mice infected with the ME7 strain of scrapie. Two 
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alleles of this gene were identified, designated s7 and p7, which gave respectively, 
short or prolonged incubations periods with ME7. Later, it was shown that the sinc 
gene controlled the incubation period of all strains of scrapie.  Since these early 
studies further evidence has came to light that the host encoded protein PrP is the 
major gene involved in the control of scrapie pathogenesis. Mice with Sinc s7 and p7 
genotypes encoded PrPc proteins that differed at residues 108 and 189 of the Prnp 
gene. Gene targeting experiments have now proved that Sinc and Prnp are the same 
(Moore et al, 1998) and that PrPc is the product of sinc. This discovery and the 
importance of the Prnp gene and PrPc in TSE research has overshadowed Dickinson’s 
early work and usage of the sinc terminology is now obsolete. In current literature the 
sincs7 and p7 alleles are more commonly referred to as Prnpa and Prnpb , respectively. 
1.5.3 Vacuolar pathology and lesion profiles 
 
TSE strains can be distinguished on the pathological changes they produce in the 
brains of infected mice. The most obvious change observed in routine histological 
sections is a vacuolation of the neuropil.  This vacuolation appears as tiny holes in 
both the white and grey matter of the brain (Figure 1&2A). This vacuolar 
degeneration gave rise to the terminology spongiform degeneration or spongiosis,  
that describes the microscopic appearance but not the texture of the brain. 
Vacuolation of the brain is one of the classical lesions associated with TSE pathology.  
These vacuoles are defined as small round or oval empty spaces in the neuropil. 
Ultrastructural examination of vacuoles within brains of mice infected with the ME7 
strain of scrapie showed that they contained a limiting double membrane which 
showed protrusion or proliferation of the inner most lamella. Sometimes whorled 
membrane configurations were also seen. This vacuolation was observed in neuronal 
perikarya, myelinated fibres, dendrites and axonal presynaptic terminals (Jeffrey et al, 
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1991). It is suggested that some scrapie vacuoles arise as a result of incorporation of 
abnormal membrane into organelles, possibly mitochondria, in neuronal perikarya and 
neurites (Liberski et al, 2002a). Another suggestion is that the vacuoles may develop 
through the process of autophagy (see mechanisms of neuronal loss – autophagy) 
(Liberski, 2004). 
  TSE strains show dramatic and reproducible differences in the severity and 
distribution of this vacuolar degeneration in the brains of genetically uniform mice. 
This forms the basis of a semiquantitative method of strain discrimination in which 
the severity of pathology is scored from coded sections in nine grey matter and three 
white matter brain areas. Grey matter vacuolation is scored on a scale of 0-5 and 
white matter vacuolation is scored on a scale of 0-3, where 0 represents no lesion and 
5 the most severe (Bruce, 1996). The resulting lesion profile is formed by the line that 
joins the points of the average of the scores from the individual areas. Each 
combination of agent strain and mouse genotype has a characteristic lesion profile. 
This method of strain typing has been used at NPU for more than 30 years resulting in 
a ‘tried and tested’ reliable system. Using this methodology Bruce et.al showed that 
vCJD victims died from an agent that was indistinguishable from BSE (Figure 5) and 
concluded that the most likely scenario for developing the disease was from dietary 
exposure to BSE (Bruce et al, 1997). 
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Figure 5.  Comparison of lesion profiles in wild type mice infected with vCJD, 
sCJD and BSE. Lesion profiles for PrPa mice infected with vCJD from three patients 
and sCJD from two patients. In each case these are compared with the lesion profile 
for BSE in the same mouse strain. Lesion profiles constructed from the mean 
vacuolation scores in nine areas of the brain. BSE and vCJD profiles are almost 












1.5.4 PrPSc isoform analysis 
 
PrP is a host-encoded glycoprotein involved in the pathogenesis of TSEs. PrP has two 
N-glycosylation sites and can exist as mono, di or unglycosylated forms. PrPc is 
glycosylated at both sites but PrPSc varies in its degree of glycosolation, which can be 
influenced by the strain of TSE (Somerville et al, 1997). PrPSc may also vary 
independently in the amount and pattern of glycosylation in different brain regions.  
(Somerville,1999). PrPSc glycoform analysis has been used in the differential 
diagnosis of human TSEs. The biochemical characteristics of PrPSc were studied in 19 
cases of sCJD. Four groups of subjects defined by the genotype at codon 129 of the 
PRNP gene, and two types of protease-resistant PrPSc that differed in size and 
glycosylation were discovered. The four Creutzfeldt-Jakob disease groups showed 
distinct clinicopathological features that corresponded to previously described 
variants. The typical Creutzfeldt-Jakob disease phenotype or myoclonic variant and 
the Heidenhain variant were linked to methionine homozygosity at codon 129 and to 
"type 1" protease-resistant PrPSc. The atypical and rarer variants such as that with 
dementia of long duration, the ataxic variant, and the variant with kuru plaques were 
linked to different genotypes at codon 129 and shared the "type 2" protease-resistant 
PrPSc. (Parchi et al, 1996).  
The significance of PrP glycosolation and its role in TSE susceptibility and 
strain identification is not yet fully understood. Gene targeting studies using PrP 
glycosylation knockout mice infected with strains of TSE revealed that differences in 
host PrP glycosylation can alter TSE strain and disease targeting characteristics (Tuzi 
et al, 2008). Although this may be the case, glycoform analysis is not universally 
accepted as an ideal method to distinguish between strains. Differences in PrPSc 
glycoform ratios have been observed between CNS and lymphoid tissues from 
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infected individuals, between brain and spleen of scrapie infected mice (Rubenstein et 
al, 1991) and within brain and tonsil of vCJD patients (Hill et al, 1999b) This 
technique has been successfully used as a biochemical tool to differentiate sporadic 
from vCJD (Collinge et al, 1996) and to support the finding that BSE and vCJD (Hill 
et al, 1997) were due to the same agent strain, and can provide useful supporting data 
in strain-typing experiments.  
1.5.5 The 87V/VM and ME7/CV scrapie models 
 
The 87V/VM and ME7/CV combinations are two contrasting murine scrapie models 
which differ in their sequence of pathological hallmarks, incubation periods of disease 
and targeting of neuronal populations when infected by intracerebral (i.c.) inoculation. 
PrPSc in both models was located within neurons and the surrounding neuropil. 
Deposition of PrPSc in both models is targeted to the hippocampus, although to 
different neuronal populations (Figure 6B &7B) 
The VM mice (Prnpb) inoculated with the 87V agent of scrapie results in an 
incubation period of disease of approximately 320 days post injection (dpi).  
Pathology is targeted to the CA2 of the hippocampus, the dorsal lateral geniculate 
nucleus, and the thalamus. PrPSc is first detected in this model in the red nucleus of 
the medulla at 80dpi and is not detected in the hippocampus until 200dpi (Bruce et al, 
1989) (Figure 6B). This deposition is preceded by dendritic dysfunction, astrogliosis, 
vacuolation and neuronal damage (Belichenko et al, 2000; Jeffrey et al, 1994a). 
Dendritic abnormalities are observed at 70dpi and are restricted to the CA2 pyramidal 
neurons (Jamieson et al, 2001b). A common pathological feature observed in this 
model is the deposition of amyloid plaques within the hippocampus and cerebral 
cortex (Bruce et al, 1989). These plaques contain amyloid fibrils and are surrounded 
by microglia (Wisniewski et al, 1975). 
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The CVF1 cross (Prnpab) infected with the ME7 strain of scrapie results in 
consistently severe pathology of the hippocampus and an incubation period of 
approximately 250 days (Scott & Fraser, 1984). PrPSc deposition is widespread within 
the hippocampus (Figure 7B), whereas vacuolation and neuronal loss are specifically 
targeted to the CA1 of the hippocampus. At the terminal stage of disease, vacuolation, 
gliosis and diffuse granular deposits of PrPSc are widespread in all brain areas. Using 
immunohistochemistry,  PrPSc is first detected in the hippocampus at 70 dpi (Jeffrey et 
al, 2001), followed by vacuolation at 90 dpi. Infectivity in this model is detected at 50 
dpi, before the detection of PrPSc, this would suggest a lack of correlation between 
infectivity and PrPSc in this model. By 100 dpi astrogliosis is evident in the 
hippocampus and a decrease in long term potentiation is observed in CA1 neurons 
infected with ME7. Also observed at this time point is the loss of axon terminals and 
synapses from the dendrites of CA1 neurons (Jeffrey et al, 2000). This correlates with 
dendritic damage observed in these neurons; dendritic spine loss is detected at 100 
days, becoming marked by the terminal stage of disease (Brown et al, 2001). The few 
remaining neurons show a grossly altered morphology, with irregularly swollen 
dendrites containing varicosities (Belichenko et al, 2000). In contrast to the 87V/VM 
model PrPSc deposition in the form of plaques is rare. PrPSc deposition in the ME7/CV 
model can be seen in an aggregated fibrillar (Jeffrey et al, 2000) form or as a 
widespread diffuse labelling throughout the neuropil (Figure 7B). 
 Both these scrapie mouse models target the hippocampus, a brain structure in 
which neuronal connections have been well characterised (Freund, 2002), providing a 





           
         
Figure 6. 87V/VM scrapie mouse model :- neuropathological changes observed in 
the hippocampus of VM mice infected with 87V. A) haematoxylin and eosin 
staining showing vacuolation in the CA2 of the hippocampus. B) 6H4 labelling of 
PrPSc in the CA2 of the hippocampus. C) GFAP labelling of reactive astrocytes in the 
CA2 of the hippocampus. D) Iba1 labelling of microglia in the CA2 of the 







Figure 7.  ME7/CV scrapie mouse model :-neuropathological changes observed 
in the hippocampus of CV mice infected with ME7. A) Haematoxylin and eosin 
staining showing vacuolation in the neuropil of the hippocampus and neuronal loss in 
the CA1. B) 6H4 labelling of diffuse PrPSc in the CA1 of the hippocampus. C) GFAP 
labelling of reactive astrocytes  in the CA1 of the hippocampus. D) Iba1 labelling of 











1.6 Peripheral pathogenesis of TSE 
Introduction 
 
Although the ultimate target of TSE infection is the CNS, there is evidence that both 
the lymphoreticular system (LRS) and the peripheral nervous system (PNS) may be 
involved in the disease pathogenesis prior to CNS invasion. Initial studies in rodent 
models analysing the pathogenesis of the TSEs were performed using the 
intracerebral (ic) route of infection. This route is not a natural route of infection and it 
was soon recognised that more biologically relevant routes of infection should be 
examined i.e. oral and peripheral routes. The identity of the source and mode of 
transmission of many TSE diseases is unclear. However strong evidence indicates that 
BSE in cattle and vCJD and kuru in humans occurred through the oral route of 
transmission. Also transmission of TSEs via the skin (scarification) is known to be an 
effective route of peripheral transmission (Mohan et al, 2004; Mohan et al, 2005; 
Taylor et al, 1996). Following exposure, many of the acquired TSE agents accumulate 
in lymphoid tissues such as the spleen, lymph nodes, tonsil, appendix and Peyer’s 
patches before spreading to the CNS, a process termed neuroinvasion (Mabbott & 
MacPherson, 2006). This occurs in sheep with natural scrapie (van Keulen et al, 
1996), mule deer with CWD (Sigurdson et al, 1999), mink with TME (Hadlow et al, 
1987) and humans with vCJD (Hilton et al, 1998); (Hill et al, 1999b) 
1.6.1 The lymphoreticular system in TSE pathogenesis 
 
After oral or peripheral routes of infection, several TSE agents replicate in the LRS 
prior to neuroinvasion (Ehlers et al, 1984; Farquhar et al, 1994; Fraser, 1992; 
Kimberlin & Walker, 1979; Kimberlin & Walker, 1989; Kimberlin, 1988; Mabbott et 
al, 1998) (Figure 8). Early studies measuring infectivity levels after intraperitoneal 
(i/p) infection of mice with the Chandler strain (Eklund et al, 1967) or in natural 
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scrapie (Hadlow et al, 1982) showed that, outside the CNS, the highest titres of 
infectivity are found in the spleen and lymph nodes. During this period of infection 
there are no clinical signs of disease and detection of infectivity in the spleen precedes 
that of the CNS by many weeks or longer (Dickinson & Fraser, 1969; Dickinson et al, 
1975). Following splenectomy the incubation period of disease was extended, 
although this was dependent on route of infection, time of splenectomy (Fraser & 
Dickinson, 1978) and was strain and species dependent. Splenectomy had no effect on 
hamsters i/p infected with the 263K strain of scrapie (Kimberlin & Walker, 1989) 
Studies to identify which cell types in the LRS may play a role in the 
peripheral pathogenesis of TSE have demonstrated the importance of the follicular 
dendritic cell (FDC) (Figure 8). These cells are radiation resistant and support scrapie 
replication in the spleen of mice (Brown et al, 1999; Montrasio et al, 2000). They are 
non-lymphoid cells, which are found within germinal centres of secondary lymphoid 
follicles where they trap antigens in the form of antigen antibody complexes (Kosco 
et al, 1992). In mice, PrPc is expressed by  FDCs in both uninfected and TSE infected 
mice (McBride et al, 1992; Ritchie, 1999). These PrPc expressing FDCs may be key 
players in the mechanisms of peripheral infection but the uptake and transfer of the 
TSE agent by these cells, has still to be elucidated (Mabbott & MacPherson, 2006).  
Some TSEs do not appear to involve or depend on the peripheral lymphoid 
system for pathogenesis. In cattle experimentally inoculated with BSE, accumulation 
of PrPSc is observed in the tonsil and distal ileum (Terry et al, 2003), which contrasts 
with its abundant lymphoid-tissue distribution following transmission to humans 
(Wadsworth et al, 2001) and sheep (Foster et al, 2001; van Keulen et al, 2008).  Very 
low levels of PrPSc have been observed in the spleen in a minority of sCJD cases with 
a lengthy history (Glatzel et al, 2003). Involvement of the LRS is not observed in 
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humans suffering from iCJD (Head et al, 2004) or kuru (Brandner et al, 2008).  The 
lack of involvement of the LRS in kuru is consistent with the hypothesis that kuru 
originated from the chance consumption of an individual with sCJD (Alpers & Rail, 
1971). Although the transmission of kuru to humans is through the oral route, the 
peripheral pathogenesis resembles that of sCJD and not vCJD (Brandner et al, 2008), 
suggesting that the pathogenesis of vCJD may be determined by the strain type rather 






               
Figure 8. Route of TSE neuroinvasion following peripheral exposure. 1.  Natural 
TSE diseases are often acquired by peripheral exposure such as orally or through skin 
lesions. 2.  Following exposure the TSE agent often first accumulates in follicular 
dendritic cells (FDC) in local lymphoid tissue i.e. lymph node, Peyer’s patches and 
mesenteric lymph nodes. 3. shortly afterwards the TSE agent is disseminated to most 
other lymphoid tissues including the spleen. 4. After accumulating in FDCs the TSE 
agent infects the sympathetic nerves and fibres of the vagus nerve, and spread along 
these to the CNS. 5. Accumulation of the TSE agent (PrPSc) in the brain is 
accompanied by neurodegeneration and the death of the host.  Diagram from Mabbott 






1.6.2 Peripheral nervous system in TSE pathogenesis 
 
The involvement of the peripheral nervous system in the pathogenesis of TSEs was 
first demonstrated in experiments involving sciatic nerve transection. If the infectious 
agent was injected directly into nerves the extraneural involvement could be bypassed 
(Kimberlin et al, 1987; Kimberlin et al, 1983a; Kimberlin et al, 1983b; Kimberlin & 
Walker, 1980). Substantial amounts of infectivity have been found in a number of 
fore and hind limb peripheral nerves of scrapie infected sheep (Groschup et al, 1996). 
 Numerous findings indicate that after peripheral exposure, the peripheral 
nervous system plays an essential role in the spread of the agent to the brain and 
spinal cord. This holds true for scrapie in sheep (Groschup et al, 1996; van Keulen et 
al, 1996), experimental scrapie in mice (Fraser, 1982; Kimberlin, 1993; Kimberlin & 
Walker, 1982) and in hamsters (Baldauf et al, 1997; Beekes et al, 1996), as well as for 
experimental forms of CJD (Muramoto et al, 1993) and BSE (Wells et al, 1998) in 
animals. Studies in which the spatial-temporal course of replication of the infectious 
agent in parenterally infected mice and hamsters was investigated, showed that the 
infectious process spreads to the spinal cord at the thoracic level, and from there 
moves upwards into the brain (Kimberlin, 1993; Kimberlin et al, 1983b; Kimberlin & 
Walker, 1980; Kimberlin & Walker, 1982). In the 263K hamster model neuroinvasion 
appears to occur very rapidly, with extremely short incubation periods of 
approximately 65 days (Kimberlin & Walker, 1986).  
 How the infection reaches the CNS after oral infection with the scrapie agent 
has been systematically investigated in Syrian hamsters orally challenged with the 
263K strain of scrapie. On the basis of a close quantitative association of infectivity 
and PrPSc in this experimental model (Baldauf et al, 1997; Beekes et al, 1996), PrPSc 
was used as a biochemical marker for tracing the spread of infection through the body 
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in a time course study. In this study PrPSc accumulated in a defined temporal 
sequence, in sites that accurately reflected known autonomic and sensory relays. The 
infectious agent primarily uses synaptically linked autonomic ganglia and efferent 
fibers of the vagus and splanchnic nerves to invade the initial target sites in the brain 
and spinal cord (Beekes et al, 1996; Beekes & McBride, 2000; Beekes et al, 1998; 
McBride et al, 2001).  
 Both the parasympathetic and sympathetic nervous system seem to play an 
important role in the infectious spread of the agent from the gut to the CNS (Figure 
5). Studies in naturally occurring scrapie of sheep (van Keulen et al, 1996), in cattle 
BSE (Schulz-Schaeffer et al, 2000) and in CWD (Sigurdson et al, 1999; Williams, 
2000) of deer have confirmed experimentally established parasympathetic pathways 
of infection.  
 Although most studies suggest that the spread of infection from peripheral 
sites to the brain occurs primarily along neural routes, haematogenous spread may 
also occur in TSE infection. Infectivity in the blood of hamsters i/p infected with the 
263K strain of scrapie could be detected for 40 days after infection (Diringer, 1984). 
This hamster model has been used successfully in experimental studies of infectivity 
through blood transfusion, and hamster blood has been shown to be a good substitute 
for human blood for investigations of the component distribution of TSE infectivity in 
blood (Brown et al, 1998; Elliott et al, 2005). Infectivity has also been efficiently 
transmitted by blood transfusion in sheep. Both BSE and scrapie had unexpectedly 
high transmission rates (Houston et al, 2008; Hunter et al, 2002). Also the 
neuropathological phenotype of experimental ovine BSE was maintained after blood 
transfusion (Siso et al, 2006), suggesting that a change in the pathologic phenotype of 
vCJD would not be expected as a result of exposure to infected blood. Sheep blood 
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would be a more realistic substitute for human blood for investigations of the 
component distribution of TSE infectivity in blood.     
1.6.3 The CNS and TSE pathogenesis 
 
The CNS is the ultimate target for TSE infection. The characteristic  
neuropathological changes observed in the brain include vacuolation, gliosis, 
accumulation of PrPSc and neuronal loss.  Neuronal loss is not due solely to 
differences in the susceptibility of different subsets of neurons to the disease process, 
but is influenced by the agent strain and the host genotype (Bruce, 1976). For 
example, in the ME7/CV model used in these studies, infection of CVF1 mice, an F1 
cross between C57BL (Prnpa) and VM (Prnpb) mice, with the ME7 strain of scrapie 
produces severe pathology in the pyramidal cell layer of the CA1 sector of the 
hippocampus (Scott & Fraser, 1984). This pathology is not observed in the VM 
mouse strain when challenged with ME7. 
Although neuronal loss is a classic feature of TSEs, the cellular pathways 
leading to this are still unclear. There are three mechanisms by which neurons may 
die: autophagy, necrosis and apoptosis. Apoptosis has become the most popular 
concept of cell death in neurodegeneration, and there is considerable evidence 
supporting a role for this type of cell death in TSEs (Giese et al, 1995; Gray et al, 
1999; Lucassen et al, 1995; Williams et al, 1997a). Mechanisms of neuronal loss and 
their role in TSE-induced neurodegeneration are discussed below in section 1.7. The 
role that apoptosis plays in the neuronal loss is investigated further in Chapter 4.   
 It seems obvious that neuronal dysfunction must lie at the root of clinical 
disease, yet the extent and progression of neurodegeneration, and its relationship with 
the other pathological processes are not yet known. Using the ME7/CV scrapie mouse 
 45
model the relationship between neuronal loss, vacuolation, gliosis and the deposition 
of PrPSc in TSEs will be investigated. This is discussed fully in Chapter 3.  
1.7 Mechanisms of neuronal loss 
1.7.1 Autophagy 
 
One of the suggested mechanisms of neuronal cell death in TSEs is autophagy. 
Cellular autophagy is a physiological degradative process involved, like apoptosis, in 
embryonic growth and development, cellular remodelling and the biogenesis of some 
subcellular organelles (Filonova et al, 2000; Hariri et al, 2000; Sattler & Mayer, 
2000). Nascent immature autophagic vacuoles coalesce with lysosomes to form 
degradive autophagic vacuoles (Figure 9). Electron microscopy techniques revealed 
that these vacuoles were composed of areas of the cytoplasm sequestered with single, 
double or multiple membranes originated from the endoplasmic reticulum. 
Sequestered cytoplasm contained ribosomes, occasionally mitochondria, small 
secondary vacuoles with vesicles, or had a homogenously dense appearance (Liberski 
et al, 2002b; Liberski et al, 2004). Autophagy may co-exist with apoptosis or may 
precede it and the process may be induced by apoptotic stimuli (Xue et al, 1999). 
Autophagy has been observed in CJD and animal models of TSE. In CJD, autophagic 
vacuoles were formed within synapses and may contribute to the synaptic loss 
observed in brains affected in TSEs (Sikorska et al, 2004). These autophagic vacuoles 
were also observed in CJD and scrapie infected rodent brains (Boellaard et al, 1991; 
Boellaard et al, 1989; Liberski et al, 2002a). Although there is strong evidence that 
autophagy is a common ultrastructural feature of TSEs, it is still unclear how the 
autophagy contributes to the overall pathology and, especially, to the neuronal loss 
underlying TSE diseases.  
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Figure 9. Autophagic neuron. Many characteristic autophagic vacuoles observed 
within an autophagic neuron of a hamster brain infected with the 263K strain of 
scrapie. Some vacuoles have single membranes and others are surrounded by double 
membranes. Image from Liberski et.al. Acta. Neuropathol. 2002  
   
1.7.2 Necrosis 
 
When stressed beyond their tolerance cells undergo necrosis, an acute, non-apoptotic 
form of cell death. A wide range of factors can trigger necrotic cell death. Both 
extrinsic and intrinsic signals can initiate necrotic cell death; for example, hostile 
environmental conditions or mutated genes (Walker et al, 1988). Acute energy 
depletion is one of the most potent necrosis-triggering conditions in neurons 
(Ankarcrona et al, 1995; Leist et al, 1997). Energy depletion can rapidly develop 
during ischaemic or hypoglycaemic episodes.  Cells undergoing necrosis display 
gross morphological and ultra structural features that contrast sharply with those 
exhibited by cells undergoing apoptosis. Death is accompanied by extensive swelling 
of the cell, distension of various cellular organelles, clumping and random 
degradation of nuclear DNA, extensive plasma membrane endocytosis and autophagy 
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(Figure 10) (Ferri & Kroemer, 2001; Hall et al, 1997; Syntichaki & Tavernarakis, 
2002). 
Neurodegenerative disorders such as Alzheimer’s, Parkinson’s, Huntington’s, 
motor neuron and prion diseases all share a conspicuous common feature: aggregation 
and deposition of abnormal proteins in the brain (although the nature and site of 
deposition of these abnormal proteins varies according to the disease). Neurons are 
particularly vulnerable to the toxic effects of mutant or misfolded proteins (Taylor et 
al, 2002) ; these toxic effects may contribute to the neuronal cell death observed in 
these diseases which may be a combination of apoptosis and necrosis (Martin, 1999; 
Martin, 2001). There is little evidence in the literature about the involvement of 
necrosis in TSE diseases. In one study were hamsters were treated with the 139H 
strain of scrapie, these animals developed a generalized endocrinopathy, including 
lesions in the hypothalamus, pituitary and pancreas. Further observations using EM 
techniques revealed that the cellular death observed in the islets of Langerhans in 
139H infected hamsters was due to necrosis (Ye et al, 1997). The role of necrosis in 
the neuronal cell death observed in TSE diseases is still unclear, evidence so far for its 
involvement in the disease indicates that it may not play an important role in the cell 
death observed in these diseases.  
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Figure 10. Necrotic neuron. Neuron observed in the advanced stages of ischemia 
showing swelling of the cell, clumping and random degradation of nuclear DNA,  
extensive plasma membrane endocytosis. Vacuoles within the cytoplasm represent 
dilated cisternae and vesicles of smooth and granular endoplasmic reticulum and the 
remains of swollen mitochondria. Image from Greenfield’s Neuropathology, third 




Apoptosis is a programmed cell death regulated by a series of events. It is essential for 
cell development, maturation, normal tissue turnover and regulation of immune 
systems (Wyllie et al, 1980). The identification of apoptotic cells is based upon the 
morphological detection of cellular and nuclear membrane shrinkage, condensation 
and fragmentation of nuclear chromatin (Figure 11), and biochemically by 
endonuclease-mediated internucleosomal fragmentation of DNA into multiple 
oligosomal sub-units of 180 bp (DNA laddering). Apoptosis can be induced by cell 
surface receptor engagement, growth factor withdrawal, and DNA damage triggered 
by toxic compounds and exposure to γ– and UV-irradiation. The involvement of 
apoptosis in the neuronal cell death observed in TSE diseases has been well 
documented, although the exact mechanisms in which this occurs is still not fully 
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understood. In vitro studies using the toxic peptide PrP 106-126 in cell culture have 
shown the upregulation of pro-apoptotic markers of disease i.e. caspase-3, 6 and 8 
(White et al, 2001) and the induction of multiple transduction pathways such as the 
JNK c-jun pathway (Carimalo et al, 2005), P38 MAP Kinase (Corsaro et al, 2003) and 
the glycogen synthase kinase pathway (Perez et al, 2003), which lead to apoptotic cell 
death, and may be involved in prion induced neurodegeneration. In vivo, neuronal 
apoptosis has been observed in scrapie mouse models of disease (Giese et al, 1995; 
Lucassen et al, 1995; Siso et al, 2002; Williams et al, 1997a), in sheep infected with 
scrapie (Fairbairn et al, 1994) and humans affected by CJD (Ferrer, 2002).  
Several families of proteins and specific biochemical signal transduction 
pathways regulate cell death. Caspases are a family of proteins involved in apoptosis 
that will be discussed further in Chapter 4, along with their role in the caspase 
dependent pathway of apoptosis.  
 
 
Figure 11. Apoptotic neuron. Apoptotic neuron from the brain of an ME7 terminally 
infected CV mouse. Showing the characteristic chromatin clumping within the 
nucleus and blebbing of the cell membrane. Image courtesy of Dr Martin Jeffrey 
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1.8 Aims of this study 
Neuronal loss is one of the characteristic neuropathological features observed in TSE 
induced neruodegeneration, the mechanisms leading to the death of these neurons is 
not yet fully elucidated. The aims of this study are to investigate the fundamental 
mechanisms of neurodegeneration in the TSEs. Using murine scrapie models of 
disease, the relationship of neuronal loss with the deposition of PrPSc, gliosis and 
synapse loss will be investigated. Considerable evidence in the literature suggests that 
neuronal cell death in TSEs occurs through an apoptotic mechanism, although the 
trigger for this event is unknown. In this thesis the role of apoptosis and the caspase-
dependent pathway in the neuronal cell death observed in TSEs will be investigated.  
 The relationship between the pathological changes occurring in the brain and 
the development of clinical disease in the TSEs is not known ; however any strategy 
aimed at intervening to halt the degenerative process must be aimed at the 
fundamental lesion and not its sequelae.  
Therefore the specific aims of this thesis are to : 
• Perform a time course study of the neuropathological changes observed in the 
hippocampus of the ME7/CV scrapie mouse model and to identify at which 
time point in the progression of the disease, these changes initially occur. 
• Identify the relationship between these neuropathological changes and the loss 
of CA1 neurons observed in the hippocampus. 
• Establish whether apoptotic mechanisms play a role in the neuronal cell death 
observed in the CA1 sector of the hippocampus. 
•  Investigate the role of the neuronal cytoskeleton and synaptic changes in the 
neuronal damage observed in the CA1 sector of the hippocampus, and to 
establish their relationship with the subsequent neuronal loss.   
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Chapter 2 : Materials and methods 
 
 
2.1 Experimental animal procedures 
 
2.1.1 Experimental animal groups and murine strain combinations 
 
Animals were taken from the specified pathogen free colony maintained at the 
Neuropathogenesis Unit. Animal related procedures comply with the Animals 
(scientific) Act of 1986 in accordance with Home Office regulations. The two inbred 
mouse strains intracerebrally (ic) inoculated in these experiments were the VM/Dk 
(VM, Prnpb genotype) inoculated with the 87V murine scrapie strain (87V/VM 
model), and the F1 cross between C57BL/Dk and VM/Dk (CV, Prnpab genotype), 
inoculated with the ME7 murine scrapie strain (ME7/CV model).  For the ME7/CV 
model a serial kill study was also set up were brains were taken at intervals as 
described in table 1 below. The incubation period and neuropathological details of 
these mouse and scrapie strain combinations have been detailed in chapter 1 section 
1.5.5.  
 
      Dpi    ME7       NB 
        69       4         3 
      102       4         3 
      130       4         3 
      160       4         3 
      200       4         3 
     term       4         3 
    
          Table 1.  ME7/CV serial kill time points taken and numbers of animals 
                          analysed.  Dpi = days post injection, ME7= ME7 infected brains, 
                          NB= normal brain injected controls 
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2.1.2 Scrapie inoculation and tissue collection procedures 
Inoculum for injection was prepared from the brains of animals which had reached the 
terminal stages of disease. Brains were removed using aseptic techniques and stored 
at -20oC, or below, until required. Mice under halothane anaesthesia were injected by 
intracerebral inoculation into the right frontal cortex with a 25 gauge needle fitted 
with a 2mm needle guard to prevent penetration of the needle beyond the outer 
cortical layers. Mice were inoculated with 20μl of 1% brain homogenates prepared in 
0.9% sterile saline. Cohorts of control animals were inoculated with equivalent 
volumes of normal brain homogenates. Mice in these experiments were inoculated by 
the trained staff of the animal facility.  
2.1.3 Mouse brain collection 
All experimental animals were culled by cervical dislocation by the experienced staff 
of the animal handling facility. Brains for histopathological anlaysis were removed 
and placed into formol saline, fixed for 48 hours, then trimmed as Figure 1 below and 
processed through to paraffin wax. Brains for biochemical analysis (western blot) 
were snap frozen in liquid nitrogen and stored in the -70oC freezer. Brains for FACS 
analysis were taken fresh into Hanks balanced salt solution and prepared as FACS 
method in appendix 3. 
2.2 Histopathological techniques 
2.2.1 processing of tissue for pathological analysis 
Mouse brains were processed for pathological analysis as shown below in Figure 1 
The hippocampal block was the main area analysed in this study as the pathology 
observed in both the 87V/VM and the ME7/CV mouse models targeted the 
hippocampus. In the ME7/CV mouse model neuronal loss was targeted to the CA1 
sector of the hippocampus. In the 87V/VM mouse model neuropathological changes 
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were targeted specifically to the CA2 sector of the hippocampus. A diagram showing 
the main areas of the hippocampus analysed is shown below (Figure 2).  
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Figure 1. Mouse brain sectioning levels for immunohistochemistry and 
Haematoxylin and Eosin staining 
Brains are cut coronally and sectioned at the 5 levels used routinely for 





          
Figure 2. Diagram of the mouse hippocampus. Haematoxylin and Eosin stained 
hippocampus section showing main areas analysed.  PCL – pyramidal cell layer, 
CA1- CA1 sector of the pyramidal cell layer,  SO – stratum oriens, SR- stratium 
radiatum, CC- corpus collosum,  CA2 – CA2 sector of the pyramidal cell layer       
CA3 – CA3 sector of the pyramidal cell layer, DG – dentate gyrus. Magnification x4  
 
2.2.2 Immunohistochemical analysis of paraffin-embedded samples 
Paraffin-embedded 6µm tissue sections were hydrated by passage through alcohols to 
water prior to immunocytochemical analysis. A generic immunocytochemical method 
was used as per appendix 1 and a list of antibodies used plus pretreatments required 
can be found in table 1.2  in appendix 1. To analyse vacuolation and neuronal loss 
haematoxylin and eosin labelling was performed using a Leica autostainer. 
The serial kill time points taken (table 1.) were chosen in line with previous 
results using the ME7/CV scrapie mouse model. The first time point of 69 days was 
chosen because previous experiments had suggested that this was the earliest time 
point at which PrPSc could be detected. The other time points were evenly distributed 
throughout the incubation period of disease. Incubation period data from the mice at 
the terminal stage of disease in this experiment were at approximately 240dpi., 









performed analysing the four infected and three normal brain controls in each time 
point.   Three normal brain control section were included at every time point but only 
one example from a single time point is shown in the immunolabelling figures. A 
table of all antibodies used, pretreatments required and source can be found in 
appendix 1. 
In these studies IHC analysis had its limitations. This methodology has been 
used successfully for years as a technique to analyse the characteristic 
neuropathological changes observed in the brains of both animals and humans with 
TSE disease. In this case IHC is a useful tool used in both research and the diagnosis 
of TSEs.  In the apoptosis studies performed in this thesis IHC was used to analyse 
which brain areas and cells were involved in TSE induced cell death.  Western blot 
analysis was also used as a confirmatory tool in some of these studies. In the 
cytoskeletal and synapse studies IHC was used in serial kill studies to identify at 
which time point throughout the course of disease that cytoskeletal changes and 
synapse loss is first observed.  In the cytoskeletal studies IHC was not sensitive 
enough to pick up the early cytoskeletal changes observed with the lucifer yellow 
studies i.e. dendritic spine loss observed at 109 days post infection. Therefore the 
Lucifer yellow microinjection technique was a more appropriate technique to use in 
order to identify subtle changes in dendritic spine loss.  
2.2.3 Analysis of vacuolation and neuronal loss 
6μm paraffin sections were stained with Haematoxylin and Eosin using the Leica 
Autostainer.  Vacuolation was analysed using the Nikon E800 microscope. Neuronal 
loss was quantified using image pro plus software. Neuronal cell numbers were 
counted in single sections from two serial kill time points in the ME7/CV scrapie 
mouse model; 160dpi and 200dpi. Two measurement tools were used within the 
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image pro plus software; the trace tool was used to measure the length of each CA1, 
and the tag point tool was used to count the neuronal cell bodies (Figure 3). All data is 
then exported to Excel for analysis 
                  
 
 
Figure 3.  Neuronal counts and image pro-plus Image showing how both 
measurement tools within the image pro-plus software where used to analyse the 
length of the CA1 and perform neuronal counts. The trace is performed first and then 
removed from the image and then neuronal cell bodies are counted using the tag point 
technique. 
 
2.2.4 Thioflavin labelling of amyloid plaques 
 
Thioflavin S (Sigma) labelling was performed to identify if the plaque like deposits 
observed in the ME7/CV scrapie mouse model contained amyloid. 6μm paraffin 
sections were dewaxed and taken down to water. Sections were counterstained with 
haematoxylin prior to Thioflavin S staining, 1minute in haematoxylin solution 
followed by 30 seconds in Scotts tap water.  Sections were washed in running tap 
water then stained with 1% Thioflavin S solution made up in distilled water for 5 
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minutes. Sections were then quickly taken through three changes of 70% alcohol, 
washed in running tap water then mounted in aquamount (Dako).   
 Thioflavin staining was imaged using a Nikon E800 microscope attached to a 
Hamamatsu fluorescent camera.  
 
2.3 Western blot analysis of murine brain samples 
2.3.1 Sample preparation 
2.3.1.1 87V/VM whole brain sample preparation  
A 10% homogenate was prepared in Tris lysis buffer (Appendix 2) and total protein 
analysed (section 3.3.3.5). Samples were diluted in x1 sample buffer to contain 10,5 
and 2.5mg/ml of total protein per 20μls of sample. Immediately prior to running gel  
2μls sample reducing agent was added, vortexed and denatured at 98oC for 5 mins and 
spun at 120g for 5 mins. Continued with generic western method in Appendix 2. 
2.3.1.2 Micro-dissection of mouse hippocampus  
The micro-dissection procedure for obtaining the hippocampal samples was 
performed following a published protocol (Barr et al, 2004). Briefly brains were 
removed from -700C storage and allowed to partially thaw on -200C cold plate. Each 
brain was cut using disposable scalpel blades (Swann Norton No 11) at the level of 
the hippocampus (Figure 1). The hippocampus was excised using a punch technique 
involving the hollow cannula of a biopsy needle (Scottish Medical) (Figure 4). 
Several punches were required to remove each hippocampi, and tissue was expelled 
into an eppendorf tube from the cannula using an empty 5ml syringe attached at one 













Figure 4. Micro-dissection of hippocampus for western blot analysis 
Frozen (-700C) mouse brains are thawed on a -200C cold plate and cut at the level of 
the hippocampus (Figure 3). A hollow bore of a biopsy needle was used to gently 
collect both hippocampi (green circles). 
 
2.3.1.3 Sample preparation of dissected hippocampus  
 A 10% homogenate was prepared in Tris lysate buffer. If subcellular fractionation 
required, tissue was lysed in sample buffer 1 using a proteome extraction kit 
(Calbiochem), continued with sub-cellular separation of cytosol, nuclear, organelle 
and cytoskeletal fractions (section 2.3.2). Total protein analysis of samples was 
performed, where necessary samples were concentrated using a methanol 
precipitation technique. To methanol precipitate samples, a x4 volume of ice-cold 
methanol/2% acetic acid was added to each sample, the tube was gently inverted 
twice and precipitated overnight at -20oC. Samples were centrifuged at 16,000g for 10 
minutes, methanol/2% acetic acid supernatants were carefully removed and the 
protein pellet dried for up to 2 hours in a centrifugal vacuum concentrator (Therm 
Savant Speed-Vac). Dried samples were each re-suspended in 20μl 1x sample buffer, 
sample-reducing agent added at 1x, and samples gently vortexed. Samples were 
heated at 98oC for 5 minutes prior to SDS-PAGE. 
 
2.3.2 Subcellular fractionation  
Subcellular fractionation was performed using the ProteoExtract subcellular proteome 
extraction kit (Calbiochem). Briefly, extraction buffers I-IV and centrifugation steps 
are used sequentially to isolate the four cell fractions. I- cytosolic, II – 
membrane/organelle, III – nucleic protein and IV – cytoskeletal matrix , from 
dissected hippocampus. The four subcellular fractions were stored in a -70oC freezer 
and protein estimations performed on each sample. 
2.3.3 BCA total protein determination assay 
Total protein estimation was determined using the microplate protocol of the 
bicinchoninic acid (BCA) assay (Pierce). This assay uses BCA to detect cuprous ions 
generated from cupric ions by reaction with protein in the samples under alkaline 
conditions. Bovine serum albumin (BSA) standards (Pierce) and samples to be 
analysed were diluted in the lysis buffer used to produce the original tissue 
homogenate. BSA standards were prepared (1500μg/ml, 1000μg/ml, 750μg/ml, 
250μg/ml, 100μg/ml and 50μg/ml) and samples to be analysed were diluted in the 
ratio of 1:5 and 1:10 to calculate the total protein content in each sample as derived 
from the standard curve. 25μl of each standard and diluted sample were added in 
duplicate to wells of a 96 well microplate. 200μl of BCA working solution was added 
to plate and also used as a blank. Microplate was incubated at 37oC for 30mins and 
absorbance values at 570nm were read and analysed on a V-max microplate reader 
(Molecular devices). Protein concentrations for each sample were derived from the 





2.3.4 Western blot procedure 
All biological reagents and experimental equipment were purchased from invitrogen, 
unless otherwise stated. Proteins were transferred from 4-12% Bis-Tris gels to 
polyvinylidine difluoride (PVDF) membranes using the Novex Transblot module; 
3MM filter paper and PVDF membranes were purchased pre-cut.  PVDF membranes 
were blocked with 20ml 3% non-fat dried milk (Upstate) in TBS for 2 hours prior to 
incubation with primary antibody of choice (Appendix 2 table 2.2.). PVDF 
membranes were then incubated overnight at 4oC in 20ml of antibody solution in 
freshly prepared 3% non-fat dried milk in TBS. Rest of method as Appendix 2. 
 Western blot analysis has its limitations it can be used semi-quantitatively to 
analyse the expression of proteins within specific brain areas and can inform on 
expression levels and up or down regulation of specific proteins. This technique 
cannot identify specific cell types involved and is therefore normally backed up by 
IHC analysis in brain sections.    
2.4  Fluorescent activated cell sorter (FACS) analysis 
FACS analysis as a tool to analyse cells in the CNS is predominantly used in in vitro 
cell culture systems. This study was set up to determine whether FACS analysis could 
be used successfully ex vivo and also to establish if it could be used to analyse 
apoptotic cell loss. The initial pilot study was set up to analyse microglial cells within 
the mouse brain. As there is a marked upregulation of microglia in the ME7/CV 
scrapie mouse model at the terminal stage of disease this was an ideal candidate cell 
to initially use to test the suitability of the method. 
FACS analysis was performed on brain tissue using a method adapted from 
one used for analysis of spleen tissue. Briefly brains were removed and placed into 
growth medium without buffers, RPMI or HBSS can be used. Brains were dissected 
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into three parts: frontal lobe, mid and hind brain. Single cell suspension was prepared 
for each sample as protocol in Appendix 3.   
2.4.1 Cell viability 
One ME7 infected and one NB control (CV mouse) were analysed. Brains were 
dissected into three parts as above, and single cell suspensions prepared. Cell viability 
was analysed by using both trypan blue and FACS analysis. A one in four dilution of 
the cells was prepared in trypan blue and cells analysed and counted. Cell suspension 
was made up to a 1x106 dilution for FACS analysis. Cells were then put through the 
FACS machine without any markers to analyse numbers of cells viable in solution. 
(Results in chapter 4). 
2.4.2 Microglial study 
One ME7 infected and one NB control (CV mouse) were analysed. Brains were 
dissected into three parts, as above and single cell suspensions prepared. Cells were 
labelled with F4/80 conjugated to FITC and FACS analysis performed. F4/80 is a 
mouse macrophage marker that is expressed on microglia.  
2.4.3 Neuron study 
 
One normal mouse brain was taken and a single cell suspension was prepared.  One 
step was added to this methodology, as the cells seemed to be prone to clumping. The 
brain was crudely dissected and placed into dissociation medium in the incubator at 
37o C for 30mins. At 15 mins the pieces of brain were disaggregated by sucking them 
up through a syringe and placing the suspension back into the incubator for 15mins. 
The rest of the method as in Appendix 3 was followed. Neurons were identified using 
the NeuN antibody conjugated to Alexa 488 at 1/100. NeuN is a neuron specific 
nuclear protein observed in CNS and PNS neurons.  
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 A cytospin preparation was made from cells labelled with NeuN conjugated to 
Alexa 488. A cell suspension containing 1x106 cells was spun in the cytospin 
centrifuge (Shandon). These cells where analysed using the Zeiss pascal 5 confocal 
microscope. Single scanned images were produced using an Argon 488 laser and an 
FITC filter. Images were prepared from the cytospin preparations at x20 and x60 oil 
magnification.  
In these studies FACS analysis had its limitations. The technique was applied 
successfully to the analysis of microglia and could be used in the future in time course 
studies to investigate the timing of the microglial response in TSE infected mouse 
brains. On the other hand FACS may not be the method of choice for analysis of 
neurons ex vivo. Neurons seemed to be more prone to clumping and have a complex 
morphology, the crude FACS methodology may sheer of their dendrites and axons 
which may initiate cell death. This could make it impossible to distinguish between 
cell death due to the disease or that produced in the preparation of the single cell 





















Chapter 3: Time course study of the neuropathological 
 changes observed in the hippocampus of the 
 ME7/CV scrapie mouse model 
 
 
3.1 Introduction  
 
TSE diseases of animal and man cause a progressive degeneration of the central 
nervous system (CNS) that is eventually fatal. Neuropathological changes 
characteristic of these diseases include vacuolation, gliosis, accumulation of the 
disease specific form of the normal cell-surface sialoglycoprotein, PrP and neuronal 
loss. Much of our understanding of the TSEs has come from the study of murine 
scrapie models. The strain of scrapie and the strain of mouse infected produces 
distinct patterns of disease (Bruce & Fraser, 1991). Vacuolation of the brain also 
known as spongiform change is one of the classical lesions associated with TSE 
pathology. It appears as tiny holes in the neuropil of the grey matter and can also be 
observed within the cytoplasm of neurons (Fraser, 1993). TSE strains show dramatic 
and reproducible differences in the severity and distribution of this vacuolar 
degeneration in the brains of genetically uniform mice (Fraser & Dickinson, 1967). 
This pathological feature has been historically used as a method of strain typing and is 
discussed in chapter 1.  
  Another characteristic pathological features observed in these mouse models 
of disease is the deposition of disease specific PrP (PrPSc).  PrP is a normal cellular 
membrane-bound sialoglycoprotein (PrPc), which when converted to its abnormal 
form (PrPSc), undergoes a conformational change to a predominantly β-pleated 
structure. Ultrastructural studies have shown that it is localized to amyloid fibrils, 
accumulates on the plasmalema of neurite membranes and coincided with intense 
vacuolation of the neuropil (Ersdal et al, 2004; Jeffrey et al, 1994b). Visualised 
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immunohistochemically, PrPSc deposition in the TSE infected brain takes several 
different forms: amyloid plaques, fine granular or synaptic deposits, and coarser 
deposits including perineuronal and perivacuolar forms (Bruce et al, 1989). 
Experimental studies in scrapie mouse models have revealed that the pattern of PrP 
deposition within the brain depends on the strain of agent used, route of injection and 
the mouse genotype (Bruce et al, 1989) (Figure 1). The isolation of PrP allows for the 
production of many PrP epitope specific antibodies and with the developing technique 
of immunohistochemistry, can be used as a diagnostic tool and to define phenotypes. 
Several PrP antibodies are available from a number of donor species that recognise 
the full length protein or that recognise different epitopes on the PrP molecule. The 
mouse monoclonal antibody used in this study, 6H4, recognises the epitope 
DWEDRYYRE (amino acids 143-151) and has been used successfully to 
immunolabel PrPSc in the brains of mice infected with scrapie (Jamieson et al, 2001b; 
Liu et al, 2003). The diagnosis of scrapie strains is usually performed using a scoring 
system for vacuolation observed in specific areas of the mouse brain (lesion profile).   
One of the other pathological features observed in mouse models of TSE is 
glial activation. The gliosis observed in TSE infected brains involves a lesion-related 
increase in size and number of astrocytes and microglia (Figure 2). Glial activation 
within the brain can occur generally in response to neurological disease or trauma and 
is not a specific indicator of TSE disease. However the role of the glial response in the 
development of TSE disease in the brain is still to be elucidated. Although there is no 
evidence for a classical immune response in the CNS in TSEs, microglial activation 
and recruitment of CD8 T cells has been shown to occur early in the incubation period 
(Betmouni et al, 1996). There is a marked activation of both microglia and astrocytes 
observed in the brains of both humans and animals at the terminal stage of TSE 
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disease (Rezaie & Lantos, 2001). This activation parallels the temporal and spatial 
patterns of PrPSc deposition, precedes neuronal cell death in vivo and displays 
characteristic patterns in different models of CJD (Baker et al, 1999; Giese et al, 
1998). Studies in mouse models of disease have shown that microglial activation 
correlates with the accumulation of disease specific PrP (Williams et al, 1997a; 
Williams et al, 1997b; Williams et al, 1994).  Microglial processes have been 
observed around vacuoles and at the periphery of amyloid plaques (Wisniewski et al, 
1990), it is not yet known if microglia are involved in the formation or phagocytosis 
of amyloid fibrils. In both in vivo and in vitro studies, activated microglia have been 
shown to be neurotoxic, secreting potentially harmful mediators such as nitric oxide, 
reactive oxygen intermediates, excitatory amino acids, proteases, chemokines and 
cytokines, exacerbating the damage observed in TSE disease (Burwinkel et al, 2004; 

















Figure 1. Pattern of disease specific PrPSc in two scrapie mouse models (A) 
ME7/CV : the deposition of PrP in the brain is diffuse, targeting the hippocampus 
(Hip), thalamus (Th) and cortex (Ctx) and (B) 87V/VM : diffuse accumulations are 
observed in the thalamus (Th) and also precisely targeted to the CA2 of the 
hippocampus. Plaques are also typically numerous with this strain, observed 






 Figure 2. 87V/VM scrapie mouse model :-   targeting of the glial response in the 
CA2 of the hippocampus in VM mice infected with the 87V strain of scrapie.  
(A) GFAP labelling of reactive astrocytes in the CA2 of the hippocampus.  




Reactive astrocytosis observed in prion diseases is most apparent in areas where 
severe spongiform change and neuronal loss occur.  Reactive astrocytes are also 
closely associated with the deposition of PrPSc (Bruce et al, 1994), which has been 
shown to accumulate within astrocytes in both mouse and hamster models of scrapie 
(Diedrich et al, 1991; Ye et al, 1998)  This is not always the case and depends on the 
TSE model studied. In C57BL and CV mice infected with vCJD, the pattern of 
astrocytosis within the hippocampus differed from the distribution of PrPSc (Brown et 
al, 2003b) 
In the past, the neuronal network was considered the most important system in 
the brain, and astrocytes were looked upon as “gap fillers”. Now they are thought to 
play a number of active roles in the brain including structural and metabolic support, 
transmitter reuptake and release, regulation of ion concentration in the extracellular 
space, modulation of synaptic transmission, vasomodulation and nervous system 
repair (Farfara et al, 2008; Gibbs et al, 2008; Schwab & McGeer, 2008; Taber & 
Hurley, 2008). 
The exact role of astrocytes in the propagation and pathogenesis of the TSE 
agent is still uncertain. In the model studied here astrocytosis and microglial 
activation occurs after the deposition of PrPSc which may be the trigger for this glial 
response. 
Neuronal loss is another characteristic hallmark of TSE disease. Neuronal loss 
has been identified and quantified in BSE infected cattle. The vestibular nuclei from 
BSE cattle had an approximately 50% reduction in total numbers of neurons when 
compared with controls (Jeffrey et al, 1992a). Neuronal loss has also been observed in 
scrapie mouse models of disease, in an intra-ocularly infected murine scrapie model a 
significant loss of neurons in the dorsal lateral geniculate nucleus (dLGN) was 
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observed (Jeffrey et al, 1995a).  In the model used in this study, the ME7/CV mouse 
model, neuronal loss was observed in the CA1 of the hippocampus, in this model 50% 
of neurons died by day 160 of a 250 day incubation period. Murine scrapie models 
target many different brain areas but due to the well characterised nature of the 
neuronal connections of the hippocampus, a large quantity of research has 
concentrated on the effects of these strains on this area. The targeted neuronal loss 
observed in the CA1 field of the hippocampus in the ME7/CV scrapie mouse model 
makes it an ideal model to study the mechanisms involved in the neuronal loss 
observed in TSEs. 
The ME7/CV mouse model was used in these studies. The CVF1 
(C57BLxVM) cross (Prnpab) intracerebrally infected with the ME7 strain of scrapie 
results in consistently severe pathology of the hippocampus and an incubation period 
of approximately 250 days (Scott & Fraser, 1984). Previous studies performed using 
this mouse model observed early changes in CA1 neurons of the hippocampus. At 100 
days post infection synapse loss, axon terminal degeneration was observed (Jeffrey et 
al, 2000), and the ability of these neurons to maintain LTP was disrupted (Johnston et 
al, 1998b). Also observed at this time point was the loss of dendritic spines from the 
apical dendrites of CA1 neurons (Brown et al, 2001).  
The relationship between pathological changes and the development of 
clinical disease in the TSEs is not known; however any strategy aimed at intervening 
to halt the degenerative process must be aimed at the fundamental lesion and not at its 
sequelae. Previous studies on specific aspects of the neuropathological changes 
observed in the ME7/CV scrapie mouse model have been performed. For the first 
time all of the characteristic neuropathological changes observed in this model have 
been analysed and compared in a single study. The time course study performed in 
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this thesis using the ME7/CV scrapie mouse model was used to analyse the 
relationship between the deposition of PrPSc, vacuolation, activated microglia and 
astrocytes, and the subsequent neuronal loss observed in this mouse model.  
 
3.2 Aims of Chapter  
The principal aims of the work in this chapter are to perform a time course study of 
the neuropathological changes observed in the hippocampus of the ME7/CV scrapie 
mouse model, to identify at which time point in the progression of the disease, these 
changes initially occur, and to relate these changes to the loss of CA1 neurons 
observed in the hippocampus. The identification of the key events involved in the 
mechanisms of neurodegeneration in TSE diseases may lead to the development of 
therapeutic strategies to inhibit the neurodegenerative process. 
Specific aims 
• To analyse the deposition of PrPSc in the hippocampus of the ME7/CV 
mouse model throughout the incubation period of disease (Table 1. time 
points analysed) 
• To analyse the astrocytic and microglial response in the ME7 infected  
hippocampus throughout the incubation period of disease  
• To investigate at which stage in the disease process do the first signs of 
vacuolation occur. 
• To relate the above pathological changes with the neuronal cell loss 





3.3 Materials and Methods 
3.3.1 Immunohistochemical analysis of PrPSc, astrocytes and microglia 
Immunohistochemical (IHC) labelling was performed for PrPSc using 6H4 , a mouse 
monoclonal antibody that recognises the epitope DWEDRYYRE (amino acids 143-
151) on the PrP gene. This antibody was chosen as it has been used successfully on 
mouse brain with excellent staining results with no non specific background 
(Jamieson et al, 2001a; Liu et al, 2003). Astrocytes were labelled using the 
cytoskeletal marker glial fibrilliar acidic protein (GFAP), this antibody specifically 
labels intermediate filaments found within astrocytes only. For microglia labelling 
Iba1 was used, this is a calcium binding protein found within resident microglia. 
Historically microglia have been difficult to label in paraffin sections, with citrate 
buffer pretreatment Iba1 is an excellent marker that labels both resting and reactive 
microglia. For methodology see Chapter 2 materials and methods and appendix 1. 
3.4 Results 
3.4.1. First PrPSc deposition in the ME7 infected hippocampus is observed at 
          69dpi, increasing in intensity throughout the incubation period of disease. 
 
In the ME7/CV mouse model of disease the first neuropathological changes observed 
in the hippocampus is the deposition of disease specific PrP (PrPSc) at 69 dpi, 
observed as punctuate deposits in the pyramidal cell layer (PCL) of the CA1 sector 
and in the corpus callosum (CC) (Figure 3A). By 102 dpi, both the intensity and 
distribution of PrPSc has increased, revealing a widespread diffuse labelling 
throughout the CA1 of the hippocampus in both the stratum oriens (SO) and the 
stratum radiatum (SR). Also observed was an increase in the punctate deposition of 
PrPSc observed in the pyramidal cell layer and the corpus callosum (Figure 3B).  PrPSc 
deposition increased in intensity throughout the incubation period of disease, but in 
some brains unexpected lower levels were observed. In two brains inspected at 130 
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days post ME7 infection the deposition of PrPSc in the hippocampus was low 
compared with earlier time points and other brains at the same time point. (Figure 
3C). From 160 dpi (Figure 3D) onwards diffuse and punctuate forms of PrPSc increase 
in amount and intensity until the terminal stage of disease. At the terminal stage of 
disease the deposition of PrPSc in the hippocampus is widespread and intense, a 
dramatic loss in CA1 neurons is observed and there is shrinkage of both the SO and 
SR (Figure 5F). In TSE models of disease PrPSc deposition is observed in different 
forms; in the ME7/CV scrapie mouse model diffuse labelling is prominent in the 
hippocampus (Figure 3D). Plaque like deposits, which contain amyloid (Figure 5), are 
observed in the corpus callosum increasing in number by the terminal stage of disease 
(Figure 4), and neurons encircled by PrPSc are also observed at this stage in the 
hypothalamus. 
 Thioflavin labelling was performed on sections containing the plaque like 
deposits to identify if they contained amyloid. A terminally infected 87V/VM mouse 
brain was included as a positive control, as a characteristic pathological feature of this 
model is amyloid plaques observed throughout the cortex (Figure 5A). The PrP 
plaque like deposits observed in the corpus callosum labelled with thioflavin, 
revealing that they contain amyloid (Figure 5).  
 The PrPSc deposition within some of the groups of animals was variable, in 
the 200 dpi group the intensity of PrPSc deposition, but not the distribution varied.  
(Figure 6A&B).  Differences in the intensity of PrPSc immunolabelling was also 
observed in serial sections from the same brain that had been immunolabelled with 
6H4 on different days (Figure 7A&B). Therefore comparison of PrPSc 
immunolabelling was performed within the same IHC run and not between them. 
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Figure 3. Time series of the PrPSc deposition in the CA1 of the hippocampus in 
the ME7/CV mouse model. (A) First PrPSc deposition observed as punctate deposits 
in the pyramidal cell layer and the corpus collosum. (B) Increase in amount and 
intensity of PrPSc deposition at 102 dpi. (C) Decrease in amount and intensity of PrPSc 
labelling observed at 130 dpi. (D) Marked increase in intensity of the PrPSc labelling 
observed at 160 dpi. (E) Widespread PrPSc deposition in the CA1 at 200 dpi.(F) PrPSc 
deposition observed at the terminal stage of disease (note shrinkage of the Stratum 





















Figure 4. PrPSc deposition in the ME7/CV mouse model at the terminal stage of 
disease. Widespread distribution of PrPSc observed throughout the hippocampus 




















Figure 5. Thioflavin labelling of amyloid deposits observed within the ME7 
infected hippocampus. (A) 87V/VM terminal brain showing amyloid plaques 
labelled with thioflavin. (B) thioflavin labelling of amyloid in the corpus callosum 
(CC) of 160dpi ME7 infected hippocampus. (C) thioflavin labelling of amyloid in the  
CC of 200dpi ME7 infected hippocampus, arrow indicating an amyloid plaque. (D) 
















Figure 6. Difference in PrPSc deposition between animals in the 200 dpi group. 
6H4 labelling was performed in the same IHC run. (A) Diffuse labelling observed in 
the Stratum radiatum (SR) and Stratum oriens (SO) in the CA1 of the hippocampus. 
(B) More intense labelling of PrPSc observed in the CA1 also showing an increase in 






Figure 7.  Differences observed between IHC runs in serial sections from the 
same brain. PrPSc staining of serial sections from the same brain in the hippocampus 
at 102 dpi (A) 6H4 labelling performed on 25-10-07 and (B) 6H4 labelling performed 














3.4.2 Increase in astrocytes observed from 102 dpi ME7. Morphologically 
            astrocytes appear reactive from 160 dpi ME7. 
 
Astrocytes are observed in the ME7 infected hippocampus as early as 69 dpi. 
Morphologically they appear normal, with fine processes extending into the neuropil 
(Figure 8A) similar to those observed in the 102 dpi NB injected control (Figure 
10C). At 102 days post ME7 infection slight astrocytic hypertrophy and hyperplasia is 
observed with a thickening of astrocytic processes (Figure 8B). By 130 days post 
infection astrocytic hyperplasia is evident but morphologically astrocytes appear 
similar to those observed in NB infected controls (Figure 8C). From 160 dpi onwards 
astrocytic hypertrophy and hyperplasia increases, morphologically astrocytes show a 
thickening of processes, some having lost their processes entirely and show glial 
fibrillary acid protein (GFAP) labelling of cell bodies only (Figure 8F&9A). Also 
from 160 dpi astrocytes appear to increase in numbers in the PCL of the 
hippocampus, surrounding the cell bodies of the CA1 neurons (Figure 8E&F). 
Variation in astrocytic labelling was observed within the groups of animals which 
correlates with the deposition of PrPSc. For example the 102 and 130 days ME7 
infected brains labelled with GFAP in figure 8 have also been labelled with 6H4, the 
marked PrPSc deposition observed in the 102d infected ME7 brain (Figure 3B) 




















Figure 8. Time series of astrocytosis in the hippocampus in the ME7/CV mouse 
model .  GFAP labelling of astrocytes throughout the incubation period of disease.(A) 
69 days post ME7 infection showing normal morphology (B) Astrocytes at 102 dpi 
slight hypertrophy but no apparent hyperplasia. (C) Astrocytes in a NB control at 102 
dpi showing normal morphology. (D) Astrocytes at 130dpi appearing similar to the 
NB injected control. (E) At 160 dpi astrocytic hyperplasia and hypertrophy was 
observed, also astrocytes surrounding the cell bodies of the CA1 neurons, this was 
also observed at the terminal stage of disease (F). (F) Marked astrocytic hypertrophy 









Figure 9. Morphology of astrocytes in ME7 infected and normal brain injected 
controls. (A) Morphology of an astrocyte observed in the hippocampus of an ME7 
infected brain at the terminal stage of disease.(B) Astrocyte morphology observed in a 
NB injected control. Processes from both types of astrocytes surrounding the cell 
bodies in the pyramidal cell layer. Magnification x100 oil   
 
3.4.3 Increase in microglia and change in morphology observed from 102dpi 
ME7 
 
Microglia are the brain’s intrinsic immune cells and serve as damage sensors of the 
brain. Under normal conditions they are in a resting state, but when activated the 
morphology of microglia change from a highly branched, ramified resting 
morphology , with retraction of cell processes and eventually transformation into cells 
with an amoebiod appearance (Perry et al, 2007). These morphological changes are 
observed in the brains of mice infected with ME7 (Figure 11). 
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Figure 11. Morphology of microglia observed in the ME7/CV scrapie mouse 
model. (A) Microglia in a normal brain injected control showing the normal resting 
morphology. Fine processes are observed branching throughout the neuropil (B) 
Microglia in an ME7 infected brain at the terminal stage of disease, showing an 





Figure 10. Morphology of 
microglia Changes in 
morphology of microglia cells 
from  resting to amoeboid. 
Taken from Perry et.al Nat 
Rev Immunol 7: 161-167 
 
In the ME7/CV scrapie mouse model microglia are observed in their resting state at 
69dpi in both the ME7 and NB infected mice (Figure 12A&B). By 102 dpi a dramatic 
increase in numbers of microglia are observed in the hippocampus in both the stratum 
oriens and stratum radiatum. The morphology has also changed and microglia are 
observed in the active state (Figure 12C). At 130 dpi similar changes are observed 
(Figure 12D). From 160 dpi numbers of microglia are shown to increase and show 
morphological characteristics of the reactive type (Figure 12E). By the terminal stage 



























Figure 12.  Time series of microglial response observed in the ME7/CV scrapie 
mouse model.  Resting microglia observed at 69dpi NB (A) and ME7 (B). Increase in 
numbers of microglia and change in morphology at both102 (C) and 130 dpi (D). 
From 160dpi (E) an increase in numbers of microglia and reactive and amoeboid 










3.4.4 First signs of vacuolation in the CA1 of the hippocampus are observed at 
         102 dpi 
 
Vacuolation was first observed in the CA1 of the ME7 infected hippocampus at 102 
dpi (Figure 13B). At 130 dpi number of vacuoles observed in the hippocampus 
increased (Figure 13C). From 160 dpi, vacuolation observed in the hippocampus 
increased in numbers, and in some cases, size of vacuoles (Figure 13D). Considerable 
variability was observed within the groups. Vacuolation was observed in the 
hippocampus around 40 days after the first signs of PrPSc deposition and increased in 





Figure 13. Time series of vacuolation observed in the hippocampus of the 
ME7/CV scrapie mouse model (A) 102dpi normal brain showing no vacuolation (B) 
First signs of vacuolation observed in the 102 dpi ME7 infected hippocampus. (C) 
increase in vacuolation observed at 130dpi. (D) Vacuolation observed at 160 dpi, 
larger vacuoles observed at this time points. Amount of vacuolation increases at 200 
dpi (E) numerous vacuoles observed at the terminal stage of diseases appear smaller 
due to shrinkage of stratum radiatum (SR) (F) PCL=pyramidal cell layer, SO= stratum 























3.4.5 Neuronal loss in the CA1 of the hippocampus is observed from 160 dpi 
         ME7 infection 
 
Neuronal loss is one of the main pathological features observed in the hippocampus of 
the ME7/CV scrapie mouse model. When injected with the ME7 strain of scrapie, the 
CV mouse strain produces a targeted loss of neurons in the CA1 sector of the 
hippocampus. Previous studies in the ME7/CV mouse model, using morphometric 
analysis, discovered that the first significant neuronal loss was observed at 160 dpi. 
(Jeffrey et al, 2000) 
In this study, the neuronal cell loss observed in the CA1 of the hippocampus 
was analysed using haematoxylin and eosin stained sections. The number of cell 
bodies in the pyramidal cell layer of the hippocampus at each time point were 
analysed by light microscopy. Differences were observed in the thickness of the cell 
layers between animals in the same group, and in some cases, between the left and 
right side of the hippocampus (Figure 14C&D). This observation was found 
predominantly in the 160 and 200 day time points.  Morphometric analysis of neuron 
cell numbers was performed on all animals in both these time points (Figure 15&17). 
A difference in neuronal cell numbers was observed between the infected and control 
animals in each group. A dramatic difference was observed in the one animal (number 
2) between the left and right side of the hippocampus; the right side had a more severe 
neuronal loss, which appeared to relate to the injection site, the right side of the mid 
cortex. To check that the length of the pyramidal cell layer was not affected by the 
shrinkage observed in the hippocampus the length of each CA1 area used for counting 
was measured, there were no major differences between animals in the length of the 
CA1 sector measured. Microscopically, neuronal loss could be observed at 160dpi, 
but as seen previously this differed between animals, although there was neuronal loss 
in all the ME7 infected animals in comparison to the NB controls (Figure 15), only 
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one showed a dramatic loss at this time point (Figure 14C). Dark neurons were also 
observed in the pyramidal cell layer of this animal (Figure 18C arrow), this feature is 
an artefact produced by removal of the unfixed brain at autopsy, and has been 
observed in both ME7 infected and normal brain controls (Figure 18A). This artefact 
can be resolved by perfusion fixation of the brain (Cammermeyer, 1961). At 200 dpi 
there was considerable variation in the amount of neuronal cell loss observed in the 
CA1 pyramidal cell layer two out of the four ME7 infected animals showed a 
dramatic loss of neuronal cell bodies (Figure 16D&17), the other two animals differed 
in the numbers of cells lost (Figure 16B&C). Neuronal loss increased in severity 
throughout the incubation period of disease (Figure 19), although some differences 
were observed between animals the main trend observed throughout the incubation 














Figure 14. Neuronal cell loss observed in animals at 160 dpi ME7. (A) Pyramidal 
cell layer in the CA1 of the hippocampus of a 160dpi NB. (B) Pyramidal cell layer 
from one of the ME7 infected animals at 160dpi. (C) Marked neuronal loss observed 
in one animal at 160dpi (D) pyramidal cell layer from a third animal at 160 dpi. In (C) 
and (D) vacuolation in the neuropil of both the stratum radiatum and stratium oriens is 
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Figure 15. Neuronal counts from 160dpi ME7 and NB CA1 sector of the 
hippocampus. Animals 1-3 are from the left (L) and right (R) of the 160dpi ME7 
infected CA1, 4&5 are normal brain controls. Difference observed in neuron number 
in animal 2 between the left and right hippocampus, and differences observed 













Figure 16. Neuronal cell loss observed in animals at 200dpi ME7. (A) Pyramidal 
cell layer in the CA1 of the hippocampus in a 200 dpi NB. (B) Pyramidal cell loss 
observed in an ME7 infected brain at 200dpi. (C) No pyramidal cell loss observed in 
this ME7 infected brain at 200 dpi. (D) Obvious pyramidal cell loss observed in this 
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Figure 17. Neuronal counts from 200 dpi ME7 and NB CA1 sector of the 
hippocampus. Animals 1-3 are from the left (L) and right (R) of the 200dpi ME7 
infected CA1, 4&5 are normal brain controls. No major difference is observed 
between the left and right of the hippocampus, but differences in neuron number 


















Figure 18. Dark neurons observed in both a NB control and an ME7 infected 
brain (A) Two dark neurons (arrow) observed in the 102d NB control. (B) increase in 
dark  neurons in the 160d ME7 infected hippocampus. Magnification x 40 
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Figure 19. Time series of neuronal cell loss observed in the ME7/CV scrapie 
mouse model. (A) pyramidal cell layer in a 130 dpi NB injected animal. (B) 130 dpi 
ME7 infected animal showing no apparent pyramidal cell loss (C) 160 dpi ME7 
infected animal the right side of the hippocampus (D) The left side of the 
hippocampus from the same 160 dpi infected animal showing a marked pyramidal cell 
loss. Also showing dark neurons (arrow) (E) Pyramidal cell loss observed at 200 dpi. 
(F) Single pyramidal cell neurons in the CA1 in the ME7 infected hippocampus at the 
terminal stage of disease (arrows). Also observed is shrinkage of the stratum oriens 










Summary of results 
 
 
Figure 20. Sequence of development of neurodegeneration in the hippocampus of 
the ME7/CV scrapie mouse model.  Time line of days post injection from injection 
at day 0 to terminal disease at 240 days. Summary of results from the study on the 
neuropathological changes observed in the ME7/CV mouse model, results depicted as 
a time line of events. 
 
 
3.5  Discussion     
In the ME7/CV scrapie mouse model neuronal loss is not observed until 160 days of a 
240 day incubation period. A fundamentally important question is what happens to 
these neurons prior to their loss? It is important to establish the key neurodegenerative 
events that contribute to the loss of neurons as any strategy aimed at intervening to 
halt the degeneration would be better aimed at the initial insult rather than the final 
event.  
The first neuropathological change observed in the CA1 of the hippocampus 
in the ME7/CV mouse model is deposition of PrPSc at 69 dpi, followed by the first 
signs of vacuolation and a glial response at 102 dpi. Neuronal loss, although variable, 
was not observed until 160 dpi, which correlates with previous morphometric analysis 
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The initial pathological insult observed in the CA1 of the hippocampus in the 
ME7/CV mouse model, is PrPSc deposition, followed closely by vacuolation and then 
a glial response. The extent of microglial and astrocytic activation increased with 
disease progression and paralleled increases in PrPSc deposition. In the ME7/CV 
scrapie mouse model the deposition of disease specific PrP in the CA1 of the 
hippocampus may be the trigger for the activation of both microglia and astrocytes 
and the consequent damage to CA1 neurons. The type of PrPSc deposition observed in 
the ME7/CV model is mainly in the diffuse form and intense accumulations are 
observed in the stratum radiatum, the area within the hippocampus where the apical 
dendrites of the CA1 neurons lie. Although there was some differences in deposition 
of PrPSc observed within the brains of animals in the same group the main trend 
observed throughout the incubation period of disease was an increase in PrPSc 
deposition, becoming widespread at the terminal stage of disease (Figure 4). In this 
study the amount of PrPSc observed at 69 dpi was increased in comparison to that  
observed in previous studies at this time point. Therefore an earlier time point 
included in this study may have revealed the initial deposition of PrPSc even earlier in 
the incubation period of disease.    
The role that PrPSc deposition plays in the neuronal loss observed in TSE 
diseases is still to be determined. In contrast, in the 87V/VM scrapie mouse model, 
where targeted neuronal loss is observed in the CA2 of the hippocampus, cytoskeletal 
damage is observed in the CA2 neurons long before the deposition of PrPSc (Jamieson 
et al, 2001b). The differences observed in PrPSc toxicity in these two models may 
relate to the type of PrPSc deposited in the brains of these mice. In the 87V/VM model 
PrPSc is observed mainly in the form of amyloid plaques, whereas a diffuse form of 
PrPSc predominates in the ME7/CV model. 
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A glial response is first observed in the hippocampus of the ME7/CV model at 
102 dpi. Prior to this is the deposition of PrPSc which may initiate the upregulation of 
microglia and astrocytes. Microglia in their normal resting state are known to be 
motile, extending their processes into the neuropil scanning the brain for damage. 
Astrocytic signalling in the brain may lead microglia to the sites in need of inspection 
(Raivich, 2005).  
In the ME7/CV scrapie mouse model activated microglia were observed in the 
hippocampus after the deposition of abnormal PrP and co-exists with the upregulation 
of astrocytes. This corresponds with previous studies in TSE mouse models were 
PrPSc deposition initiates a glial response (Bruce et al, 1994; Williams et al, 1997a; 
Williams et al, 1997b). The role of microglia in the TSE infected brain is not fully 
understood. The results observed here reveal the activation of microglia as early as 
100 days, although variation between animals is observed, this activation increases 
throughout the incubation period of disease, and parallels the deposition of PrPSc. In 
contrast, previous results analysing microglial activation in this model revealed 
activation at a much later stage in the diseases process (Fraser, 2002).The earlier 
activation of microglia observed in this study may be due to the increase in the 
amounts of PrPSc observed at the earlier time points. The glial response observed in 
the ME7/CV mouse model may be due to the initial damage caused by the increase in 
PrPSc deposition and could be playing a protective role in the brain. As this glial 
activation occurred after PrPSc deposition this indicates that astrocytes and microglia 
were responding to rather than initiating the related pathology. This is enforced by the 
fact that in this model microglia are shown to have an anti-inflammatory phenotype .    
Most studies concerning the activation of microglia by PrP have been 
performed using the amyloid fibril-forming PrP-derived peptide, PrP 106-126.  In cell 
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culture this peptide activates microglia (Brown et al, 1996), and supernatants from 
these stimulated cells are also known to induce the proliferation of astrocytes and are 
toxic for neuronal cells (Brown & Mohn, 1999; Hafiz & Brown, 2000). These cell 
culture studies also revealed that PrPSc mediated neurotoxicity requires activation of 
microglia in combination with the expression of PrP on neuronal cells (Giese et al, 
1998). However the rapid addition of PrP peptides to microglia in culture does not 
represent the progression of PrPSc as observed in the brains of mice infected with 
ME7. Therefore the relevance of these in vitro studies and the role of the microglial 
response to the deposition of PrPSc observed in vivo, are limited. 
An increase in astrocytes along with microglia are also observed in the brains 
of mice infected with ME7.  Activated astrocytes in the ME7/CV scrapie mouse 
model are first observed at 102 days in both the stratum radiatum and stratum oriens 
of the ME7 infected hippocampus. Astrocytic hypertrophy is observed at this time 
point but no apparent hyperplasia is observed until 160 days, a time point at which 
CA1 neurons are known to be lost.  Also observed at this time point is an increase in 
the numbers of astrocytes observed surrounding the neuronal cell bodies, which 
increases with severity of neuronal loss (Figure 10F).  Astrocytes perform many 
functions in the brain that mainly involve the support of neurons. The distribution of 
the astrocytic response observed in the ME7 infected hippocampus corresponds with 
the progression of degeneration observed in CA1 neurons. A marked astrocytic 
response is observed in the stratum radiatum of the hippocampus where the initial 
damage observed in CA1 neurons is detected. Observed prior to this neuronal damage 
is the accumulation of PrPSc. In rodent models of TSEs, astrocytes have been shown 
to be associated with (Bruce et al, 1994) and accumulate PrPSc (Brown et al, 2003b 
Diedrich, 1991; Ye et al, 1998) This phenomenon is strain dependent and astrocytosis 
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is not always observed in association with PrPSc deposition (Aoki et al, 1999; Brown 
et al, 2003b; Van Everbroeck et al, 2002). In the ME7/CV scrapie mouse model PrPSc 
deposition is observed prior to the activation of astrocytes, and ultrastructurally has 
been shown to be released by neurons, suggesting that in this mouse model astrocytes 
do not play a role in the production of PrPSc.  The role astrocytes play in the 
production of PrPSc in TSE disease is uncertain. In mice devoid of murine PrP, but 
expressing hamster PrP transgenes driven by the astrocyte-specific GFAP promoter, 
astrocytes produced and expelled PrPSc into the neuropil, where it caused neuronal 
damage (Jeffrey et al, 2004; Raeber et al, 1997).  
An emerging role for astrocytes in the nervous system is in synaptogenesis. 
Astrocytes form an intimate association with synapses throughout the adult CNS, 
where they help regulate ion and neurotransmitter concentrations. (Theodosis et al, 
2008). In vivo astrocytes are involved in activity-dependent structural and functional 
synaptic changes throughout the nervous system (Slezak et al, 2006; Ullian et al, 
2004). The astrocytosis observed in the ME7/CV scrapie mouse model may play a 
role in controlling synaptic plasticity and synaptic loss observed in the CA1 neurons 
of the hippocampus.  
Vacuolation of the ME7 infected hippocampus was first observed at 102 dpi, 
as small holes in the pyramidal cell layer and larger holes in the stratum radiatum 
(Figure 13B). Vacuolation occurs over 30 days after the first deposition of PrPSc, and 
is observed firstly in the stratum radiatum, the area of the hippocampus that contains 
the apical dendrites of the CA1 neurons. This vacuolation increases rapidly towards 
the terminal stage of disease and is more widespread throughout the hippocampus 
(Figure 13). The vacuolation observed in the ME7 model appears to be associated 
with the deposition of diffuse PrPSc and increases throughout the incubation period of 
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disease. Ultrastructural studies have shown that vacuoles are mainly contained within 
dendrites with smaller numbers occurring in axons, axon terminals and the neuronal 
perikaryon (Jeffrey et al, 1995b; Jeffrey et al, 1991; Jeffrey et al, 1992b; Kim & 
Manuelidis, 1983; Kim & Manuelidis, 1986; Liberski et al, 1990). The vacuolation 
observed in the ME7/CV model may contribute to the neuronal damage and eventual 
loss of CA1 neurons in the hippocampus. Furthermore, the varicosities observed 
within the apical dendrites of CA1 neurons at the terminal stage of disease 
(Belichenko et al, 2000; Brown et al, 2001) may actually be a product of vacuolation 
within these dendrites (Figure 21). 
 
              
 
Figure 21. Varicosities observed within the apical dendrite of an ME7 infected 
CA1 neuron at the terminal stage of disease.  Confocal z-series of an ME7 infected 
CA1 neuron injected with Lucifer yellow.  
 
The loss of CA1 neurons in the ME7 infected hippocampus was observed 
from 160 dpi this correlates with previous morphometric analysis of neuronal loss in 
this model (Jeffrey et al, 2000). The neuronal loss observed in this scrapie mouse 
model is preceded by the deposition of abnormal PrP from 69 days, synapse loss and 
axon terminal degeneration at 100 days. The dendrites of the CA1 neurons become 
shrunken and contorted by the end of the incubation period, and lose most of their 
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spines, a process which starts around 100 days post infection (Brown et al, 2001). The 
evidence from this model suggests that abnormal PrP is the primary trigger for 
neurodegeneration, and that the subsequent damage is part of a cascade of events 
involving glial activation. As in some mouse models of Alzheimers disease (Shankar 
et al, 2008; Viola et al, 2008) the deposition of abnormal protein produces a 
synaptotoxicity which leads to the loss of synapses and neuronal function, which is 
exacerbated by a glial response. By the terminal stage of disease the CA1 
hippocampal layer can be reduced to just one cell thick with almost total loss of 
neurons.  
Neuronal loss is observed in the ME7 infected hippocampus but the 
mechanisms involved in this cell loss are still to be determined. Apoptosis is the 
suggested mechanism of neuronal loss in TSEs, but which apoptotic pathways are 
involved have still to be elucidated. In chapter 4 the role of apoptosis in the neuronal 


















Chapter 4: Apoptosis and the caspase dependent pathway in  
                   TSE induced neuronal loss  
 
 




Apoptosis has been proposed as an important mechanism of cell death involved in 
neurodegeneration. Apoptosis is a programmed cell death regulated by a series of  
events. It is essential for cell development, maturation, normal tissue turnover and 
regulation of immune systems (Wyllie et al, 1980). Identification of apoptotic cells is 
morphologically based upon the detection of cellular and nuclear membrane 
shrinkage, condensation and fragmentation of nuclear chromatin, and biochemically 
by endonuclease-mediated internucleosomal fragmentation of DNA into multiple 
oligosomal sub-units of 180 bp (DNA laddering). Most of the evidence in the 
literature indicates that apoptosis may play a role in the neuronal loss observed in TSE 
diseases, but it is not clear which pathways are involved in this apoptotic loss.   
Caspases 
 
Caspases are a family of cysteine proteases that have been identified as being key 
regulators and effectors of the apoptotic response in a variety of species. The 
discovery of a role for the caspases in apoptosis has its origins in observations made 
by Horvitz’s group on the regulation of programmed cell death during development  
of the nematode worm Caenorhabditis elegans (C. elegans) (Ellis et al, 1991). Further 
work was instigated to try and identify similar proteases that could play a role in 
regulation of mammalian apoptosis, and several were soon discovered. To date, 14 
human caspases have been identified and these proteases appear to comprise a 
complex proteolytic system, similar to the complement system (Salvesen & Dixit, 
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1997; Slee et al, 1999). Caspases can be subdivided on the basis of their activity into 
“initiator” (cell death signalling) caspases and “effector” (cell disassembly) caspases. 
The initiator caspases, such as caspases 8 and 9 appear to activate other caspases at 
the effector end of the cascade such as caspases – 3, 6 and 7 (Figure 1). It is the 
effector caspases that are largely responsible for the morphological and biochemical 
changes that are the hallmarks of apoptosis. 
 There are two different caspase-dependent mechanisms by which a cell 
commits itself to apoptosis: 1) The extrinsic or death receptor mediated pathway, and 
2) The intrinsic or mitochondrial pathway (Figure 1). The role of these pathways in 
the neuronal loss observed in TSEs will be investigated in this chapter. A third 
pathway is involved in the induction of apoptosis, the caspase independent pathway, 
this pathway is initiated by the release of Apoptosis Inducing factor (AIF) from the 
mitochondrial membrane and is discussed below. 
Caspase-independent pathway 
This pathway of programmed cell death is initiated through a caspase independent 
mechanism. Upon induction of apoptosis, AIF (apoptosis inducing factor), a protein 
that normally resides in the intermembrane space of the mitochondria, is released 
from the mitochondria into the cytosol and translocates to the nucleus. When in the 
nucleus it binds to DNA triggering chromatin condensation and DNA fragmentation. 
The DNA fragmentation is not the characteristic 180-200bp observed in caspase 
cleaved apoptosis, it is in the form of high molecular weighted fragments of 50kB 
(Susin et al, 1999) 
There is no evidence in the literature of a role for the caspase-independent 
pathway in TSE induced neurodegeneration. In Alzheimers,  a disease analogous to 
TSEs , AIF  was expressed in cortical and hippocampal neurons (Reix et al, 2007). 
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Studies in animal models of disease (Bertrand et al, 2001) and cell cultures treated 
with Aβ peptides (Giovanni et al, 2000) suggest a role for the caspase-independent 
pathway in cell death in AD. 
Translocation of AIF from the mitochondria to the nucleus has been observed 
in  ischemia induced apoptotic lesions in the rat brain (Chaitanya & Babu, 2008; Cho 
& Toledo-Pereyra, 2008; Ferrer et al, 2003), demonstrating the involvement of the 
caspase-independent pathway following transient focal ischaemia and reperfusion.  
Further studies are required to identify which apoptotic pathways are involved 




























Figure 1. Caspase Cascade  
 
This pathway shows the cascade of events that occur when apoptosis is initiated through a 
caspase dependent manner.  This proteolytic system can be initated in two ways, either 
extrinsic (receptor mediated) (A) or intrinsic (mitochondrial from within the cell) (B) 








4.1.1 The extrinsic or death receptor mediated pathway 
 
Extrinsic or receptor mediated cell death is initiated by a TNF (tumour necrosis 
factor) superfamily of ligands which include, TNF, FasL and TRAIL (TNF related 
apoptosis inducing ligand). These ligands bind to their receptors to evoke the 
formation of a death inducing signalling complex (DISC) that is comprised of death 
receptors, adaptor molecules and initiator caspases. The assembly of a DISC results in 
the activation of caspase 8, which can activate downstream executioner caspases 
leading to apoptosis. The up-regulation of Fas and caspases as markers for 
neurodegeneration in TSE disease has been observed in the brains of mice infected 
with the 87V strain of scrapie (Jamieson et al, 2001a). However, this was not the case 
in mice infected with the RML strain of scrapie, where active caspase-3 was observed 
in the same areas of the brain as TUNEL expression, but no difference in Fas 
expression was shown (Siso et al, 2002) . Gene expression levels of both the Fas 
receptor (Fas) and active caspase-8 were increased in C57BL mice infected with 
ME7, but no difference was observed in the levels of Fas ligand ( Fas-L) expression 
(Stobart et al, 2007). One study examining the expression of proteins linked with the 
signalling pathways involved in the cell death observed in the cerebellum in 
Creutzfeldt-Jakob disease (CJD) found no modifications in the expression of Fas, Fas-
L, MEK, ERK, Bcl-2 or Bax,  in vulnerable granule cells in this disease.. Although 
Purkinje cells of the cerebellum are relatively resistant to CJD, increased diffuse Fas,  
Fas-L, MEK, ERK and Bax expression, and enhanced granular active caspase-3 
immunoreactivity was observed in the cytoplasm of these cells. The expression of 
these proteins did not lead to cell death suggesting that these proteins have functional 
roles differing from those related with apoptosis (Puig & Ferrer, 2001). 
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These studies have demonstrated that the role of the extrinsic receptor mediated 
pathway in the apoptosis observed in TSE disease is still unclear. In this study, the 
involvement of this apoptotic pathway, in the neuronal loss observed in the CA1 of 
the hippocampus in the ME7/CV model, will be analysed.     
4.1.2 The intrinsic or mitochondrial pathway 
 
The intrinsic or mitochondrial pathway of apoptosis is triggered by internal signals 
within the cell i.e. reactive oxygen species that in turn interact with a family of 
proteins, the Bcl-2 proteins that are located in the mitochondrial membrane. The Bcl-2 
family consists of anti-apoptotic members, Bcl-2 and Bcl-XL and pro-apoptotic 
members Bax and Bak. The anti-apoptotic members maintain the integrity of the 
mitochondrial membrane, preventing the release of cytochrome c (Kluck et al, 1997; 
Yang et al, 1997), while the pro-apoptotic members interact with the mitochondrial 
membrane resulting in membrane permeabilisation and the release of cytochrome c. 
Cytochrome c release is mediated through balanced interactions of pro- and anti-
apoptotic members of the Bcl-2 family. When cytochrome c is released into the 
cytosol it interacts with apoptotic protease activating factor 1 (Apaf-1) to form the 
apoptosome, a complex consisting of cytochrome c, ATP, procaspase-9 and Apaf-1, 
resulting in the activation of caspase 9 and downstream effector caspases and 





Figure 2. Intrinsic (mitochondrial) pathway of caspase dependent apoptosis 
Increase in reactive oxygen species inside the cell interact with the Bcl-2 proteins to 
induce permeabilisation of the mitochondrial membrane releasing cytochrome C into 
the cytoplasm which initiates formation of the apoptosome leading to activation of the 
caspase cascade and apoptotic cell death 
 
  Both in vivo and in vitro studies into the role of these anti and pro-apoptotic 
proteins in TSE diseases have revealed conflicting results. In a study analysing the 
expression of Bcl-2 and Bax in the brains of hamsters infected with scrapie, Bcl-2 was 
significantly decreased, whereas the expression levels of Bax were significantly 
increased (Park et al, 2000). Over expressing Bcl-2 in GT1-7 neural cells protected 
against prion toxicity (Ferreiro et al, 2007), but this was not the case in vivo; Bcl-2 
overexpression and Bax deletion did not protect against prion toxicity in mice infected 
with the RML strain of scrapie (Steele et al, 2007). ER stress induced by the 106-126 
PrP peptide required functional mitochondria for the apoptotic cell death to occur 
(Ferreiro et al, 2008) . The differential expression of these proteins and their role in 
the neuronal loss observed in TSE disease is still to be determined. In this study two 
scrapie mouse models will be used to analyse the role of the mitochondrial pathway in 
TSE induced neuronal loss. 
4.1.3 FACS analysis as a method to identify apoptotic cells in vivo 
 
FACS analysis is a tool that is predominantly used in in vitro cell culture systems and 
analysis of cell types in the blood. In vivo it is mainly used to analyse morphologically 
simple and small cell types like those found in the lymphoreticular system i.e. B cells 
in the spleen. In the brain most in vivo research using FACS as a tool is performed on 
brain tumours i.e. astrocytomas and gliomas (Rainov et al, 2000). To determine 
whether FACS analysis could be used as a tool to analyse, in vivo, cells in the CNS a 
pilot study on the analysis of microglia was performed. Microglia have been analysed 
successfully in vivo by FACS analysis in other rodent models of disease (Marques et 
al, 2008; Mensah-Brown et al, 2005), and are also known to be upregulated in the 
ME7 infected brain. Therefore this was an ideal candidate cell to initially use in a 
pilot study to test the suitability of FACS analysis as a tool to use for in vivo analysis 
of cells in the CNS. If successful analysis of neurons using the FACS methodology 
and its use in the analysis of apoptotic markers in vivo will be determined. FACS 
analysis has been used successfully in analysing  pro-apoptotic markers in neuronal 
cell cultures (Awasthi et al, 2005,Igosheva, 2005 ; Boccellino et al, 2003), and in vivo 
to successfully identify neuronal cells within the CNS (Bowen et al, 2007). But this 
methodology has not been widely used in vivo to analyse pro-apoptotic markers in the 
CNS. 
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4.2  Aims of Chapter  
• To establish through a variety of approaches if apoptotic mechanisms are 
involved in the loss of neurons in TSEs. 
• To determine if the FACS analysis technique has the potential to be used in 
the analysis of apoptotic cells.  
 Specific aims and approaches 
Using two scrapie mouse models of disease :- the 87V/VM and ME7/CV mouse 
models the following approaches were taken:- 
• Analysis of TUNEL and active caspase-3 was performed on animals at the 
terminal stage of disease in both mouse models. Active caspase-3 analysis was 
also performed on a time series from the ME7/CV model. 
• To investigate the role of both the extrinsic (receptor mediated) and the 
      intrinsic (mitochondrial) apoptotic pathways several markers were analysed. 
 
4.3 Materials and Methods 
4.3.1 Immunohistochemical analysis of proapoptotic markers  
Active caspase-3 
Caspase-3 is observed within cells in two forms; the pro-form which is constitutively 
expressed in all cells, and the active form which is produced by the cleavage of the 
proform by upstream caspases in the caspase-dependent pathway of apoptosis. Once 
cleaved the cell is then destined for cell death via an apoptotic mechanism. Therefore 
it is essential that when trying to identify apoptotic cell death via a caspase-dependent 
mechanism that the antibodies used identify the cleaved form of caspase-3 and not the 
procaspase form. 
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  Initial studies analysing active-caspase-3 expression were performed using the 
antibody from R&D systems used previously on the 87V/VM scrapie mouse model 
(Jamieson et al, 2001a). As both the ME7 and the NB infected sections showed 
similar staining patterns with this antibody another active caspase-3 antibody was 
used. The active caspase-3 antibody from Oncogene worked well and staining was 
observed in single cells in the infected samples only. This antibody was chosen on 
recommendation from another laboratory.   
 In addition suitable positive controls to include in the IHC studies were 
assessed. These included paraffin sections from a mouse model of Semliki Forest 
Virus (SFV), a mouse model of ischaemia, human tonsil tissue and mammary tissue. 
TUNEL labelling 
TUNEL labelling was performed on brains fixed in formol saline for a total of 48hrs. 
Brains were immersed in formol saline overnight, trimmed and left for a further 24 
hours and then processed through to paraffin wax. When developing the TUNEL 
technique the best results were achieved by light fixation in formol saline and sections 
that were cut straight after processing to wax. Optimisation of proteinase K (PK) 
digestion of tissue sections was essential as over digestion can cause false positives. A 
concentration of 2.5μg/ml of PK for 15mins was used in these studies. Full TUNEL 
technique can be found in appendix 1 under immunohistochemical methods. 
Fas receptor labelling 
Two antibodies were used to assess the expression of the Fas receptor in both the 
87V/VM and ME7/CV scrapie mouse models. Both antibodies were purchased from 
Santa Cruz, The C20 antibody was raised to the C terminus of the Fas protein and had 
been used previously on the 87V/VM mouse model (Jamieson et al, 2001a), the A20 
antibody was raised to the N terminus of the Fas protein and had been used in a 
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previous study analysing Fas expression in the RML/C57BL scrapie mouse model 
(Giese et al, 1995). (see appendix 1 and table 1.2 for IHC method and concentration 
of antibodies) 
Mitochondrial proteins Bax,Bcl-2 and cytochrome C 
The expression of the mitochondrial proteins Bax, Bcl-2 and cytochrome c were 
analysed to identify the role,if any, of the intrinsic (mitochondrial) pathway in the 
apoptotic cell loss. Both the Bax and Bcl-2 antibodies were purchased from upstate as 
on their specification sheets they were shown to work well in both IHC and western 
blot analysis on mouse tissue. The cytochrome C antibody had been used successfully 
on human sections in huntington’s disease (Kiechle et al, 2002) and from the 
specification sheet for the antibody, it also reacted well with mouse cytochrome C.   
4.3.2 Western blot analysis of proapoptotic markers 
In the identification of a suitable active caspase-3 antibody to use in western blot 
analysis, initially 87V infected whole brains were used as in the previous study by 
Jamieson et al. Further experiments analysed both scrapie mouse models. Dissected 
hippocampus (ME7) and thalamus (87V) was used in active caspase-3 analysis using 
the Cell Signaling antibody. The thalamus was used in the 87V/VM model as this area 
is also targeted in this model and more tissue could be collected in dissection. It was 
almost impossible to dissect out the CA2 sector of the hippocampus and to obtain 
enough tissue for western blot analysis. See Chapter 2 materials and methods for more 









4.4 Results  
 
4.4.1. TUNEL labelling is detected in the hippocampus of the ME7/CV scrapie 
          mouse model at the terminal stage of disease and not in the normal brain 
          injected controls 
 
Studies in the ME7/CV model revealed TUNEL labelling in the hippocampus in 
brains at the terminal stage of disease (Figure 3). Single cells were observed in the 
dentate gyrus in the hippocampus. A positive control of mammary tissue was included 
from the apoptag TUNEL kit. Apoptosis during lactation is a normal function of 
mammary tissue (Iizuka et al, 2006) and therefore a useful tissue to use as a positive 
control in the TUNEL technique (Figure 3B). Morphology of the cells labelled in the 
ME7 infected hippocampus resembled those labelled in the mammary tissue, cells 
looked shrunken and condensed nuclei stained intensely with TUNEL technique. The 
numbers of cells labelled with the TUNEL technique were similar in both the 
87V/VM and ME7/CV model. However, whereas in the 87V/VM model the TUNEL 
labelling was observed in the nucleus of CA2 neurons, the sector of the hippocampus 
were neuronal damage is observed, here no TUNEL positive cells were observed in 
the CA1 of the ME7 infected hippocampus where neurons are known to be lost. 
TUNEL labelling in the ME7 infected hippocampus was confined to the dentate gyrus 
where there was no obvious neuronal loss. The morphology of the cells labelled with 
the TUNEL method in the ME7 infected brain (Figure 3C&D) was similar to that 








Figure 3. TUNEL labelling in the ME7/CV model at the terminal (ME7 T) stage 
of disease (A) Normal brain injected control with no TUNEL labelling (C)&(D) 
TUNEL labelling of single cells observed in the dentate gyrus of the hippocampus in 
ME7 infected animals at the terminal stage of disease. (B) TUNEL labelling in the 



















4.4.2. Identification of antibodies that recognise the active form of caspase-3 
           
 
Four antibodies were compared to identify a suitable antibody that will recognise the 
active form of caspase-3. All these antibodies claimed that they recognised the 
cleaved form of active caspase-3. A list of antibodies tested are shown in Appendix 1. 
In western blot analysis both the R&D system and the Pharmingen antibody detected 
the procaspase form of caspase-3 as a 32kDa band (Figure 4&6). IHC analysis using 
the R&D systems antibody revealed similar labelling in both ME7 infected and 
normal control brains (Figure 5). Two antibodies were identified that could be used 
successfully for the identification of active caspase-3 in immunohistochemical and 
western blot analysis. For IHC an active caspase-3 antibody was purchased from 
Oncogene. This active caspase-3 antibody was used successfully in 
immunohistochemical analysis of active caspase-3 in brains from both the 87V/VM 
and ME7/CV models at the terminal stage of disease (Figure 9), and also the time 
series analysis of the ME7/CV mouse model (Figure 10). An active caspase-3 
antibody from Cell Signalling Technology was used successfully in western blot 
analysis of terminally infected brains from both the 87V/VM and ME7/CV mouse 
models (Figure 7), a positive control supplied with this antibody revealed active 











Figure 4. Western blot analysis of three different dilutions of 87V infected whole 
brains with the caspase-3 antibody from R&D systems. Results shown here reveal 
that this antibody recognised the procaspase form (32kDa) of caspase-3 (A) Western 
blot analysis of caspase-3 expression in two terminal 87V infected mouse brains 
added to gel at 2.5, 5& 10mg/ml. No bands were observed at 17-19 kDa, bands were 
observed at 32kDa, the molecular weight (MW) of the procaspase form of caspase-3. 






















Figure 5. Casapse-3 imunolabelling of both ME7 infected and normal brain (NB) 
injected controls with R&D antibody used on westerns in Figure 4. (A) Punctate 
labelling observed in the cytoplasm of cortical neurons in the NB injected controls, 
and also in the medulla (B). Similar labeling was also observed in the ME7 infected 










         
 
Figure 6. Western blot analysis of 87V T whole brains with the Pharmingen 
antibody.  Results shown here reveal that it recognised the procaspase form only. 
Whole brain lysates were added at 2.5,5 and 10 mg/ml and the Pharmingen antibody 
was used at 1/2000 and 1/4000 concentration. Bands were observed at 32kDa 
recognising the procaspase form of active caspase-3 but nothing was observed 
between 17&19 kDa were bands would be observed if caspase-3 was cleaved.  
 
 
             
 
Figure 7. Western blot analysis of active caspase-3 in both the 87V/VM and the 
ME7/CV scrapie mouse models using an active caspase-3 antibody from cell 
signalling technology.  Dissected hippocampus (ME7) and thalamus (87V) samples 
methanol precipitated and added to the gel. In both the 87V and ME7 infected 
samples two bands were recognised at 17 and 19 kDa denoting active caspase-3, no 
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4.4.3 Identification of suitable controls to use in IHC anlaysis of active caspase-3 
The most suitable positive control to use in the IHC studies was the SFV infected 
mouse model. Active caspase -3 labelling revealed intense labelling in cells within the 
olfactory bulb of the SFV infected mouse (Figure 8A). Single cells were labelled in 
the dentate gyrus in the ischaemia mouse model (Figure 8B), although active caspase-
3 labelling is observed it was not as intense as that shown in the SFV mouse model. 
The human tonsil section stained well and was used in each IHC run as a positive 
control to ensure the IHC technique was successful. Mammary tissue was provided as 
a positive control to use with the TUNEL technique, positive cells were always 










Figure 8. Positive controls to use in IHC analysis of active caspase-3 and TUNEL 
labelling 
 
Figures (A)-(C) labelled with active caspase-3 Oncogene antibody and (D) TUNEL 
labelling (A) Olfactory bulb from Semliki Forest Virus infected mouse brain showing 
marked upregulation of active caspase-3 in SFV infected cells. (B) Mouse model of 
Ischaemia after 6 hours reperfusion, showing only single cells labelling in the dentate 
gyrus, not many cells dying through apoptosis in this model. (C) Active caspase-3 
labelling of human tonsil, rapid turnover of B cells in the tonsil undergoing apoptosis. 
(D) TUNEL labelling of apoptotic cells observed in mammary tissue, the positive 
control provided with apoptag TUNEL labelling kit. Magnification (A)&(B) x40, 














4.4.4. Active caspase-3 labelling is observed in both the 87V/VM and ME7/CV 
          mouse model at the terminal stage of disease 
 
The Oncogene antibody was used to immunolabel active caspase-3 in terminally 
infected brains from both the 87V/VM and ME7/CV mouse models. This antibody 
labelled both positive control and experimental tissues. Active caspase-3 labelling 
was observed in single cells in the thalamus of the 87V infected brain (Figure 9D), 
and in the dentate gyrus of the ME7 (Figure 9B) infected brain at the terminal stage of 
disease. These cells had similar morphology to those labelled previously with the 
TUNEL technique. No labelling was observed in aged matched normal brain controls 
(Figure 9C). High expression of active caspase-3 was observed in the SFV infected 











Figure 9. Active caspase-3 labelling in terminal brains from both the ME7/CV             
and 87V/VM model. (A) Olfactory bulb from a Semliki Forest Virus (SFV) infected 
mouse brain demonstrating upregulation of active caspase-3 labelling in SFV infected 
cells. (B) Active caspase -3 labelling of single cells in the ME7 infected hippocampus. 
(C) NB control showing no labelling with the active caspase-3 antibody. (D) Active 
caspase-3 labelling of single cells in the 87V infected thalamus. Magnification (A) 



















4.4.5. Analysis of active caspase-3 in the ME7/CV time series :- active caspase-3 
          is observed in single cells in all time points 
 
Active caspase-3 labelling of single cells in the hippocampus was observed in all the 
ME7 infected serial kill time points. None of the cells labelled were in the CA1 of the 
hippocampus, where neuronal cell loss takes place. Active caspase-3 positive cells 
were observed in the dentate gyrus (Figure 10A&B), cortex (Figure 10C&E) and 
white matter tracts in the corpus collosum (Figure 10D). The cells labelled did show 
the characteristic morphological changes that are observed in cells undergoing 
apoptosis such as shrinkage of the cell and pyknotic nuclei. No labelling was observed 









      
 
 
Figure 10. Active caspase-3 labelling in the time series of the ME7/CV scrapie mouse 
model.  Single cells labelling in the hippocampus in the ME7 infected brains throughout 
the time series from 69dpi – terminal (A)-(E). (F) Single cells labelling in the dentate 
gyrus (arrows) in an ischaemia mouse model (positive control). Magnification (A), (B) 














4.4.6. Fas is not upregulated in the brains of mice infected with the ME7 strain of 
          Scrapie 
 
To investigate the role of the extrinsic pathway in the neuronal loss observed in TSE 
disease the expression of the Fas receptor was analysed in the brains of two scrapie 
mouse models. 
Using a Fas receptor antibody raised to the C terminus of the Fas protein, 
weak expression of Fas was observed in the CA2 of the 87V infected hippocampus 
(Figure 11A), an area that is a known pathological target in this model, but not in the 
NB injected control (Figure 11C). In the ME7/CV model only astrocytic like 
expression was observed in the CA3 of the hippocampus (Figure 11B), no labelling 
was observed in the NB control (Figure 11D). To confirm these results a second Fas  
antibody was acquired, this antibody was raised to the N-terminus of the Fas protein. 
A different staining pattern was observed with this antibody in infected brains from 
both the ME7/CV and 87V/VM scrapie mouse models (Figure 12). Fas expression 
was observed in the cytoplasm of neuronal cell bodies in both the CA2 (87V) and 
CA1 (ME7) of the hippocampus, a slight increase in intensity observed in the NB 
controls (Figure 12A&B). Fas expression was also observed within glial cells in the 
ME7 infected hippocampus (Figure 12D). Both these antibodies labelled glial cells in 













Figure 11. Fas expression in both the 87V/VM and ME7/CV scrapie mouse 
models using the antibody raised to the C terminus of the protein (A) Faint 
expression of Fas in the CA2 of the 87V infected hippocampus. (B) Fas expression 
observed in glial cells in the CA3 of the ME7 infected hippocampus. No labelling 
observed in the VM (C) or CV (D) normal brain injected controls. Magnification x20, 





Figure 12. Fas expression in both the 87V/VM and ME7/CV scrapie mouse 
models using the antibody raised to the N-terminus of the protein (A) Fas 
expression in the CA2 in a VM normal brain control (B) Fas expression in a CV 
normal brain control. (C) Loss of expression observed in the CA2 of the 87V infected 
hippocampus. (D) Fas expression in the CA1 of the ME7 infected hippocampus 

























4.4.7. Cytochrome c deposition in the hippocampus of terminal stage 
         murine scrapie infected brains and normal brain injected controls is similar  
 
To investigate the role of the mitochondrial pathway in the neuronal loss observed in 
scrapie mouse models, the deposition of Cytochrome c was analysed in both the 
87V/VM and ME7/CV models. Cytochrome c labelling in the 87V and NB injected 
controls was similar. Diffuse labelling was observed in the cytoplasm of CA2 neurons 
in the hippocampus in both the 87V infected and NB control. A slight difference was 
observed in the 87V infected CA2 (Figure 13A), in addition to diffuse labelling, 
single cells with intense labelling were also observed (Figure 14C). In the ME7/CV 
model diffuse labelling was observed in the cytoplasm of CA1 neurons in the NB 
controls (Figure 14C). Single cells with intense labelling were also observed within 
the pyramidal cell layer (Figure 14A arrow) these cells resembled the dark neurons 
observed in haematoxylin and eosin stained sections in Chapter 2. In the ME7 
infected brain the type of deposition had changed and punctate intense cytochrome c 
labelling was observed in single neurons in the CA1 of the ME7 infected 





















Figure 13. Cytochrome c expression in the 87V/VM scrapie mouse model. (A) 
CA2 of the hippocampus in the 87V infected mouse showing diffuse labelling in the 
cytoplasm of CA2 neurons, and single cells within the pyramidal cell layer (C). 
(B)&(D) CA2 of the hippocampus in a normal brain injected control, also showing 
diffuse labelling in the cytoplasm of CA2 neurons. Magnification (A)&(B) x40 and 




























Figure 14. Cytochrome c expression in the ME7/CV scrapie mouse model. 
(A)&(C) Diffuse labelling observed in the cytoplasm of CA1 neurons in the 
hippocampus. (B)&(D) Diffuse labelling observed in the cytoplasm of CA1 neurons 
in the ME7 infected hippocampus. More intense labelling observed in a single neuron 
in the ME7 infected brain (block arrow in D). Arrows between figures denotes a 





















4.4.8. Active caspase- 9 is upregulated in the brains of mice infected with 87V. 
 
To investigate which pathway, the extrinsic or intrinsic, is involved in the activation 
of caspase-3 , the role of active caspase-8 and 9, caspases found upstream of caspase-
3, was determined. Antibodies that react with both active caspase-8 & 9 were used to 
analyse the expression of these proteins in both the 87V/VM and ME7/CV mouse 
models.  As both these caspases reside in the cytosol, subcellular fractionation was 
performed on dissected hippocampus from both the 87V/VM and ME7/CV model and 
the lysates from the cytosolic fraction used for analysis. The 87V infected samples 
showed a slight upregulation of active caspase-9 (Figure 15) in comparison with the 










Figure 15. Expression of Active caspase-9 (37kDa) in cytosol fractions from 87V 
and NB/VMs. Active caspase-9 observed in terminal brains from 87V infected 
animals and not in the normal brain controls ( 87V- 87V infected brain, NB- normal 
brain, BL- blank Ct = +ve control Std = molecular weight markers) samples methanol 
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4.4.9.    Bax expression in the hippocampus of the ME7/CV and 87V/VM scrapie 
            mouse models is similar in both infected and normal brain controls 
 
Cytochrome c release from the mitochondria is mediated through the balance of pro 
and anti apoptotic members of the Bcl-2 family of proteins. To determine the role 
these proteins play in the scrapie infected mouse brain, the expression of Bax (pro-
apoptotic) and Bcl-2 (anti-apoptotic) were analysed. Brains from both the ME7/CV 
and the 87V/VM scrapie mouse models at the terminal stage of disease were analysed 
and compared to aged matched NB controls. No difference in Bax expression was 
observed between the infected and NB controls in both scrapie mouse models. Diffuse 
cytoplasmic staining was observed surrounding cell bodies in the CA1 of both the NB 
control (Figure 16A) and the ME7 infected hippocampus (Figure 16B). Strong 
cytoplasmic labelling was observed surrounding cell bodies in the CA2 of both the 
NB/VM controls (Figure 16C) and the 87V infected (Figure 16D) hippocampus. A 
section from a human tonsil was included as a positive control. Bax expression was 
observed within tingible body macrophages, these cells phagocytose dying cells, and 
the Bax labelling observed within these cells may be due to the clearance of debri 
from apoptotic B cells. Non-specific (artefactual) Bax expression within the cells of 
the squamous epithelium surrounding the tonsil was also observed (Figure 16E).  
Western blot analysis of Bax in subcellular fractions: cytosol, nuclear and 
organelle from ME7 and normal brain controls revealed expression of Bax in the 
cytosol fractions only (Figure 19). No difference was observed between the infected 










        
 
        
 
 
Figure 16. Bax expression in the CA1 (ME7) and the CA2 (87V) of the 
hippocampus. Bax expression observed in the cytoplasm of neuronal cell bodies in 
the CA1 of the hippocampus in the ME7/CV mouse model (A) NB control and (B) 
ME7 infected, faint expression observed in glial cells (arrow), and the CA2 of the 
hippocampus in the 87V/VM model (C) NB control. and (D) 87V infected. No 
differences were observed in Bax expression between the controls and infected in 
both mouse models. (E) Non-specific (artefactual) labelling of the squamous 
epithelium in the tonsil, and (F) Bax expression observed in tingible body 
macrophages within the follicles of the tonsil and surrounding T zone (arrows). 











4.4.10. Increase in Bcl-2 expression is observed in the infected hippocampus of 
the ME7/CV and 87V/VM scrapie mouse models  
 
 
Bcl-2 is an anti-apoptotic member of the Bcl-2 family of proteins that resides in the 
mitochondrial, endoplasmic reticulum and nuclear membranes. Its main function is to   
maintain the integrity of the mitochondrial membrane preventing release of 
cytochrome c into the cytoplasm and apoptotic cell death. A Bcl-2 mouse monoclonal 
antibody from Upstate was used in both IHC and western blot analysis.   
In the ME7/CV mouse model Bcl-2 expression was observed within glial cells in the 
pyramidal cell layer and the stratum radiatum of the hippocampus (Figure 17B). Faint 
expression was observed in the cytoplasm surrounding the pyramidal cell bodies in 
the NB control (Figure 17A). In the 87V/VM mouse model faint membranous 
labelling was observed surrounding the cell bodies of the CA2 neurons in both the NB 
control (Figure 16C) and the 87V infected hippocampus (Figure 17D). A slight 
increase in labelling was observed in the 87V infected cell bodies in the CA2.  
Western blot analysis of Bcl-2 was performed on the organelle and nuclear  
subcellular fractions. Western blot analysis of Bcl-2 in the ME7 infected and NB 
controls at the terminal stage of disease revealed expression of Bcl-2 in the nuclear 
fractions only with an increased expression observed in the ME7 infected brains 












     
 
        
 
 
Figure 17. Bcl-2 expression in the CA1 (ME7) and the CA2 (87V) of the 
hippocampus Bcl-2 expression observed in the ME7/CV mouse model (A) faint 
labelling in the cytoplasm of pyramidal cell bodies in the NB control. (B) Bcl-2 
expression observed within glial cells in the pyramidal cell layer (PCL) and stratum 
radiatum (SR) of the ME7 infected hippocampus. Bcl-2 expression in the CA2 of the 
hippocampus in the 87V model (C) faint cytoplasmic labelling observed around cell 
bodies in the CA2 of a NB control (D) increased expression in the 87V infected CA2.  
(E) Expression of Bcl-2 in tonsil mainly observed surrounding follicles in the T cell 
zone. (F) Bcl-2 labelling also observed in cells within the germinal centre (arrows). 


















Figure 18. Bcl-2 expression in ME7 infected and normal brain control nuclear 
fractions. Each well was loaded with 20μg protein in 20μl. Protein estimation  
performed in each sample and an equivalent amount of protein added in each sample. 
Expression of Bcl-2 was increased in two of the three ME7 infected nuclear fractions 
in comparison to the normal brain control.  Expression of Bcl-2 was only observed in 






Figure 19. Bax expression observed in the Cytosol fractions only. 
Each well was loaded with 20μg of protein in 20μl. Protein estimation performed in 
each sample and an equivalent amount of protein added in each sample. Expression of 
Bax was observed in both the NB controls and the ME7 infected samples from the 
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4.5 Results of FACS analysis study 
 
4.5.1  Brain cells are viable after FACS methodology 
 
The viability of brain cells were tested after preparation using the FACS 
methodology. A high percentage of cells were viable in both the infected and control 
brains. Cell suspensions analysed with both trypan blue and FACS (Figure 20) 
revealed a high percentage of cells were viable. Not as many cells were observed in 
the ME7 infected brain specifically in the midbrain portion which contains the 
hippocampus, where neurons are known to be lost. 
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Figure 20. Testing cell viability by analysing cells in the FACS machine without a 
fluorescent label.  Example of cell viability after preparation with FACS 
methodology. ME7 infected hind brain (A) Whole number of viable cells observed in 
FACS machine. (B) Total cell population observed in ungated sample. (C) Cell 
population observed in gate one (R1 from Fig. A). 
4.5.2 FACS analysis of microglia labelled with F4/80 
 
As a high percentage of brain cells were viable a further study was undertaken to  
analyse the microglial response in the ME7 infected brain.  
A high percentage of cells labelled with the microglial marker F4/80. Two 
gates were applied to the cell suspension and most of the fluorescently labelled cells 
were observed in gate 1 (R1), where smaller less complex cells are observed (example 
Figure 21). In both the NB and ME7 infected cell suspensions F4/80 microglial 
labelling was increased in comparison with the control cells with no label (NB 
example Figure 22). In comparing the percentage of total cell numbers labelled in 
both the normal and ME7 infected cells in the three areas dissected, the area showing 
the greatest increase in microglia was the mid brain (Figure 23&25). This section of 
the brain contains the hippocampus an area in the ME7 infected brain were microglia 
are know to be activated and increase in numbers (see chapter 3 Figure 13F). On 
analysis of the gated cell suspension (R1) from both the normal and ME7 infected 
cells, differences were observed in both the forebrain and mid brain (Figure 24). This 
correlates with IHC analysis of the microglial response in the ME7 infected brain.  
FACS analysis of the microglial response in the ME7 infected brain successfully 
recognised the main areas of the brain involved in the increase in reactive microglia, 







Figure 21. Example of FACS analysis of cell numbers labelled with F4/80 
microglial marker. ME7 infected midbrain labelled with F4/80 two gates applied.    
R1 is the region where all smaller less complex cells would be observed and R2 
represents the region where larger more complex cells would be observed. Most 










































































Figure 22. FACS analysis of microglia in normal brain versus control cells with 
no label. The blue filled in trace are the control cells with no label and the green line 
are cells labelled with F4/80 microglial marker. (A) midbrain (B) Forebrain and (C) 
hindbrain from normal brain. A marked difference was observed between control cells 
and those labelled with F4/80 in midbrain, forebrain and hindbrain. 
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= control 
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Figure 23. FACS analysis of normal brain and ME7 infected cells labelled with 
F4/80 microglial marker. Total numbers of cells analysed with no gate. (A) 
Forebrain showing no difference in numbers of microglia labelled in both the normal 
and ME7 infected brains. (B) Midbrain showing upregulation of microglia in the ME7 
infected cells in comparison to the normal brain. (C) Hindbrain showing no difference 


























Figure 24. FACS analysis of normal brain and ME7 infected cells labelled with 
F4/80 microglial marker.  Total numbers of cells analysed from gated sample. (A) 
Forebrain showing a difference in numbers of microglia labelled with F4/80 in the  
ME7 infected brains in comparison to the normal brains. (B) Midbrain showing 
upregulation of microglia in the ME7 infected cells in comparison to the normal brain. 
(C) Hindbrain showing no difference in numbers of microglia labelled in both the 






Figure 25.   Percentage of cells labelling with the microglial marker F4/80 in both 
the normal brain and ME7 infected brain in the forebrain (FB), midbrain (MB) 
and hindbrain (HB).  Graph from data in figure 24 above. The greatest increase in 
microglial response is observed in the ME7 infected midbrain which contains the 
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F4/80 labelling of ME7 & NB injected mouse brains 
 
4.5.3. FACS analysis of neurons in a normal mouse brain 
 
Inspection of cell suspension when performing cell counts with trypan blue revealed 
less clumping of cells when tissue was treated with dissociation medium prior to 
FACS methodology. 
FACS analysis of cells labelled with NeuN showed many cells labelling in the 
whole cell suspension (Figure 27). Most cells labelled with NeuN were observed in 
the R1 gate where the cells would be smaller in size and less complex (Figure 26). 
Cells in both gates 1 (R1) (Figure 28) and 2 (R2) (Figure 29) labelled with the Neu N 
antibody, with a higher proportion observed in gate 1 (R1). Analysis of a cytospin 
prepared from the cell suspension revealed that the cells labelled with NeuN were 
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Figure 26. FACS analysis of cells labelled with NeuN.  Most cells labelled with 
NeuN were observed in gate 1 (R1) where smaller and less complex cells would be 
observed. A cut off point just before 200 on the forward scatter was used to eliminate 










 Fluorescent intensity 
 
Figure 27. FACS analysis of control cells with no label and NeuN labelled cells 
with no gate.  Comparison of total cell numbers in NeuN labelled and unlabelled 
control cells. Fluorescent intensity of NeuN labelled cells in purple trace in 
comparison with control cells with no label in the black trace 
= control 












Figure 28. FACS analysis of control cells in comparison to NeuN labelled cells 
from gate 1.  Increase in fluorescent intensity observed in NeuN labelled cells in 
comparison to control cells from gate 1 in Figure 26. Black trace are cells with no 
label and purple trace are fluorescing cells labelled with NeuN. 
 






Figure 29. FACS analysis of control versus NeuN labelled cells in gate 2. Black 
trace filled in with blue are control cells with no label . Blue trace are NeuN labelled 
cells from R2 in Figure 26. 
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Figure 30. Confocal images of cytospin preparation of cells labelled with NeuN. 
(A) x20 magnification of cells labelled with NeuN. (B) x60 oil magnification of cells 
labelled with NeuN. Cells are rounded and do not show a typical neuronal 
































4.6  Discussion 
 
In the ME7/CV model both TUNEL and active caspase-3 labelling was observed in 
single cells in the hippocampus. These cells were not observed in the CA1 sector of 
the hippocampus, where the targeted neuronal loss is observed, and the numbers of 
apoptotic cells detected were very low. Single cells were observed in the dentate 
gyrus, cortex and white matter tracts in the corpus collosum. Also western blot 
analysis of active caspase-3 was only observed in dissected hippocampus samples 
following protein concentration with methanol precipitation.  
The time course study performed in the ME7/CV scrapie mouse model did not 
show any increase in apoptotic cells throughout the incubation period of disease. 
Single active caspase-3 cells were observed in the brains of mice throughout the 
progression of the disease, and as in the terminally infected mice few cells were 
detected. This correlates with analysis of active caspase-3 in the brains of C57BL 
mice infected with the ME7 strain of scrapie (Cunningham et al, 2003). In this model 
single active caspase-3 cells were first observed in the dentate gyrus at 19 weeks post 
injection and not in the CA1 where cells are known to be lost.  
The TUNEL labelling technique can produce false positives (Stahelin et al, 
1998), and is also known to label cells undergoing necrotic cell death (Frankfurt & 
Krishan, 2001). Therefore TUNEL labelling on its own is not a reliable marker for the 
identification of apoptosis, this marker labels dead cells but cannot identify which 
type of cell death is occurring in the cell. Active caspase-3 is known as the central 
executioner of the apoptotic pathway (Cohen, 1997) and is a reliable marker that can 
be used in conjunction with the TUNEL method to positively identify cells dying 
through an apoptotic mechanism (Mazumder et al, 2008; Yakovlev & Faden, 2001). 
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Using both TUNEL methodology and active caspase-3 labelling, apoptotic 
neurons have been shown in both naturally occurring and experimentally induced 
TSEs (Dorandeu et al, 1998; Ferrer, 2002; Jamieson et al, 2001a; Jamieson et al, 
2001b; Jesionek-Kupnicka et al, 1999; Puig & Ferrer, 2001; Williams et al, 1997a). In 
rodent models of TSE disease apoptotic cells have been identified using the TUNEL 
method and an inconsistency was observed between numbers of cells labelled with 
this technique (Jesionek-Kupnicka et al, 1997; Jesionek-Kupnicka et al, 2001). In the 
ME7/CV scrapie mouse model TUNEL labelling was observed in a few cells in the 
hippocampus at 170dpi (Brown et al, 2003a), labelling resembled that observed in this 
study. In C57BL mice infected with the 79A strain of scrapie, a marked retinopathy is 
observed along with degeneration in the cerebellum. In these mice a massive cell loss 
was observed in the retina, identified with TUNEL labelling, but only a few cells 
labelled in the cerebellum of terminally ill mice (Giese et al, 1995). In a BSE mouse 
model where neuronal loss is also observed in the CA1 of the hippocampus, a few 
TUNEL labelled cells were detected at the end stages of disease. TUNEL labelling 
and active caspase-3 are useful markers for detecting apoptosis in vivo when there is a 
marked induced cell death, like that observed within the retina of 79A infected mice. 
The lack of expression of these markers in the dramatic loss of neurons observed in 
the ME7 infected hippocampus may be due to a rapid clearance of these dying cells in 
vivo, or that the cell loss does not involve an apoptotic mechanism. 
Previous studies in the 87V/VM scrapie mouse model revealed an increase in 
expression of the Fas receptor in 87V infected CA2 neurons, suggesting a role for the 
extrinsic mediated pathway of apoptosis in TSE induced cell death. 
In the ME7/CV scrapie mouse model Fas expression was not upregulated in ME7 
infected CA1 neurons, although expression of this pro-apoptotic marker was observed 
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in glial cells in the CA3 sector of the hippocampus. Fas is a member of the TNF 
family of receptors that regulate a large and diverse number of cellular processes, 
many of which involve the immune system. Fas is constitutively expressed on both 
microglia and astrocytes (Bonetti et al, 1997; Lee et al, 2000; White et al, 1998). In 
murine microglia Fas is expressed at low levels and up-regulated by TNF-α or IFN-γ. 
The expression of Fas observed on glial cells at the terminal stage of disease in the 
ME7 infected brain may be induced by the expression of the pro-inflammatory 
cytokine IL-1β, found upregulated in astrocytes at this stage of the disease (Brown et 
al, 2003a; Williams et al, 1997b) and not related to apoptosis. Conflicting results were 
observed when analysing the role of the Fas receptor in the 87V/VM scrapie mouse 
model. Previous documented results revealed upregulation in the CA2 sector as early 
as 100 days, increasing in intensity at the terminal stage of disease (Jamieson et al, 
2001a). In the study performed here using the same antibody only a faint labelling of 
Fas could be observed in the CA2 at the terminal stage of disease. In a study using the 
RML strain of scrapie (Siso et al, 2002), no difference in Fas expression was observed 
between infected and control brains. Similar results were observed in both the 
87V/VM and ME7/CV models using the same antibody from this study. Evidence 
from previous studies and the work performed in this study reveal inconsistent results 
and the role of the receptor mediated pathway via Fas induction in TSE disease is 
unclear. Fas expression is often observed in cells not undergoing apoptosis in TSE 
infected brains and may have other functions unrelated to the induction of apoptosis 
(Puig & Ferrer, 2001). 
  The role the extrinsic pathway of apoptosis via Fas induction plays in the cell 
death observed in TSEs is uncertain. Therefore induction of apoptosis via the intrinsic 
(mitochondrial) pathway was investigated. When mitochondria are damaged i.e. 
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through the increase in reactive oxygen species within the cell, they release 
cytochrome c from the mitochondrial membrane into the cytosol. The expression of 
cytochrome c was analysed in brains at the terminal stage of disease in both scrapie 
mouse models. No marked difference was observed in the expression of cytochrome c  
in the ME7 (CA1) and the 87V (CA2) infected hippocampus in comparison with the 
aged matched controls. Some subtle changes where observed in the infected brains, 
single cells resembling the dark neurons identified in haematoxylin and eosin stained 
sections in Chapter 2, expressed cytochrome c. An increase in dark neurons are 
observed in ischaemic conditions in the brain. Mitochondria are a primary target in 
hypoxic conditions and when damaged release cytochrome c into the cytosol 
(Christophe & Nicolas, 2006). In the ME7 infected CA1 neurons, an increase in 
punctate labelling in the cytoplasm of some neurons was observed. A similar pattern 
of staining was observed in the brains of Huntington’s disease (HD) patients and in a 
transgenic model of HD, also shown in this study was a shift in the distribution of 
cytochrome c from the mitochondrial to the cytosolic fraction (Kiechle et al, 2002). 
The change in the pattern of staining observed in the ME7 infected CA1 neurons may 
relate to a shift in the distribution of cytochrome c from mitochondrial to cytosolic.  
The change in cytochrome c may not be due to an apoptotic mechanism, cytochrome 
c also plays a role in the antioxidant cascade and the changes observed here may be 
related to an increase in reactive oxygen species, which have been shown to be 
increased in TSE disease (Brazier et al, 2006; Choi et al, 1998; Guentchev et al, 2000; 
Kim et al, 2001; Milhavet & Lehmann, 2002).  Gene expression studies in the 
hippocampus of the ME7/CV scrapie mouse model revealed upregulation of 
mitochondrial genes involved in the apoptotic pathway, suggesting a role for this 
pathway in the neuronal loss observed in this model (Brown et al, 2003a). 
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In the caspase-dependent pathway active caspase-3 can be activated by an 
extrinsic (receptor), or an intrinsic (mitochondrial) mediated pathway. Upstream of 
caspase-3 are two caspases which upon activation initiate caspase-3 cleavage through 
either the intrinsic or extrinsic mediated pathway. On initiation of the Fas receptor 
complex activation and cleavage of caspase-8 occurs leading to the cleavage of 
caspase-3. When cytochrome c is released from the mitochondria it activates caspase-
9 resulting in its cleavage and the formation of the apoptosome complex (Figure 2). 
To analyse the role of both pathways in the cell loss observed in the two scrapie 
mouse models the expression of both active caspase-8 and active caspase-9 were 
examined.    
Upregulation of active caspase-9 was observed in the 87V infected brains only 
(Figure 15). Active caspase-9 is involved in the mitochondrial pathway of apoptosis, 
and is cleaved by cytochrome c when it is released from the mitochondria into the 
cytoplasm. This result contradicts previous results in this model where Fas was found 
to be upregulated; induction of apoptosis through a Fas mediated mechanism activates 
caspase-8 resulting in its cleavage.  The upregulation of active caspase-9 observed in 
this model indicates that there may be crossover between both the extrinsic and 
intrinsic pathways and that the activation of the caspase dependent pathway in the 
87V/VM scrapie mouse model may involve both a receptor mediated and 
mitochondrial pathway. This phenomenon has been observed in disease states, 
crosstalk between extrinsic and intrinsic cell death pathways have been observed in a 
mouse model of amyotrophic lateral sclerosis (ALS) (Tokuda et al, 2007) and in 
pancreatic cancer (Basu et al, 2006). 
 The activation of caspase-9 observed in the 87V/VM scrapie mouse model is 
suggestive of a role for the mitochondrial pathway of apoptosis in this model. The 
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role that the mitochondria may play in the activation of the caspase-dependent 
pathway was further investigated. Residing in the mitochondrial membrane is a group 
of proteins, called the Bcl-2 family. There are both pro- and anti-apoptotic members 
of this family of proteins, in which the balance of, can determine whether the cell 
commits to apoptosis. Bcl-2 is an anti-apoptotic member of this family and Bax is a 
pro-apoptotic member.  Bax translocation to the mitochondrial membrane induces the 
formation of the mitochondrial pore, releasing cytochrome c from the mitochondria 
into the cytosol. In both scrapie mouse models the expression of Bcl-2 and Bax was 
investigated.  
No difference in Bax expression was observed in the CA1 sector (ME7) or 
CA2 sector (87V) of the hippocampus in both the infected and normal brain controls 
(Figure 15&18). The expression observed on immunohistochemical and western blot 
analysis was cytosolic. In a healthy cell Bax is expressed in the cytosol and on 
induction of apoptosis translocates to the mitochondrial membrane where it interacts 
with Bcl-2 and initiates mitochondrial pore formation. No Bax expression was 
observed in the organelle fraction from either the infected or normal brain controls 
revealing no translocation from the cytosol to the mitochondrial membrane and 
therefore no Bax induced initiation of the mitochondrial pathway.  In a BSE mouse 
model Bax deletion did not protect neurons from TSE induced death and did not alter 
the development of disease (Coulpier et al, 2006). However, in a transgenic mouse 
model of inherited prion disease, Bax deletion rescued cerebellar granule neurons 
from apoptosis, although the clinical phase of disease was unaltered (Chiesa et al, 
2005). The role that Bax plays in the cell loss observed in this transgenic mouse 
model may be related to the overexpression of mutant PrP in this model. 
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The increase in gene expression and protein levels of Bax were increased in 
the brains of sheep with natural scrapie, (Lyahyai et al, 2007) and correlates with 
PrPSc deposition (Lyahyai et al, 2006) but not with active caspase-3 labelling.  In the 
sheep study active caspase-3 labelling was observed in glial cells and not within 
neurons labelling with Bax, revealing that neuronal dysfunction in natural scrapie and 
the upregulation of Bax is not related to apoptosis. 
Bcl-2 expression in the CA1 sector of the ME7 infected hippocampus was 
observed in glial cells in and around the CA1 pyramidal cell layer. Changes in 
mitochondria and increased expression of Bcl-2 has been observed in astrocytes 
undergoing stress (Ouyang & Giffard, 2004). Upregulation of astrocytes is a feature 
observed in the CA1 sector of the ME7 infected hippocampus, and the stress induced 
upregulation of Bcl-2 observed in these cells may have a neuroprotective role for both 
the neuron and astrocyte in this model.  In contrast, in the CA2 sector of the 87V 
infected hippocampus Bcl-2 labelling was observed surrounding the cell bodies of 
CA2 neurons and appeared to be increased in the 87V infected neurons. The slight 
increase in this anti-apoptotic protein in these neurons may be due to a survival role 
within these neurons, counteracting the cell death mechanisms.  Bcl-2 is inserted into 
the mitochondrial, endoplasmic reticulum and nuclear membranes where it has anti-
apoptotic functions. In the nucleus it interacts with nuclear lamins preventing 
breakage of DNA and neuronal cell death (Cassarino & Bennett, 1999). In the ME7 
infected hippocampus the expression of Bcl-2 was observed in the nuclear fraction 
only, suggesting that the upregulation of this anti-apoptotic protein in the nucleus may 
play a protective effect in the nucleus trying to counteract DNA breakage due to 
apoptosis. 
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This study provides very limited evidence for a role of apoptosis in the 
neuronal cell loss observed in TSEs. Differences observed in the two scrapie mouse 
models studied may relate to differences in susceptibility of the neuronal populations 
targeted in the hippocampus in these models. The 87V strain of scrapie targets a 
smaller more precise sector of the hippocampus, the CA2, which may ease the 
detection of apoptotic cells in vivo. Also, although a microglial response is observed 
in the CA2 at the terminal stage of disease, it is not as extensive as that observed in 
the CA1 of the ME7/CV model, therefore clearance of apoptotic cell bodies may be 
minimal in the 87V/VM model.   
Further studies analysing other cell death mechanisms i.e. autophagy, and their 
role in the neuronal cell loss observed in TSEs are required.     
FACS analysis as a tool to identify apoptotic markers in vivo 
 
The first FACS analysis study performed in this thesis was set up to identify if this 
technology could be used to identify a known phenomenon that is observed in the 
ME7 infected brains, a dramatic upregulation of microglia at the terminal stage of 
disease. This initial study was very successful revealing an upregulation of a 
microglial response in both the midbrain and forebrain but not in the hind brain. This 
result corresponds with immunohistochemical analysis of microglia in the ME7 
infected brain, in which a marked upregualtion is observed in the hippocampus, an 
area found within the midbrain. FACS analysis may be a quick and useful technique 
to use in quantification studies of the microglial response in different brain areas 
throughout the course of the disease in scrapie mouse models. 
 In the second study in the analysis of neurons in the normal mouse brain in 
vivo, a population of cells where labelled with NeuN a neuronal marker. These cells 
where predominantly found within gate 1 (Figure 28) a region where smaller less 
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complex cells are observed. On further analysis of the neurons labelled with NeuN, 
morphologically these cells were quite small and round (Figure 30) and not as large 
and complex as neurons observed after days in cell culture or in situ within the brain. 
Neurons are larger and more complex cells than microglia and their processes may be 
sheared off in the methodology used to obtain a single cell suspension for FACS 
analysis. Also the methodology used and the major disruption to neurons may induce 
apoptosis in these cells, making it difficult to interpret results and true apoptosis due 
to the disease conditions. Future studies using FACS analysis of neurons ex vivo may 
have to include steps to ensure the minimal alteration to the in vivo conditions.    
Further studies are required to determine the use of FACS analysis as a tool to study 






























Chapter 5 : Cytoskeletal changes and synaptic loss observed 
                     in the CA1 neurons of the ME7 infected 
                     hippocampus 
 
Introduction 
Neuronal cell loss is observed in the CA1 of the ME7 infected hippocampus at 160 
dpi.,  Prior to this loss at 100 dpi  cytoskeletal damage in the form of dendritic spine 
loss is observed (Brown et al, 2001), which correlates with axon terminal 
degeneration and synapse loss (Jeffrey et al, 2000). A progressive spine loss is 
observed throughout the incubation period of disease and by the terminal stage of 
disease the CA1 neurons become distorted, losing most of their dendritic spines and 
forming abnormal swellings within the apical dendrites (Belichenko et al, 2000; 
Brown et al, 2001).  
 In this chapter the role of the cytoskeleton in the neuronal cell loss observed in 
the CA1 sector of the hippocampus will be investigated and the role that it plays in the 
synapse loss in these neurons determined.    
5.1 Cytoskeleton 
 
The term cytoskeleton is used to denote a system of filamentous intracellular proteins 
of different shapes and sizes which form a complex often interconnected network 
throughout the cytoplasm. The cytoskeleton serves such functions as: establishing cell 
shape, providing mechanical strength, locomotion, chromosome separation in mitosis 
and meiosis and intracellular transport of organelles. The cytoskeleton is made up of 
three major kinds of protein filaments: actin filaments, intermediate filaments and 





Actin filaments are well defined filaments with a width of 6-8nm and are the thinnest 
of the cytoskeletal filaments. Actin filaments form a band just beneath the plasma 
membrane that provides mechanical strength to the cell, links transmembrane proteins 
(e.g. cell surface receptors) to cytoplasmic proteins, anchors the centrosomes at 
opposite poles of the cell during mitosis (Karsenti & Nedelec, 2004), and generates 
locomotion in cells such as white blood cells and interacts with myosin (thick) 
filaments in skeletal muscle fibres to provide muscular contraction (Gunst & Zhang, 
2008). A wide variety of actin-binding proteins exist and these can modulate the form 
that actin takes within the cell. Such interactions are fundamental to the structure of 
the cytoplasm and to cell shape since they regulate cytoplasmic viscosity, connect 
filaments together in large groups and cause bundles to extend or contract (Gunst & 
Zhang, 2008). Actin is the main cytoskeletal protein found within dendritic spines, 
which contributes to the motility and plasticity observed in this structure (Sekino et al, 
2007).  
Intermediate filaments 
Intermediate filaments include a family of protein filaments about 10nm thick, found 
in different cell types and often present in large numbers where structural strength is 
needed. There are several types of intermediate filaments, each constructed from one 
or more proteins characteristic of it:- 
Cytokeratins are found in epithelial cells, nuclear lamins form a meshwork that 
stabilises the inner membrane of the nuclear envelope (Gruenbaum et al, 2005), 
neurofilaments strengthen the long axons of neurons and vimentins provide 
mechanical strength to muscle and other cells . Glial fibrillary acid protein and 
peripherin are two well characterised intermediate filaments; glial fibrillary acid 
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protein is found abundantly in astrocytes and peripherin is found within peripheral 
axons in the peripheral nervous system (Perrot et al, 2008). Neurofilaments occur in 
three different molecular weight groups, some of which are located in the neuronal 
cell body rather than the axon.  Neurofilaments are the most abundant cytoskeletal 
component of large myelinated axons in the adult central and peripheral nervous 
system. The disruption to the cytoskeleton of axons due to alterations in 
neurofilament assembly is observed in the large motor neurons of patients suffering 
from motor neurone disease (Lee & Cleveland, 1996; Lin & Schlaepfer, 2006)   
Microtubules 
Microtubules are polymeric fibres with hollow cylinders about 24nm in diameter, and 
of varying length, some up to 70μm in spermatozoan flagella (Inaba, 2003; Jouannet 
& Serres, 1998). They are present in most cell types, but particularly abundant in 
neurons, leucocytes, blood platelets and in the mitotic spindles of dividing cells 
(Papakonstanti & Stournaras, 2008). Microtubules are polymers of tubulin. There are 
two major forms of this protein, α- and β-tubulin, which before assembly occur 
together as dimers (Soifer, 1986) with a combined molecular weight of 100kDa. 
Microtubules are built by the assembly of both dimers of α and β tubulin, which grow 
at each end by the polymerization of the tubulin dimers, powered by the hydrolysis of 
GTP, and shrink at each end by the release of tubulin dimers (depolymerisation) 
(Beghin et al, 2007; Hammond et al, 2008). Both processes always occur more rapidly 
at one end, called the plus end, the other less active end is the minus end. 
Microtubules participate in a wide variety of cell activities, most involving motion. 
The motion is provided by protein “motors” that use the energy of ATP to move along 
the microtubule (Hirokawa & Noda, 2008; Kolomeisky & Fisher, 2007). There are 
two major groups of microtubule motors: kinesins (most of these move towards the 
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plus end of the microtubule) and dyneins (which move towards the minus end). The 
rapid transport of organelles, like vesicles and mitochondria, along the axons of 
neurons takes place along microtubles with their plus ends pointed toward the end of 
the axon (Caviston & Holzbaur, 2006).One cause of the rare disorder Charcot-Marie-
Tooth disease is an inherited mutated gene for one of the kinesins. In these patients, 
axonal transport is defective (Shy, 2004). 
 
 
Figure 1. structure of the cytoskeleton. The cytoskeleton consists of three main 
filament types :  (A) Microtubules (B) Actin filaments and (C) Intermediate filaments 
 
5.1.1 Neuronal cytoskeleton 
 
Neurons share many structural features in common with other cells, but they are 
distinguished by their highly asymmetric shapes and by the existence of dendrites and 
axons. The cytoskeleton is an important part of a neuron and is a heterogeneous 
network of filamentous structures which includes microfilaments, neurofilaments and 
microtubules (Figure 2). The neuronal cytoskeleton is essential for establishing the 
cells shape and for axonal transport. The axon of a neuron conducts the transmission 
of action potentials from the cell body to the synapse. The axon also provides a 
physical conduit for the transport of essential biological materials between the cell 
body and the synapse that are required for the function and viability of the neuron 
(Cingolani & Goda, 2008). Disruption of the cytoskeleton within the axon can lead to 
defects in axonal transport and death of the neuron (Lin & Schlaepfer, 2006), 
therefore a candidate for examining neurodegenerative mechanisms.   
 The cytoskeleton of the neuronal dendrite consists of microtubules and 
microtubule associated proteins, which play a role in maintaining the shape of the 
dendrite and neuronal transport.  Attached to these dendrites are small protrusions 
called dendritic spines. Actin is the major cytoskeletal protein found within dendritic 
spines. A compartmentalisation of the cytoskeleton in dendrites occurs, with 
microtubule proteins limited to the dendritic shaft, whereas actin is concentrated in 
dendritic spines (Kaech et al, 2001) Many syndromes associated with mental 
retardation are characterised by cortical dendritic anomalies. Patients suffering from 
Rett syndrome (Kaufmann et al, 2000), schizophrenia (Benitez-King et al, 2004) and 
fragile-X syndrome (Zalfa & Bagni, 2004) show a reduction in dendritic arborisation, 
and a loss of the dendritic microtubule associated protein, MAP-2. Dendritic 
abnormalities are also observed in Alzheimer’s disease (AD), mainly due to the 
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deposition of hyperphosphorylated microtuble associated protein, tau (Anderton et al, 
1998).   
 
 
Figure 2. Cytoskeleton of a neuron 
 
5.1.2 Cytoskeletal proteins 
 
Within the cytoplasm or attached to the walls of microtubules are various small 
proteins that can bind to assembled tubulins, which may be either structural or 
associated with motility.  These proteins are called microtubule associated proteins 
(MAPs). The MAPs form cross bridges between adjacent microtubules (Figure 2) or 
between microtubules and other structures such as intermediate filaments, 
mitochondria and the plasma membrane. MAPs are implicated in various aspects of 
microtubule biology, including their formation, maintenance and demolition (Moores, 
2008).  
MAP-2 historically has been perceived primarily as a static, structural protein, 
necessary along with other cytoskeletal protein to maintain neuroarchitecture.  This 
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protein is in fact quite dynamic and is sensitive to many inputs and has been shown to 
be involved in the growth, differentiation, and plasticity of neurons, with key roles in 
neuronal responses to growth factors, neurotransmitters, synaptic activity and 
neurotoxins (Johnson & Jope, 1992). Its involvement in neurodegeneration will be 
discussed below. 





MAP-2 is one of the microtubule associated proteins observed in the mammalian 
brain, with an important role in neurite outgrowth and in neuronal plasticity. MAP-2 
isoforms are split into 2 groups : high molecular weight MAPs (HMWT MAP-2) 
which includes MAP-2A&B with molecular weights of 280 & 270 kDa, and low 
molecular weight MAPs (LMWT MAP-2) which includes MAP-2 C&D with 
molecular weights of 70 &75 kDa (Sanchez et al, 2000). In the central nervous system 
HMWT MAP-2 is specifically expressed in neurons (Caceres et al, 1984; Huber & 
Matus, 1984) while LMWT MAP-2 is present in glial cells (Rosser et al, 
1997);(Vouyiouklis & Brophy, 1995) HMWT MAP-2 is mainly located in neuronal 
cell bodies and dendrites where it is associated with microtubules (Caceres et al, 
1986). MAP-2 proteins are highly phosphorylated in vivo, phosphorylation at distinct 
sites on the molecule differentially affects MAP-2 function, modulating its interaction 
with microtubules and its stabilization capacity (Brugg & Matus, 1991; Itoh et al, 
1997).  
 The loss of Map-2 expression, possibly due to the activation of calpain 
mediated proteolysis, is an early indicator of ischaemia-induced neurodegeneration in 
several animal models (Ballough et al, 1995; Raley-Susman & Murata, 1995; 
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Schmidt-Kastner et al, 1998). Cytoskeletal abnormalities involving the disruption of 
microtubules have also been observed in the hippocampus in schizophrenia. Deficits 
in MAP-2 and MAP-1 were observed in the hippocampus and entorhinal cortex of 
brains from schizophrenics compared with controls (Arnold et al, 1991). Abnormal 
patterns of MAP-2 expression have been observed in neurons of the substantia nigra 
in Parkinson’s disease. MAP-2 co-localises with α-synuclein and ubiquitin in 
cytoplasmic Lewy bodies of neurons, and has been detected within fibrous aggregates 
and crystal like structures in neuronal nuclei (D'Andrea et al, 2001). These alterations 
in MAP-2 morphology and distribution suggest that impaired neuronal transport may 
be involved in the neuronal loss observed in the brains of patients with Parkinson’s 
disease. 
 The involvement of MAP-2 in the neuronal cytoskeletal damage observed in 
TSE diseases has not been well documented. Golgi studies in CJD diseased brains and 
rodent models of TSE (Hogan et al, 1987), have shown cytoskeletal abnormalities 
within pyramidal neurons of the cortex, with large varicosities being  observed within 
the dendrites and axons of these neurons (Kim & Manuelidis, 1989; Landis et al, 
1981; Machado-Salas, 1986) The involvement of cytoskeletal proteins in the damage 
observed in these cortical pyramidal neurons has yet to be determined. However the 
expression levels of MAP-2 has been used successfully to analyse dendritic 
abnormalities in CA1 neurons in the hippocampus in animal models of HIV 
(Montgomery et al, 1999), experimental depression (Reines et al, 2004) and chronic 
hypoxia (Raman et al, 2008). Therefore MAP-2 was used to assess the extent of 









Tau is a microtubule associated protein that becomes both functionally and 
structurally altered in several neurodegenerative diseases, collectively known as 
tauopathies (Williams, 2006). Tauopathies encompass more than 20 
clinicopathological entities, including Alzheimer’s disease , progressive supranuclear 
palsy, Pick’s disease, and corticobasal degeneration. Common to all these diseases is 
the deposition of abnormal tau aggregates in the brain (Brandt et al, 2005). Tau is a 
collection of microtubule associated proteins (MAPs) (Cleveland et al, 1977) 
expressed from a single gene on chromosome 17 (Andreadis et al, 1992; Neve et al, 
1986). In the adult human brain, 6 isoforms ranging between 352 and 441 amino acids 
in length are produced as a result of alternative RNA splicing (Goedert et al, 1989a; 
Goedert et al, 1989b). Tau is preferentially found in neurons (Binder et al, 1985; 
Migheli et al, 1988) but can also be detected in some oligodendrocytes and astrocytes 
(LoPresti et al, 1995; Migheli et al, 1988; Papasozomenos & Binder, 1987; Tashiro et 
al, 1997). The normal biological activity of tau, in promoting assembly and stability 
of microtubles, is regulated by its degree of phosphorylation. In tauopathies, such as 
AD, tau is abnormally hyperphosphorylated and accumulates with cross-linked 
microtubules, as intraneuronal tangles of paired helical filaments (Figure 3A). This 
abnormality is an important process leading to cell death, the severity of which 
correlates with dementia in AD patients (Iqbal et al, 2005). Pharmacological 
modulation of tau hyperphosphorylation might represent a valid and feasible 
therapeutic strategy in tauopathies. Studies designing inhibitors for the most relevant 
kinases affecting tau hyperphosphorylation – GSK3beta, CDK5 and ERK2 are 
underway and show much promise (Mazanetz & Fischer, 2007)   
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The abnormal hyperphosphorylation of tau was observed in the brains of 
transgenic mice overexpressing bovine PrP. Abnormal tau accumulation was observed 
in both neurons and glial cells of mice infected with BSE (Bautista et al, 2006). 
Studies in the 87V/VM scrapie mouse model revealed tau deposition surrounding 
amyloid plaques observed within the brain (Brion et al, 1987).  The deposition of tau 
within the brain of murine mouse models was predominantly observed in those 
models where accumulation of PrPSc was observed in the form of plaques (Figure 3B). 
In the ME7/CV mouse model in which PrPSc deposition is mainly observed as the 
diffuse synaptic type, tau deposition was not prominent. The tau accumulation 
observed in the BSE mouse model was located in the same areas as PrP deposition, 
and may be related to the overexpression of PrP in this model. Tau accumulates in 
dystrophic neurites surrounding amyloid plaques in AD, and has also been identified 
in neurites surrounding amyloid plaques in human TSEs (Sikorska et al, 2008)      
 
    
Figure 3. Tau deposition in the 87V/VM scrapie mouse model and an 
Alzheimer’s diseased brain.  (A) Tau deposition observed in neurites around an 
amyloid plaque in the cortex of an 87V infected mouse brain. (B) Tau labeling 




5.1.4 The cytoskeleton and TSEs 
 
The association between disruption of the neuronal cytoskeleton and TSE disease is 
unclear. In two contrasting hippocampal neuronal loss mouse models of TSE : the 
ME7/CV mouse model where neuronal loss is targeted to the CA1 sector of the 
hippocampus, and the 87V/VM mouse model where neurodegeneration targets the 
CA2 sector, cytoskeletal damage was observed. Analysis of Lucifer yellow 
microinjected CA1 neurons in the ME7 infected hippocampus revealed a loss of 
dendritic spines early in the incubation period of disease. The Lucifer yellow 
microinjection technique was an excellent technique to use in order to identify single 
pyramidal cell neurons within the hippocampus and was used to pick up subtle 
changes in the morphology of ME7 infected neurons. This technique identified early 
changes observed in the primary dendrites of scrapie infected neurons. Quantification 
of confocal images of Lucifer yellow microinjected neurons revealed the initial loss of 
dendritic spines from primary dendrites infected with ME7 at 109 days post injection, 
by 126 days 51% of spines are lost (Figure 5&6).  By the terminal stage of disease 
these neurons where grossly altered, losing most if not all of their dendritic spines. 
Apical and primary dendrites were thin and irregular in shape, contained varicosities 
and swellings resembling vacuoles (Figure 4B&D) (Belichenko et al, 2000; Brown et 
al, 2001). In CA2 hippocampal neurons in the 87V/VM model, cytoskeletal 
abnormalities were observed as early as 70 days of a 320 day incubation period. 
Dendritic swellings similar to those observed in the CA1 neurons in the ME7/CV 
model were observed, increasing in numbers by the terminal stage of disease 
(Jamieson et al, 2001b). Golgi impregnation studies of neurons from the brains of 
hamsters infected with scrapie (Hogan et al, 1987) and patients suffering from CJD 
(Landis et al, 1981) revealed similar cytoskeltal abnormalities. 
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The dendritic spine plays a major role in the cytoskeletal damage observed in 
TSE infected neurons. In the ME7/CV scrapie mouse model the loss of dendritic 


























Figure 4.  Confocal images of lucifer yellow microinjected CA1 neurons in the 
hippocampus of a normal brain injected control (A) and a ME7 infected brain 
(B) at the terminal stage of disease. (A) CA1 pyramidal neuron from a normal brain 
injected control showing characteristic morphology, long apical dendrite stretching 
the length of the stratum radiatum (SR), and branching primary dendrites with many 
dendritic spines (C) The ME7 infected CA1 neurons morphology has changed 
dramatically. Showing a loss of primary dendrites (B) and dendritic spines from the 
apical dendrite (D) also observed are large varicosities within the apical shaft and 
primary dendrites. All images were produced using a Biorad MRC-500 CLSM serial 
optical scanning (z-series) was performed of all images. (A) & (B) were both taken 
with an x20 objective and the zoom at 1.5 (C) & (D) were produced using a x60 oil 
immersion lens and the zoom at 4. Scale bar in (A) = 25μm & (B) = 50μm (Brown et 








































Figure 5. Quantification of dendritic spines Primary dendrites from (A) normal 
pyramidal cell neuron showing characteristic dendritic spines. (B) ME7 infected 
pyramidal cell neuron at 98 dpi showing no spine loss looking similar to the control in 
(A). (C) ME7 infected pyramidal cell neuron at 109dpi showing some gaps with no 
spines (yellow arrow). (D) ME7 infected pyramidal cell neuron at 126 dpi showing 

























Figure 6. Quantification of dendritic spine loss Bar graph of mean number of 
spines counted per 10μm of primary dendrite in normal pyramidal cell neurons 
(control) and ME7 infected pyramidal cell neurons at 98, 109 and 126 dpi. First 




5.1.5 The dendritic spine and the cytoskeleton 
Dendritic spines are specialised protrusions from dendritic shafts that receive the vast 
majority of excitatory input in the central nervous system. Within these spines are 
neurotransmitter receptors, ion channels, scaffolding proteins, actin cytoskeletal 
proteins and intracellular signaling molecules (Figure 7). Dendritic spine loss and 
abnormal spine morphology is observed in many neurological disorders accompanied 
by cognitive deficits, such as Alzheimer’s disease, Down’s syndrome, and the fragile- 
X syndrome (Fiala et al, 2002). Dendritic spines have been proposed as the primary 
sites of neuronal synaptic plasticity. Actin filaments, which consist of actin molecules 
and actin-binding proteins, form cytoskeletal networks within dendritic spines and 
play critical roles in spine maintenance and plasticity. Actin is present in monomeric 















** P<0.001 in comparison to control group by Student’s t test. 
Control   98dpi    109dpi    126dpi 
concentrations of F-actin are observed within dendritic spines. The regulation and 
organization of F-actin is controlled by actin binding proteins. Many actin-binding 
proteins have been identified in dendritic spines; one of these proteins, drebrin, is 
thought to be involved in synaptic plasticity (Imamura et al, 1992).  
Drebrin is an F-actin binding protein that has a role in regulating assembly and 
disassembly of actin filaments within the dendritic spine. Drebrin was originally 
isolated from embryonic chicken brains as developmentally regulated brain proteins 
that were expressed in the development of neurons (Shirao & Obata, 1985; Shirao & 
Obata, 1986). There are two major drebrin isoforms, drebrins E and A (Kojima et al, 
1988; Shirao et al, 1988). Drebrin E is a ubiquitous isoform, and predominates in the 
developing brain (Shirao & Obata, 1986), and drebrin A is a neuron-specific isoform, 
and predominates in the adult brain (Aoki et al, 2005; Kojima et al, 1993).  
Transfection experiments have demonstrated that drebrin A expressed in mature 
cultured neurons accumulates spontaneously in dendritic spines (Hayashi & Shirao, 
1999). Therefore, the actin cytoskeleton of dendritic spines is distinguished from that 
of dendritic shafts by its association with drebrin.  This phenomenon makes drebrin an 
ideal protein for analysis of dendritic spines, and the role they may play in the 






                                  
Figure 7. Structure of a dendritic spine. As shown the spine head contains actin and 
multiple actin binding proteins including spectrin, drebrin and alpha-actinin. The PSD 
is a compact matrix that lies just beneath the post synaptic membrane, it contains 
scaffolding molecules i.e. PSD-95 which connect to glutamate receptors and recruit 





5.2 The Synapse 
 
Synapses are functional connections between neurons, or between neurons and 
other cell types. A typical neuron gives rise to several thousand synapses, although 
there are some types that make fewer. Most synapses connect axons to dendrites, but 
there are also other types of connections, including axon-to-cell-body, axon-axon, and 
dendrite-to-dendrite. Synapses are generally too small to be recognised using a light 
microscope, but their cellular elements can be visualised clearly using an electron 





 Chemical synapses pass information directionally from a pre-synaptic cell to a 
post-synaptic cell and are therefore asymmetric in structure and function. The pre-
synaptic terminal, or synaptic bouton, is a specialised area within the axon of the pre-
synaptic cell that contains neurotransmitters enclosed in small membrane-bound 
spheres called synaptic vesicles (Triller & Choquet, 2008). Synaptic vesicles are 
docked at the pre-synaptic plasma membrane at regions called active zones. 
Immediately opposite is a region of the postsynaptic cell containing neurotransmitter 
receptors; for synapses between two neurons the postsynaptic region may be found on 
the dendrites or cell body. Behind the postsynaptic membrane is an elaborate complex 






















           
 
 




5.2.1. Synapse loss and TSEs 
Synapses appear to be primary pathological targets in TSE disease. Abnormal PrP 
accumulates in synaptic regions, and preclinical synaptic degeneration has been 
observed in the brains of patients suffering from CJD (Clinton et al, 1993; Kitamoto 
et al, 1992) and in mouse models of disease (Jeffrey et al, 2000; Siso et al, 2002).In a 
mouse model similar to the one used in this study a reduction in pre-synaptic 
synaptophysin levels correlates with disruptions in neurally driven behaviours such as 
burrowing and nesting (Cunningham et al, 2003), demonstrating the functional 
importance of synapse loss for the development of behavioural symptoms in TSE 
disease.  
 In an electron microscopic study in the ME7/CV mouse model, synapse loss is 
observed in the CA1 neurons of the hippocampus from 84 dpi approximately 80 days  
before the loss of these neurons (Jeffrey et al, 2000) . Prior to this synapse loss is the 
deposition of abnormal PrP in the stratum radiatum of the hippocampus.  In both these 
mouse models synaptic deficits precede the appearance of gross neuronal 
degeneration by several weeks, suggesting that synapse loss may be the fundamental 
lesion in TSE disease. This hypothesis is supported by the experiments attempting to 
alleviate neurological symptoms in the Tg(PG14) transgenic mouse model of 
inherited TSE disease through deletion of the pro-apoptotic factor Bax (Chiesa et al, 
2005). These mice develop a progressive neurological disorder characterised by ataxia 
and cerebellar atrophy, with massive apoptotic degeneration of granule neurons. Bax 
deletion rescued cerebellar granule neurons from apoptosis, but the onset and severity 
of neurological symptoms were not altered. Quantification of the numbers of 
synaptophysin positive synaptic endings in the cerebellum showed that synapse loss 
proceeds even when apoptotic pathways in the rest of the neuron are blocked.  
 175
The trigger for the synaptic loss and subsequent neuronal loss observed in the 
ME7/CV mouse model appears to be the deposition of PrPSc. However ultrastructural 
studies analysing the subcellular accumulation of PrPSc has found no evidence for 
PrPSc deposition at synaptic junctions or in synaptic vesicles (Godsave et al, 2008), 
therefore it appears unlikely that PrPSc acts directly on synapses. Increasing evidence 
suggests that oligomeric forms of PrPSc are those that are likely to be more neurotoxic 
(Sokolowski et al, 2003) (Baskakov et al, 2002; Baskakov et al, 2001; Simoneau et al, 
2007), although little is known about the subcellular location of these oligomeric 
forms.   
5.3  Aims of Chapter  
 
The principal aims of the work in this chapter are to investigate the role of the 
neuronal cytoskeleton and synaptic changes in the loss of CA1 neurons in the ME7 
infected hippocampus. 
 In the study performed here using the ME7/CV scrapie mouse model the role 
that the pre- and post-synaptic elements of the synapse play in the synaptic loss 
observed in CA1 neurons will be analysed and related to the cytoskeletal damage 
observed in these neurons. 
The expression of pre-synaptic protein synaptophysin and post-synaptic 
protein PSD-95 will be analysed throughout the incubation period of disease.  
The cytoskeletal changes observed within both the dendrite and dendritic spines of 
CA1 sector neurons in the hippocampus will be compared. MAP-2 and alpha tubulin 
expression, cytoskeletal proteins found within the dendrites of CA1 neurons, will be 
analysed throughout the incubation period of disease and compared with the 







• To analyse the expression of dendritic cytoskeletal proteins tubulin and MAP-
2 in the CA1 sector (ME7) and CA2 sector (87V) neurons of the hippocampus 
at the terminal stage of disease.  
• To identify at which time point in the disease progression in the ME7/CV 
scrapie mouse model changes in the expression of MAP-2 first appear.   
• To analyse and compare the expression of drebrin (dendritic spine protein) and 
tubulin (dendrite protein) in the CA1 sector neurons of the ME7 infected 
hippocampus throughout the course of the disease. 
• To analyse the expression of pre- and post-synaptic proteins synaptophysin 
and PSD-95. 
 
5.4 Materials and methods 
 
Initial studies analysing the cytoskeletal proteins MAP-2 and alpha tubulin were 
performed on terminally infected animals from both the ME7/CV and 87V/VM 
scrapie mouse models (see chapter 1 for description of models). Further studies 
concentrated on the ME7/CV scrapie mouse model and the role of the cytoskeleton in 
the loss of CA1 sector neurons in this model. 
5.4.1 Immunohistochemical labelling of cytoskeletal proteins 
MAP-2 a+b 
Immunohistochemical labelling of microtubule associated protein 2 (MAP 2) was 
performed using an antibody raised to MAP2 a+b. This antibody specifically labels 
dendrites and soma of neurons and was used to analyse cytoskeletal changes in both 
the pyramidal neurons of the CA1 (ME7) and the CA2 (87V) sectors of the 
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hippocampus. Initially this antibody was used on brains from mice at the terminal 
stage of disease in both mouse models at the suggested concentration (1μg/ml) on the 
data sheet. Labelling worked well at this concentration therefore the time course study 
was performed at the same concentration. 
Tubulin 
Microtubules consist of subunits of alpha and beta tubulin. Initially immunolabelling 
for both the α and β forms of tubulin was performed on mouse brains from animals at 
the terminal stage of disease. On analysis of this immunolabelling β tubulin did not 
label the dendrites of the hippocampal pyramidal neurons and therefore was not used 
in these studies. Alpha tubulin was used to immunolabel the dendrites of both 
CA1(ME7) and CA2 (87V) sector pyramidal neurons. The antibody was used 
successfully at the concentration suggested on the data sheet (2μg/ml).  Alpha tubulin 
labelling was not performed on the ME7 time course series as it gave similar results to 
the MAP2 immunolabelling. 
Drebrin 
Ideally the drebrin antibody used in these studies should have been raised to 
the neuron specific form of drebrin, drebrin A. Unfortunately no commercially 
produced antibodies are available that recognise only the A form of drebin, therefore 
an antibody raised to both the neuron specific (A) and embryonic forms (E) was used.  
This antibody was chosen from MBL international corporation as it had been used 
successfully in studies analysing human Alzheimer cases (Shim & Lubec, 2002). 
Initial trials with this antibody were performed on sections from mice at the terminal 
stage of disease, both ME7 and normal brain controls were analysed. The antibody 
worked well at the suggested concentration of 10μg/ml on the data sheet therefore 
labelling of the time course study was performed at this concentration.  
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5.4.2 Western blot analysis of Tubulin, Drebrin, PSD-95 and synaptophysin 
 
Western blot analysis of Drebrin was performed with the same antibody as that used 
for the immunohistochemistry (see above and appendix 2 list 2.2). Drebrin was used 
at 10μg/ml overnight at 4oC.  Expression of Drebrin was reduced at 160dpi ME7 
confirming the IHC results. 
 Western blot analysis of alpha tubulin was performed with the same antibody 
used for IHC.  This protein was also used as a loading control for both the 
cytoskeletal and synapse proteins. 
 The antibodies used for western blot anlaysis of synaptophysin and PSD-95 
where purchased from synaptic systems.  Initially the PSD-95 antibody used for the 
IHC (Abcam) was used in western blot analysis but did not give good results. The 
antibody from synaptic systems was successfully used at the concentration suggested 
on the data sheet. The synaptophysin antibody worked well at the suggested 














5.5 Results - Cytoskeleton  
 
 
5.5.1 Decrease in MAP2 labelling was observed in the CA2 of the hippocampus 
         in 87V infected scrapie brains and in the CA1 of the hippocampus in the  
         ME7 infected scrapie brains at the terminal stage of disease. 
 
The microtubule associated protein, MAP-2 functions as a stabiliser of 
microtubules within the neuronal cytoskeleton. MAP-2 a and b are the predominant 
types found within the dendrites and soma of neurons. 
MAP-2 a and b expression was decreased in both the CA2 neurons of the 87V 
infected hippocampus and the CA1 neurons of the ME7 infected hippocampus (Figure 
10 C&D). Total loss of this cytoskeletal protein was observed in the CA2 sector of the 
87V infected hippocampus, but in the ME7 infected hippocampus MAP-2 expression 
was still observed in the few damaged CA1 neurons surviving (Figure 10D). 
 




















                              
        
                                                                      
 
 
Figure 10. MAP-2 a and b expression in the 87V/VM and ME7/CV scrapie 
mouse models at the terminal stage of disease. (A) Normal brain VM control mouse 
showing expression of MAP-2 in the CA2 neurons of the hippocampus and (C) Loss 
of MAP-2 expression observed in the 87V infected CA2 neurons. (B) CA1 neurons 
from a normal brain CV control showing MAP-2 expression in the dendrites of these 
neurons, and (D) Loss of MAP-2 expression in the ME7 infected CA1 neurons. Note 
the marked neuronal loss also observed in the CA1 sector. Magnifications (A)&(C) 
























5.5.2. Decrease in tubulin expression observed in both the ME7 infected CA1 
          neurons and the 87V infected CA2 neurons 
 
Within the cytoskeleton microtubles consist of subunits of both α and β 
tubulin. To determine the role that tubulin may play in the cytoskeletal disruption 
observed in both the CA1 (ME7) and CA2 (87V) neurons in the hippocampus, α 
tubulin expression was analysed. Alpha tubulin expression was decreased in both the 
CA1 (ME7) (Figure 11C) and the CA2 (87V) (Figure 11D) neurons of the scrapie 
infected hippocampus. The morphology of the CA1 neurons infected with ME7 looks 
similar to those injected with lucifer yellow (Figure 5B), showing shrinkage and 
contortion of the apical dendrites. In the 87V infected CA2 neurons total loss of 
tubulin is observed in the stratum radiatum, with a loss of apical dendrites, similar to 









Figure 11. Alpha tubulin expression observed in the CA1 (ME7/CV model) and 
CA2 (87V/VM model) of the hippocampus. (A) CA1 of a normal brain infected CV 
control showing expression of alpha tubulin within dendrites of the CA1 neurons. (C) 
ME7 infected CV brain demonstrating loss of alpha tubulin expression and shrinkage 
of apical dendrites within the CA1 of the hippocampus. (B) CA2 of a normal brain 
infected VM control showing alpha tubulin expression in the dendrites of CA2 
neurons. (D) 87V infected VM brain showing loss of alpha tubulin expression in the 















5.5.3 MAP-2 expression is decreased in CA1 neurons of the hippocampus from 
         160dpi ME7 infection. 
 
The results observed analysing both dendritic proteins MAP-2 and alpha 
tubulin were similar, therefore Map-2 was used as a marker to analyse the dendritic 
changes in the ME7 infected neurons throughout the course of disease. 
A time course study of the expression of MAP-2a+b in CA1 sector neurons in 
the ME7 infected hippocampus was performed. MAP-2a+b is expressed in both the 
soma and dendrites of neurons and was used to analyse the involvement of 
microtubles in the cytoskeletal damage observed in the dendrites of ME7 infected 
CA1 sector neurons (Figure 5B&D). A decrease in MAP2a+b expression was 
observed from 160dpi in the ME7 infected hippocampus (Figure 12D), this loss 
increased with the extent of neuronal loss observed in the hippocampus. By the 
terminal stage of disease, where there is marked neuronal loss observed in the CA1 
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Figure 12. Time course study of MAP-2 expression in the hippocampus of the 
ME7/CV scrapie mouse model. Dendritic MAP-2 expression observed in the CA1 
sector of the hippocampus in (A) 69dpi NB (B) 69dpi ME7 and (C) 102dpi ME7. 
Disruption and loss of MAP-2 expression observed in (D) 160dpi ME7, (E) 200dpi 
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5.5.4 Immunohistochemical analysis of drebrin expression revealed a decrease in the 
         ME7 infected hippocampus from 160 dpi. 
 
A time course study of the expression of drebrin in CA1 neurons in the ME7 infected 
hippocampus was performed. Drebrin is an F-actin binding protein that is expressed  
within the dendritic spines of neurons. Immunohistochemistry was used to analyse the 
role of the dendritic spine in the cytoskeletal damage observed in the ME7 infected CA1 
sector neurons of the hippocampus. Any changes observed will be compared with the 
results analysing the dendritic proteins Map-2 and tubulin. Drebrin expression was 
decreased in the CA1 sector neurons of the hippocampus from 160dpi., although the loss 
of expression of this protein was variable at this time point and correlates with the extent 
of neuronal loss observed in the CA1 sector.  This loss was specifically targeted to the 
CA1 of the hippocampus, slight loss was observed in the CA3 sector mossy fibres 
(Figure 13C). By the terminal stage of disease total loss of drebrin expression was 
observed in both the CA1 and CA3 sectors of the hippocampus (Figure 13D), partial loss 
of drebrin expression was observed in the CA2 sector (Figure 14B) with no loss of 
expression in the dentate gyrus (Figure 14C). The loss of drebrin correlates with the 













Figure 13. Drebrin immunolabelling in the hippocampus (A) normal brain (NB) 
control showing widespread labelling throughout the hippocampus. (B) CA1 from NB 
control widespread labelling observed in the stratum oriens and stratum radiatum of 
the hippocampus. (C) 160dpi ME7 infected hippocampus showing loss of drebrin 
labelling in the CA1 sector of the hippocampus. (D) 160dpi CA1 of the hippocampus 
showing almost total loss of drebrin labelling. (E) ME7 infected hippocampus at the 
terminal stage of disease showing total loss of drebrin labelling in the CA1 and CA3 
sectors of the hippocampus. Intense drebrin labelling still observed in the dentate 
gyrus of the hippocampus, and in the CA2 sector of the hippocampus (arrow) (see 







Figure 14. Drebrin immunolabelling in the CA2 and the dentate gyrus (DG) of 
the ME7 infected hippocampus at the terminal stage of disease (A) drebrin 
labelling in the ME7 infected hippocampus at the terminal stage of disease, intense 
labelling still observed in the DG with partial loss in the CA2 sector. (B) drebrin 
labelling in the CA2 sector of the hippocampus. (C) intense drebrin labelling in the 
DG, no labelling observed in the stratum radiatum (SR) of the CA1 sector. 















5.5.5 Western blot analysis of drebrin, alpha tubulin and PSD-95 expression in the 
         ME7 infected hippocampus revealed a loss of drebrin from 160dpi but no  
         difference in the expression of both alpha tubulin and PSD-95 
 
The antibody used to detect drebrin expression recognises both the embryonic (E) (116 
kDa) and the adult (A) (125kDa) form of the protein. In the hippocampus of the 
developing rat brain drebrin E expression gradually decreased and was not detected in  
adulthood (Aoki et al, 2005)  In the ME7/CV mouse model drebrin E expression 
disappeared from 160dpi in both the normal and ME7 infected hippocampus, mice in this 
study were injected at 12 weeks of age therefore the embryonic form disappeared in the 
mouse hippocampus at 244 days of age. Surprisingly a faint band of drebrin E expression 
was observed in all four of the aged matched terminal normal brains at 324 days old. 
Western blot analysis of the expression of the dendritic spine protein, drebrin, revealed 
loss of this protein from 160 dpi. (Figure 15D). Semi-quantitative densitometry analysis 
confirmed this loss (Figure 17). At the 160dpi time point only one of the two infected 
samples showed a significant decrease in drebrin levels in comparison to the normal 
brain control, therefore more samples will have to be assessed at this time point in order 
to check the significance of this result. The results observed here in the western blot 
analysis correlates with the immunohistochemical results in Figure 13. 
  No differences where observed in the expression of both alpha tubulin and 
PSD-95 throughout the incubation period of disease. The expression of alpha tubulin 
assessed by western blot was constant throughout (Figure 15), this did not correlate with 
the IHC results which revealed loss of alpha tubulin in the CA1 neurons at the terminal 
stage of disease (Figure 11C). Western blot analysis of synatophysin was not performed 
on hippocampal lysates from the time series as no difference was observed at the terminal 
stages of disease using this method and immunohistochemical analysis was the preferred 
method used to analyse this protein. In light of the results obtained analysing PSD-95, 
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this would also seem to be the case for this protein. Western blot analysis was not the 
preferred method of choice to analyse subtle changes in alpha tubulin, synaptophysin and 
PSD-95 expression. Immunohistochemistry did reveal subtle changes in these proteins 



























Figure 15. Western blot analysis of Drebrin, Tubulin and PSD-95 on ME7 time 
series.  Time course study of drebrin, tubulin and PSD-95 in dissected hippocampi from 
normal (NB) and ME7 infected brains. One normal and two infected brains analysed at 
each time point. (A)&(D) Drebrin expression observed in ME7 time series, top band = 
drebrin A (125KDa), bottom band = drebrin E (116 KDa). Both bands expressed in 
infected and controls brains in blot (A) expression of bottom band, embryonic form of 
drebrin, lost in all samples except NB terminals in blot (D) Expression of drebrin A 
decreased from 160dpi ME7 infection (D),  (B)&(E) No difference in alpha tubulin 
expression observed throughout the time series. (C)&(F) No difference in PSD-95 








































Figure 16. Semi-quantification of percentage drebrin A expression from lanes 1-
11 in figure 12 calculated using densitometry. Percentage expression of each band 
measured as a percentage of the thickest band on the gel (102d ME7 lane 6). No 






















Figure 17. Semi-quantification of percentage drebrin A expression from lanes 
12-21 in figure 12 calculated using densitometry. Percentage expression of each 
band measured as a percentage of the thickest band on the gel (200d NB lane 4). First  




































































































5.6 Results – synapse loss 
 
5.6.1. Loss of intensity of synaptophysin observed from 200dpi ME7 
 
A time course study of the expression of synaptophysin in CA1 sector neurons 
in the ME7 infected hippocampus was performed. Synaptophysin is a synaptic protein 
found within pre-synaptic terminals. This marker was used to assess the role of the 
pre-synaptic synapse in the synapse loss observed in the ME7 infected CA1 sector 
neurons. Deposition of synaptophysin was observed in the ME7 infected 
hippocampus throughout the incubation period of disease (Figure 18). The 
distribution of this protein was altered in the ME7 infected brain at 160dpi (Figure 18 
D) in comparison to the 102 dpi (Figure 18C), although the intensity of the staining in 
both brains was similar. The intensity of synaptophysin expression decreased from 
200dpi (Figure 18E), although the distribution stayed the same as that observed in the 
160day infected brain. By the terminal stage of disease an obvious decrease in 
intensity can be observed (Figure 18F). Despite this change, there is still a marked 
labelling of synaptophysin observed in the stratum radiatum of the hippocampus at the 




Figure 18.  Time series study of synaptophysin labelling in the hippocampus of 
the ME7/CV scrapie mouse model. No difference in synaptophysin labelling 
observed from 69 dpi to 130dpi (A) CA1 sector of the hippocampus in a 69dpi NB 
injected animal and (B) a 69dpi ME7 infected animal.(C)102 dpi ME7 infected 
animal. (D). Intensity of labelling decreased by 200dpi (E) and by the terminal stage 





5.6.2 Loss of intensity of PSD-95 labelling observed in the CA1,CA2 and CA3  
         sectors of the hippocampus at the terminal stage of disease. 
 
In order to compare the pre- and post-synaptic density a time course study of 
the expression of  post synaptic density -95 (PSD-95) protein in CA1 neurons in the 
ME7 infected hippocampus was performed. This post-synaptic protein was used to 
assess the role of the post-synaptic synapse in the loss of CA1 neurons observed in the 
ME7 infected hippocampus. No change was observed in PSD-95 expression in the 
time course study until the terminal stage of disease (Figure 19E&F). At the terminal 
stage of disease PSD-95 expression was decreased in the CA1,CA2 and CA3 sectors 
of the hippocampus, although marked expression was still observed in the dentate 
gyrus (Figure 19E). Trypsin was used as a pretreatment at the recommended dilution 
and time scale, unfortunately it digested some of the sections causing some neuronal 
cell bodies to disappear in both the CA1 (Figure 19B) and dentate gyrus (Figure 19E) 
of the hippocampus. This is a common artefact often observed after pretreatment with 
trypsin, where over digestion of the cell membrane can lead to cell loss from tissue 











Figure 19. PSD-95 immunolabelling in the hippocampus. (A) normal brain control 
with widespread PSD-95 labelling throughout the hippocampus. (B) PSD-95 labelling 
in the CA1 sector, trypsin digestion created an artefact, resulting in loss of cell bodies 
from the CA1 (C) 160dpi ME7 infected hippocampus PSD-95 labelling still observed 
although neuronal loss is evident. (D) 160dpi CA1 showing PSD-95 labelling. (E) 
ME7 infected hippocampus at the terminal (T) stage of disease showing loss of PSD-
95 in CA1-CA3 of hippocampus, intense labelling still observed in the dentate gyrus 
(DG). (F) ME7 T CA1 sector showing loss of PSD-95 labelling. Magnification 
A,C&E x 4, B,D&F x20  
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5.6.3 No difference observed in the protein expression of synaptophysin or PSD- 
         95 at the terminal stage of disease.   
 
Using immunohistochemical analysis a decrease in the expression of both 
synaptophysin (Figure 18F) and PSD-95 (Figure 19E) in the ME7 infected 
hippocampus at the terminal stages of disease was observed. Could the decrease in 
expression of these proteins also be detected by western blot analysis of dissected 
hippocampus? 
Western blot analysis of synaptophysin and PSD-95 expression in the 
hippocampus at the terminal stage of disease showed no differences between the 
normal brain controls and ME7 infected brains (Figure 20). Ten mice were compared, 
three control and seven ME7 infected homogenates from dissected hippocampus were 
analysed.  Each blot was stripped and reprobed with alpha tubulin, which revealed no 


















Figure 20. Western blot analysis of Synaptophysin and PSD-95 in ME7 terminal 
and aged matched normal brain controls. No difference observed between the ME7 
infected and the NB controls in both the expression of synaptophysin and PSD-95. Blot 
was stripped and reprobed with alpha tubulin which revealed no difference between 
































 5.7  Discussion 
 
 
The role of the dendritic cytoskeleton in the events leading to neurodegeneration was 
analysed using the dendritic cytoskeletal proteins MAP-2 and alpha tubulin.  A loss of 
both proteins was observed at the terminal stage of disease in both CA1(ME7) and 
CA2(87V) scrapie infected neurons. A total loss of MAP-2 expression was observed 
in the CA2 sector of the 87V infected hippocampus revealing dramatic changes within 
the dendritic cytoskeleton of these neurons. Previous studies in this model revealed 
cytoskeletal damage in CA2 neurons as early as 70 days observed as varicosities 
within the apical dendrites (Jamieson et al, 2001b). In this study by the terminal stage 
of disease at 320dpi a total loss of MAP-2 expression is observed in the dendritic 
compartment of these neurons, although expression is still observed in the few 
remaining cell bodies. In the ME7 infected hippocampus at the terminal stage of 
disease only a few cell bodies remain in the pyramidal cell layer, MAP-2 
immunohistochemistry reveals a total loss of neuronal dendrites. MAP-2 plays a 
major role in stabilising microtubules and their role in neuronal transport. The loss of 
MAP-2 and damage to the microtubules within both the scrapie infected CA1 and 
CA2 neurons may contribute to impaired neuronal transport and subsequent death of 
these neurons. 
 A time course study of the expression of MAP-2 within the dendrites of ME7 
infected CA1 neurons revealed the initial disruption to the dendritic cytoskeleton at 
160dpi, a time point at which neurons are known to be lost in this model (Jeffrey et al, 
2000). The loss of expression of MAP-2 and dendritic damage within ME7 infected 
CA1 neurons is observed late in the progression of the disease. Earlier cytoskeletal 
changes in these neurons, i.e. the loss of dendritic spines, may initiate the disruption 
to the dendritic cytoskeleton and the eventual loss of MAP-2 within these neurons. 
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The initial loss of the expression of the dendritic spine protein, drebrin, within 
the ME7 infected CA1 neurons was observed at 160dpi, at a time point in the disease 
where dendritic cytoskeletal damage is first observed. Quantification of dendritic 
spine loss in ME7 infected CA1 neurons injected with Lucifer yellow revealed a 
much earlier loss of these spines, at 109 dpi. (Brown et al, 2001) The Lucifer yellow 
microinjection of CA1 neurons was a more sensitive technique that detected earlier 
changes observed in the dendritic spines of these neurons. In this study drebrin 
expression was used as a marker to analyse and compare the role of the dendritic 
spine cytoskeleton with that of the dendrite.   A specific targeted loss of this protein 
was observed in the CA1 sector of the hippocampus at 160dpi. This loss was observed 
in both the stratum radiatum and the stratum oriens of the hippocampus revealing 
cytoskeletal abnormalities within the spines of both the apical and basal dendrites of 
the CA1 neurons. Intense drebrin expression was observed throughout the other 
sectors of the hippocampus, at the terminal stage of disease, expression was still 
observed in the dentate gyrus and CA2 sector of the hippocampus. Similar expression 
patterns of drebrin were observed in the brains of Alzheimer’s disease patients, where 
a loss of drebrin expression was observed throughout the hippocampal formation, 
with some slight staining remaining in the dentate gyrus (Harigaya et al, 1996). This 
loss of drebrin reflects the loss of dendritic spines observed in hippocampal neurons 
in mouse models of Alzheimers disease (Grutzendler et al, 2007; Knobloch & 
Mansuy, 2008; Moolman et al, 2004; Scheff et al, 2007).  The loss of drebrin 
expression observed in the CA1 sector also reflects the targeted neuronal damage 
observed in the hippocampus of the ME7/CV scrapie mouse model. 
The CA1 neurons are connected to the CA3 neurons through the Shaffer 
collateral pathway, and the axons of the CA3 neurons have synaptic connections with 
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the apical dendrites of CA1 neurons (Spruston, 2008). Therefore the loss of drebrin 
and damage to the CA3 neurons observed at the terminal stage of disease may be 
related to the initial damage and spine loss observed in the apical dendrites of CA1 
neurons. In immunohistochemical analysis the initial loss of drebrin expression at 
160dpi correlates with the loss of MAP-2 and dendritic damage observed in ME7 
infected CA1 neurons, suggesting that cytoskeletal changes occur at the same time 
within dendritic spines and the dendritic shaft. However, the previous lucifer yellow 
studies show that damage to dendritic spines appears over 50 days earlier.  The results 
observed in this study demonstrated that disruption of the dendritic spine cytoskeleton 
plays a role in the cytoskeletal damage observed in the CA1 neurons, but what 
initiates this damage is still to be determined. 
    To analyse the role of the pre- and post-synaptic synapse in the synaptic 
loss observed in the ME7/CV mouse model the expression of synaptophysin and the 
post synaptic density protein PSD-95, were analysed.  
Synaptophysin labels a component of the synaptic vesicle membrane and is 
found predominantly within axon terminals. In the immunohistochemical time series 
study of synaptophysin labelling in the ME7 infected hippocampus the intensity of 
synaptophysin labelling was reduced at the terminal stage of disease, a slight 
reduction was observed in the 200 day group. Although the intensity of synaptophysin 
was decreased in the stratum radiatum of the ME7 infected hippocampus a marked 
labelling was still observed. Previous immunohistochemical studies quantifying the 
loss of synaptophysin at the terminal stage of disease in the ME7/CV model, revealed 
a significant loss in both the apical and basal dendrites of CA1 sector neurons 
(Belichenko et al, 2000). Both the basal and apical dendrites of CA1 sector neurons 
receive innervation from the CA3 sector neurons in the hippocampus. The presynaptic 
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axon terminals from CA3 neurons make connections with postsynaptic dendritic 
spines on basal and apical dendrites of CA1 neurons (Spruston, 2008). The loss of 
synaptophysin labelling observed at the terminal stage of disease in both the basal and 
apical dendrites is suggestive of a loss of innervation from the CA3 neurons at the end 
stage of disease. 
  Ultrastructural studies in the stratum radiatum of the ME7 infected 
hippocampus revealed early axon terminal degeneration (Jeffrey et al, 2000). 
Although these axons have degenerated the synaptic vesicles and their contents are 
still detectable, this may be due to a compensatory role played by the damaged axon.      
These results were similar to a previous study analysing the mechanisms involved in 
the neuronal loss observed in the scrapie infected dorsal lateral geniculate nucleus 
(dLGN). In mice injected intraocularly with the ME7 strain of scrapie, neuronal loss 
was observed in the dorsal lateral geniculate nucleus (dLGN) (Fraser et al, 1995). 
Synaptophysin labelling was decreased in the dLGN of mice terminally infected with 
ME7, but no loss of synaptophysin was detected on or before 150days of a 240 day 
incubation, suggesting that neuronal loss in this area was not the result of 
deafferentation.  
 Excitatory synapses are characterised by an electron-dense thickening of the 
post synaptic membrane, termed the post synaptic density (Figure 4). PSD-95 is a 
scaffolding protein enriched in the post-synaptic density, which binds and brings into 
close proximity, neurotransmitter receptors, signalling molecules and regulators of the 
actin cytoskeleton.  Most excitatory synapses in the mammalian CNS occur on 
dendritic spines (Fiala et al, 2002; Hering & Sheng, 2001). Dendritic spines are 
complex structures that have at their surface a post synaptic density.  
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 In the ME7/CV scrapie mouse model dendritic spine and synapse loss is 
observed early in the incubation period. What role, if any does the post synaptic 
density, and the scaffolding protein PSD-95, play in this loss? 
Using immunohistochemical techniques the loss of expression of PSD-95 in the 
hippocampus was not observed until the terminal stage of disease, when this deficit 
was found in all of the hippocampal formation, except for the dentate gyrus .The 
ultrastructural studies involved in the counting of synapses lost in ME7 infected CA1 
neurons reflect the loss of postsynaptic densities. The synapse counts in the ME7/CV 
model were performed between 84 and 181 dpi ME7 infection. Analysis of the actual 
numbers of synapses counted at each individual time point does not show a severe 
decline in numbers of synapses lost, although there is an overall significant loss. If 
synapse numbers relate to the intensity of PSD-95 labelling, a major difference might 
not be observed.  The intensity of PSD-95 immunostaining observed in the 
hippocampus may be a true reflection of how much of the PSDs that are actually still 
intact in the synaptic disruption observed in the ME7 infected CA1 neurons. PSD-95 
can also be moved around the cell in a preassembled package as a PDZ-based 
membrane bound complex. These complexes are transported along microtubule tracts 
by Kinesin motor proteins. Therefore PSD-95 expression may accumulate in dendritic 
shafts contributing to the expression levels observed in the ME7 infected 
hippocamapus. (Kim & Sheng, 2004).  
  The role of the post-synaptic density and PSD-95 in the synaptic loss 
observed in TSE disease has not yet been determined. PSD-95 plays a role in synaptic 
plasticity and in the clustering of the NMDA and AMPA receptors at the PSD and is 
involved in the maintenance of a form of synaptic plasticity know as long-term 
potentiation (LTP). In the mouse model studied here the maintenance of LTP in ME7 
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CA1 neurons was disturbed from 100dpi. Studies analysing the role of the NMDA 
receptor in this disruption have shown that this receptor complex was not 
compromised in scrapie infection, and that altered potassium currents rather than 
increased calcium entry via voltage-sensitive calcium channels or the NMDA receptor 
complex may be the mechanism involved in scrapie induced neurodegeneration 
(Johnston et al, 1998a).   
 In summary, the data from the present study together with previous 
observations show that synaptic dysfunction plays a role in the loss of CA1 sector 
neurons, although the mechanisms involved and the trigger for the synaptic loss have 
still to be determined.  
The first neuropathological change observed in the hippocampus of the ME7 
infected brain, is the deposition of PrPSc. The deposition of PrPSc has been observed 
on synapses in CJD (Kitamoto et al, 1992; Kovacs et al, 2005) and rodent models of 
disease (Fournier et al, 2000; Haeberle et al, 2000) suggesting a role for this abnormal 
protein in the synaptic degeneration observed in TSE disease. A more recent 
publication analysing the subcellular location of PrPSc in the stratum radiatum of the 
RML infected murine hippocampus revealed that there was no evidence for 
deposition of PrPSc at synaptic junctions or associated with synaptic vesicles, it 
therefore appears unlikely that PrPSc acts directly on synapses. 
 Astrocytes are known to play a role in synaptic plasticity, they ensure 
normal neuronal excitability, and participate in glutamate and potassium reuptake 
from the synaptic region (Seth & Koul, 2008). In the ME7 infected hippocampus 
astrocytes are activated early in the disease progression increasing in numbers by the 
terminal stage of disease. Disruption to the normal function of astrocytes and a build 
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up of glutamate in the surrounding neuropil may contribute to the synaptic 
degeneration and subsequent synaptic loss observed in CA1 neurons.        
 The results obtained in this chapter analysing the role of the cytoskeleton and 
the synaptic loss in the ME7 infected CA1 neuron will be compared with the results 
observed in Chapters 3 and 4 analysing the neuropathological changes and the 
mechanism of cell death involved in the neurodegeneration observed in the ME7 




















Chapter 6: Final discussion and future work  
 
 
The aims of this research were to investigate the mechanisms of neurodegeneration 
and subsequent neuronal cell loss observed in TSEs. In this study two contrasting 
scrapie mouse models were used : the ME7/CV model, and the 87V/VM model in 
which neuronal loss is targeted to different areas of the hippocampus, the CA1, and 
CA2 respectively.  Detailed studies of the progression of neurodegenerative changes 
in the ME7/CV scrapie mouse model revealed that the initial pathological change 
observed in the hippocampus was the deposition of PrPSc followed by a glial response, 
spongiform change and subsequent neuronal degeneration. The role of the 
cytoskeleton and synaptic dysfunction in the neuronal damage observed in the CA1 of 
the ME7 infected hippocampus was investigted. The results observed in these studies 
suggest that cytoskeletal disruption in the post-synaptic dendritic spine plays a major 
role in the neuronal dysfunction observed in ME7 infected CA1 neurons, although the 
post-synaptic density does not seem to be involved. Pre-synaptic changes and 
disruption to the innervation of CA1 neurons occur relatively late in the disease 
process as a consequence of earlier degenerative changes in the TSE infected neuron. 
One of the main aims of this thesis was to investigate the mechanism of cell 
death involved in the neuronal loss observed in the CA1 of the ME7 infected 
hippocampus. Apoptosis is the suggested mechanism of cell death associated with 
TSE-induced neuronal loss. This research was designed to address the mechanisms 
leading to the activation of and also subsequent execution of cell death through an 
apoptotic mechanism. The findings in this study have revealed that the mechanisms of 
neuronal loss in TSEs may follow different biochemical pathways, which might not 
necessarily involve an apoptotic mechanism.  
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 The trigger for the cytoskeletal disruption, synaptic dysfunction and 
subsequent neuronal loss may be the early deposition of PrPSc in the extracellular 
space, but the precise mechanisms involved are still to be elucidated. Recent studies 
analysing the role of PrPSc in the synapse loss observed in the ME7/C57BL scrapie 
mouse model correlate with the results obtained in this study and show that 
presynaptic indices were not compromised (Asuni et al, 2008).  Although it has been 
suggested that PrPc may play an important role in the maintenance and function of 
synapses (Westergard et al, 2007) the precise role of PrPSc at the synapse has still to 
be determined. The studies in the ME7/CV scrapie mouse model would suggest that 
the increase in PrPSc plays a role in the damage to the post-synaptic element of the 
synapse, the dendritc spine, most likely involving changes in actin dynamics within 
the spine head. However recent ultrastructural studies have revealed that PrPSc was 
not deposited on synapses (Godsave et al, 2008) and therefore may not play a 
significant role in synaptic dysfunction.  
The role of PrPSc and glial activation in the synaptic dysfunction observed in 
the ME7 infected CA1 neurons is unclear. Glial cells have many functions in the CNS 
and are known to actively contribute to neurotransmission, neuronal excitability, and 
several forms of synaptic plasticity, such as long term potentiation (LTP) (Bains & 
Oliet, 2007; Volterra & Meldolesi, 2005); (Vesce et al, 1999). The deposition of Aβ 
oligomers in combination with Aβ-mediated activation of microglia and astrocytes in 
Alzheimer diseased brains results in disruption of both hippocampal LTP and the 
memory of learned behaviours (Klyubin et al, 2005; Walsh & Selkoe, 2004a; Walsh 
& Selkoe, 2004b). The deposition of PrPSc in combination with a marked glial 
response may play a role in the early disruption of LTP (Johnston et al, 1998b)   
observed in ME7 infected CA1 neurons.  
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 LTP is a post-synaptic phenomenon involved in synaptic plasticity. Actin 
dynamics within dendritic spines are known to play a major role in synaptic function 
(Calverley et al, 1990). Disruption to the cytoskeleton and the loss of the F-actin 
binding protein, drebrin, may contribute to the synaptic dysfunction observed in the 
ME7 infected CA1 neurons. Surprisingly, the post-synaptic density (PSD) is not 
involved in the cytoskeltal disruption observed within dendritic spines. This may be 
due to the fact that different components show a differential dependence on F-actin 
for localisation within the spine. Although the PSD is a core component observed 
within the dendritic spine it is known to function independently of conventional 
cytoskeletal elements (Allison et al, 2000), and therefore may not play a major role in 
the cytoskeletal disruption observed in the dendritic spine.  
The work involved in this study was initiated to obtain a better understanding 
of the mechanisms involved in the characteristic neurodegeneration and resulting 
neuronal loss observed in TSEs.  Although apoptosis cannot be categorically ruled out 
the results obtained in this study do not support this type of programmed cell death as 
the main mechanism by which neurons die in TSEs. Also other mechanisms of 
apoptosis not studied in this thesis may play a role in the cell death observed in TSEs. 
Another apoptotic pathway suggested to play a role in the cell death observed in TSEs 
involves the induction of endoplasmic reticulum (ER) stress. Protein aggregation in 
the ER triggers the activation of an ER-resident caspase, caspase-12 (Nakagawa et al, 
2000). Active caspase-12 and the ER stress inducible chaperon protein Grp58 was 
shown to be upregulated in the brains of mice infected with the 139A strain of scrapie 
at the terminal stage of disease (Hetz et al, 2003). However, scrapie infection of mice 
deficient in caspase-12 showed no differences in behaviour, pathology and incubation 
time of disease in comparison with wild type mice (Steele et al, 2007a), suggesting 
 208
that caspase-12 is not necessary for mediating the toxic effects of prion protein 
misfolding.  
Autophagy is another form of cell death that has been observed in TSE 
diseases. Most of the data to support autophagy as a mechanism of cell death in TSEs 
comes from electron microscopic studies (Liberski et al, 2008; Liberski et al, 2002b; 
Liberski et al, 2004; Liberski et al, 1990; Sikorska et al, 2007.  Autophagy, or cellular 
self digestion, is a lysosome mediated cellular pathway involved in protein and 
organelle degradation. Autophagy is thought to be a cell survival mechanism and 
growing evidence reveals that alterations in autophagy occur in neurodegenerative 
diseases, and has been shown to play a role in degredation of disease-related mutant 
proteins {Mizushima, 2008 ). Transmission electron microscopy (TEM) is very labour 
intensive and more recently useful protein markers of autophagy have been 
discovered. The molecular mechanisms of the autophagy pathway has been well 
defined, and a subset of genes, denoted as ATGs (autophagy related) (Figure 1), is 
conserved from yeast to human (Huang & Klionsky, 2002; Ohsumi, 2001).The 
expression levels of the microtubule associated protein light chain 3 (LC3), one of the 
mammalian Atg8 homologues, is localised to the autophagosomal membrane and can 
be used to estimate the abundance of autophagosomes before they are degraded by 






Figure 1. Autophagy pathway In the presence of adequate nutrients, growth factors 
are able to activate the class 1 P13K proteins which in turn signal via the AKT 
pathway to activate mTOR. This leads to the inhibition of ATG1- the key signal in 
autophagy induction. Inadequate nutrients or the presence of mTOR inhibitors 
(rapamycin) activates ATG1 leading to the induction of the autophagy pathway. 
Figure from Abcam datasheet.  
 
The role of both PrPc and PrPSc in the autophagy pathway has been 
investigated. The expression levels of LC3 by monitoring the conversion from LC3-I 
into LC3-II, was increased in Prnp-/- hippocampal neuronal cells in comparison to 
wild type cells under serum deprivation. Interestingly, this up-regulated autophagic 
activity was retarded by the introduction of PrPc into Prnp-/- cells but not by the 
introduction of PrPc lacking the octapeptide repeat region, suggesting a role for the 
octapeptide repeat region of PrPc in the control of autophagy (Oh et al, 2008). 
Autophagy induction by trehalose, a known inducer of autophagy, significantly 
reduced PrPSc in neuronal cells in vitro and delayed appearance of PrPSc in the spleen 
of intraperitoneally TSE infected mice but did not result in prolongation of incubation 
times (Aguib et al, 2009). 
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In addition scrapie responsive gene 1(scrg1), a gene shown to have increased 
expression levels in the brains of mice infected with scrapie and BSE and patients 
with CJD, was associated with autophagy (Dron et al, 2006). The scrg1 protein was 
observed in autophagic vacuoles within neurones in the scrapie infected mouse brain. 
Although no significant difference was observed in the disease progression of ME7 
infected transgenic mice specifically expressing Scrg1 in neurons (Dron et al, 2005 ). 
A decrease in mRNA levels of Beclin1 and Atg5 two autophagy related genes, was 
observed in  mice infected with the 139A strain of scrapie, although autophagosome 
formation was unchanged (Mok et al, 2007). The role of autophagy in the neuronal 
cell death in TSEs is still to be determined, it may play a role in degrading and 
removing abnormal forms of the prion protein (Aguib et al, 2009; Heiseke et al, 
2009). Future studies analysing the role of autophagy in the neuronal loss observed in 
the CA1 of the ME7 infected hippocampus could utilise some of the markers of 
autophagy mentioned above. Expression levels of scrg1 have been observed in vivo in 
brains of mice infected with scrapie and would be an ideal candidate to analyse the 
role of autophagy in the loss of CA1 neurons in the ME7 infected hippocampus. 
TSEs or prion diseases fall into the category of protein misfolding diseases. 
One of the characterisitc pathological changes observed in the brain in these diseases 
is the deposition and accumulation of PrPSc in different forms. In protein misfolding 
diseases many studies have been performed in order to find the toxic component of 
the protein. There is growing evidence that in brain amyloidoses, such as Alzheimers 
disease, prefibrillar soluble protein aggregates, rather than insoluble fibrils, are toxic 
(Cerpa et al, 2008; Haass & Selkoe, 2007. In mouse models of Alzheimer’s disease 
oligomers of Aβ protein have been shown to impair synaptic plasticity, disrupt LTP 
and produce changes in dendritic spine shape in CA1 neurons {Shankar, 2008 ; Kayed 
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et al, 2003; Selkoe, 2008; Stefani & Dobson, 2003; Taylor et al, 2002; Viola et al, 
2008). Recently, oligomers of PrPSc have been shown to be neurotoxic and produce 
neuronal loss in the CA1 of the mouse hippocampus, while monomeric and fibrillar 
forms of PrP did not (Simoneau et al, 2007). In the ME7/CV scrapie mouse model 
diffuse, non-fibrillar forms of PrPSc accumulate in the ME7 infected hippocampus, in 
contrast in the 87V/VM scrapie mouse model the main form of PrP observed is in the 
form of amyloid palques. Further studies are required to compare and analyse the 
different forms of PrP deposited in the brains of these mice, to determine which forms 
are neurotoxic. Antibodies raised to the oligomeric form of Aβ have been shown to 
react with oligomeric forms of PrP (Kayed et al, 2003) which include the hydrophobic 
PrP106-126 domain of PrPSc , and could be used in IHC studies to identify the 
neurotoxic form of PrP. 
The identification of the key events involved in the mechanisms of 
neruodegeneration in TSE diseases may lead to development of therapeutic strategies 
to inhibit the neurodegenerative process. The fundamental research within this thesis 
contributes towards understanding the mechanisms involved in the neuronal 
degeneration observed in the TSE infected brain and may contribute to the 
development of potential therapeutic strategies for TSEs. This research may also have 
wider implications for the treatment of other neurodegenerative diseases associated 
with hippocampal pathology, such as Alzheimer’s disease.   
The data in this thesis has been presented at local, national and international 
meetings. I have attended the Edinburgh Neuroscience day every year for the past 10 
years were different aspects of the work within this thesis has been presented in poster 
format.  I have presented the work within this thesis at the TSE joint funders meeting 
held in Warwick. Internationally the work has been presented at the Cell death 
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meeting in Luxombourg in 2005 and at the FENS meeting in Geneva in 2008.  The 
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 Appendix 1. Immunohistochemistry methods and reagents 
 
1.1 ABC method for immunolabelling  
 
1. Take sections to water i.e. remove paraffin wax by immersion in xylene, 
graded alcohols (IMS 99) and water – 10mins 
2. Antigen retrieval steps – depends on antibody used see table of antibodies  
3. Wash in water. 
4. Block with 1% hydrogen peroxide ( H2O2 ) in methanol 10mins. 
5. Wash in water then 1 x 5 mins in PBS/BSA. 
6. Block with normal goat serum 1/20 for 15 mins. 
7. Tap off serum and apply primary antibody.  
8. Wash in 3 x 5 min in wash buffer. 
9. Apply secondary antibody –  either goat  anti mouse biotinylated (for mouse 
monoclonals) or goat anti rabbit (for rabbit polyclonals) at 1/600 - 1 hr. 
For fluorescent labelling of alpha tubulin a goat anti mouse Alexa 488 
secondary was used. 
 NB: At this point make up Avidin-Biotin-Complex (ABC) - 10μl A + 10μl B in 
1ml PBS/BSA buffer. This must be prepared at least 30mins before use. 
10. Wash 3 x 5 min in PBS/BSA. 
11. Incubate in ABC for 30 mins. 
12. Wash 3x5 mins in PBS/BSA. 
13. Incubate in DAB for 5-10 mins. 
14. Counterstain in haematoxylin 1min and blue in scotts tap water. 




1.2. List of antibodies used in IHC in this thesis 
Antibody Antibody 
type 
























buffer 10 mins 
microwave 
1/1000 1hr at 
room temp 
Wako,USA 
Active caspase-3 Rabbit 
Polyclonal 
none 0.03μg/ml for 
1hr at room 
temp 
R&D systems 
Active caspase-3 Rabbit 
Polyclonal 
0.1M citrate 




at room temp 
Oncogene 
Fas receptor (A20) Rabbit 
Polyclonal 
none 1/600 overnight 
at 4oC 
Santa Cruz 
Fas receptor (C20) Rabbit 
Polyclonal 
0.1M citrate 
buffer 10 mins 
microwave 
1/100 for 1hr 
at room temp 
Santa Cruz 
Cytochrome C Mouse 
Monoclonal 
0.1M citrate 
buffer 10 mins 
microwave 
1μg/ml for 30 






buffer 10 mins 
microwave 
1/100 for 1hr 





buffer 10 mins 
microwave 
1/40 for 1hr 






none 2μg/ml for 






buffer 10 mins 
microwave 
10μg/ml for 1hr 
at room temp 
MBL  
International 




10mins at 37oC 
10μg/ml for 








Ready to use 
for IHC 
Dako 
MAP-2 a+b Mouse 
Monoclonal 
0.1M citrate 
buffer 10 mins 
microwave 
1μg/ml 30mins 






1.3 Immunolabelling Reagents 
PBS/BSA wash buffer 
Dissolve 5g BSA (bovine serum albumin) in 250mls stock PBS (10x PBS) top up to 
2500ml with distilled water 
10x PBS 
400g Sodium Chloride 
10g Potassium Chloride 
57.5g DiSodium Hydrogen Orthophosphate 
10g Potassium DiHydrogen Orthophosphate 
5 litres of deionised water  
1% PBS/BSA – antibody diluent 
1g BSA in 100mls PBS (1x PBS tablet in 200ml distilled water) 
Methanol/H2O2 
1% - 232mls methanol + 8mls H2O2 
0.3% - 198mls methanol + 20mls H2O2 
DAB chromagen 
Stock solution :- 1g 3,4,3,4, Tetra amino biphenyl hydrochloride + 40ml distilled 
water. Frozen in 1ml aliquots 
Working solution :- dissolve 2ml of stock DAB solution in 200ml PBS, add 200μl 
30% H2O2 prior to use. 
Scotts Tap Water 
8.75g Sodium Hydrogen Carbonate 
50g Magnesium Sulphate 
2500ml tap water 
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0.1M Citrate Buffer 
0.1M Citric Acid :- 1.92g citric acid anhydrous in 100ml distilled water 
0.1M Sodium Citrate dihydrate :- 14.7g Na citrate in 500ml distilled water 
Citrate buffer working solution :- 
9.0 ml of 0.1M citric acid 
41.0 ml of 0.1M Na citrate 
Bring to 500ml total volume with distilled water and PH to 6.0 with 5N sodium 

























1.4 TUNEL method- Intergen APOPTAG TUNEL kit protocol 
1. REHYDRATE – 5 mins xylene, 3 mins per alcohol (Make sure all xylenes and 
alcohols are fresh) 
2. PICRIC ACID – 2mins in saturated solution, thorough water washes until all acid    
removed. 
3. 5 min PBS wash, ring round section with PAP pen. 
4. PK : Try 15 mins at 10 ,5 and 2.5μg/ml - 100μl per slide @ RT 
5. Wash in 2 changes of distilled water 2x2mins. 
6. QUENCH -  in 3% H2O2  in PBS for 5mins. 36mls PBS + 4ml H2O2 
7. Wash 2 x 5min in PBS. 
8. EQUILIBRATION BUFFER supplied in kit -  apply 75μl per slide for at least 10 
secs. Slides may be left in equilibration buffer for 60mins at 4oC as a stopping point. 
9. TdT ENZYME -  No washes tap off excess liquid add 55μl per slide 
            -ve control RB + water instead of TdT enzyme.  
   77μl Reaction Buffer (RB)  38μl RB  
   33μl TdT    11μl TdT  
   110μl total   enough for 2 slides  5μl Dnase free water 
        54μl total for 1 slide 
apply for 1 hour @ 37oC cover sections with plastic coverslips 
 
10. STOP BUFFER supplied in kit -  agitate for 15 secs, incubate for 10 mins 
   1ml stop buffer stock(freezer) + 34 ml dist. water 
 
11. Wash 3x 1 min in PBS. Take out an aliquot of anti-digoxigenin enough for 
number of slides and let warm up to room temp. 
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12. ANTI-DIGOXIGENIN : tap off excess liquid, apply 65μl per slide, coverslip and 
leave for 30 mins at room temp. 
13. Wash 4x2mins in PBS. 
14. DAB 5-10 mins – prepare as for ABC methods in immunohistochemistry 
15. COUNTERSTAIN – 0.5% methyl green for 5-10 mins. Then wash specimens in 
three changes of dist. water leaving in last one for 30 secs. Then in 3 changes of  
100% n-butanol leave in last one for 30 secs ( all done in coplin jars) then take 
straight to xylene. This will prevent methyl green coming out of the section. 
16. Mount in d.p.x. 
1.5 Solutions for use with APOPTAG protocol 
• Dnase free water – from biochemistry, in autoclaved bottle, 1x 400ml and two 
small bottles. 
• PK buffer – make up in autoclaved bottle : 500ml 30g TRIS (Bor min) 
9.25g EDTA 
Dnase free water 
PH7.6 with HCL 
 
• PK – Stock in freezer @ 1000μg/ml a 1/50 dilution gives 20μg/ml double diluting 
for 10,5 etc 
• PBS – 3 PBS tablets in 600ml distilled water. 
 








Appendix 2:  Western blot analysis 
 
2.1 western blot method 
 
1. Use Invitrogen 4-12% Bis-Tris gels, MES running buffer and appropriate transfer     
     buffer and sample buffer for these gels.  
2.  After sample preparation add 20ul sample, 8ul sea blue 2 standard and appropriate 
amount of positive control to gel.  12 well 4-12% Bis-Tris gels are used. 
3.  Prepare running buffer as per Bis-Tris method book, run samples on gel at 200v 
for approx 45 mins until both sample buffer and protein has run to bottom of gel. 
4.  Remove gels and transfer to PVDF membrane as per instructions in Bis-Tris 
method book. 
5.  Remove pvdf membrane from transfer block wash in methanol and rinse in tap 
     water. 
6.  Place in blocking solution - 3% non fat milk in TBS for approx 2 hours. 
7.  Add primary antibody diluted in blocking solution at appropriate concentration, 
leave in fridge overnight. 
8.  3x5min washes in TBST (TBS with 0.05% tween 20) 
9.  Block 10mins in blocking solution. 
10. Add appropriate secondary antibody diluted in blocking solution. Use at 1/30,000 
dilution and leave on at room temp for 1 hour. 
11. Copious washes in TBST- 6x10mins. 
12. 2x 5min washes in water. 
 Chemmiluminescent visualisation using solutions A and B from upstate kit. For 
two blots add 500ul A + 1000ul B vortex to mix cover with foil and let warm up 
to room temp before use. 
13. Add chemmiluminescent solution to blot for 5mins. 
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14. Develop blot using Kodak imager, monitoring development of protein bands. 
 Semi-quantitative analysis of amounts of protein observed on gel is performed. 
 
2.2 List of antibodies used in western blot analysis 
 
Antibody Antibody type Conc./time Source 
Synaptophysin Rabbit polyclonal 1/1000 overnight at 
4oC 
Synaptic systems 
Drebrin Mouse monoclonal 10μg/ml overnight 
at 4oC 
MBL international 
PSD-95 Rabbit polyclonal 1/1000 overnight at 
4oC 
Synaptic systems 
Active caspase-3 Rabbit polyclonal 0.5μg/ml overnight 
at 4oC 
R&D systems 
Active caspase-3 Rabbit polyclonal 1/2000,1/4000 
overnight at 4oC 
pharmingen 












Alpha tubulin Mouse monoclonal 1/2000 overnight at 
4oC 
Lab vision 
Bcl-2 Mouse monoclonal 0.5μg/ml overnight 
at 4oC 
Upstate 


















Appendix 3: FACS analysis method 
 
3.1 FACS analysis method 
 
1. Remove brain and place into growth medium without buffers, RPMI or HBSS 
can be used. 
2. Incubate all tissue on ice. 
3.  Brain dissected into three pieces the front, mid and hind brain and placed into 
dissociation medium (sigma) for 15mins at 37oC. Remove after 15 mins and 
gently suck the tissue up in a syringe and expel back into dissociation medium 
and leave in incubator for a further 15mins. 
4. Pour tissue and dissociation medium into a 100μm sieve and gently strain 
tissue through sieve using a 1ml syringe containing HBSS. 
5. Centrifuge at 1500-2000 rpm for 5-10mins at 4oC. 
6. Resuspend cells in 1ml FACS buffer (see below). 
7. Perform cell count using trypan blue and haemocytometer and calculate 
number of cells/ml and add 1x106 cells to 50μl of FACS buffer. 
8. Add cells to microtitre plate and incubate with appropriate primary antibody ( 
for microglia – F4/80 FITC conjugated, neurons- NeuN mouse monoclonal), 
incubate on ice for 40mins 
9. wash x3 in FACS buffer, spin microtitre plate at 1500rpm/5mins at 4oC and 
resuspend cells in fresh buffer. 
10. Incubate with appropriate secondary antibody if needed. For NeuN used goat 
anti mouse FITC.  





3.2 Solutions for FACS analysis 
FACS buffer 10x  
di-sodium hydrogen orthophosphate       25.6g 
sodium chloride         74.8g 
potassium di-hydrogen orthophosphate   3.88g 
potassium chloride        2.01g 
make up to 1litre with distilled water 
 
FACS buffer working solution 
 
For 1 litre 
100ml of 10x made up to 1litre in distilled water add: 
Sodium azide 1g 
BSA               1g 
EDTA            0.2g 
           
 
